2018N362439_01 CONFIDENTIA L
GlaxoSmithKline group of companies 207871
1TITLE PA GE
Protocol Title: A Phase I/II, Open -label, Two Part Study  of GSK3359609 in 
Combination with Tremelimumab in Participants with Selected, Advanced Solid Tumors
Protocol Number : 207871 /Amendment 01
Compound Number: GSK3359609
Study Phase: Phase I/Phase II
Short Title : GSK3359609 plus Tremelimumab for the Treatment of Advanced Solid 
Tumors
Sponsor Name and Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Medical Monitor Na me and Contact Information can be found in the Study 
Reference Manual
Regulatory Agency Identifying Number(s):
IND: 140485
EudraCT:  2018-002868-12
Approval Date : 20-SEP-2018
Copy right 2018 the GlaxoSmithKline group of companies. All rights reserved .
Unauthorised cop ying or use of this information is prohibited.
2018N362439_01 CONFIDENTIA L
207871
3PROTOCOL AMENDMENT SUM MARYOF C HANGES TABLE
DOCUMENT HISTORY
Document Date DNG Number
Amendment 1 20-Sep-2018 2018N362439 01
Original Protocol 03-Aug-2018 2018N362439 00
Amendment 1 [20-SEP- 2018]
Overall Rationale for the Amendment: Protocol was amended at the request of a 
regulatory  authorit y to provide additional clarification and guidance on specific aspects 
of the protocol as described in the table below.
Section # and 
NameDescription of Change Brief Rationale
Section 1.3 
Schedule of 
ActivitiesSoA line for EQ -5D needs to 
change in notes/ footnote from 
Week 21 to Week 22Correct t ypo.
Section 7 .1.1
Discontinuation
of Study
TreatmentClarification of the RECIST 
guideline to be followed in allowing 
continuation of study treatment 
beyond progression: original text 
was by iRECIST; the revised text is 
by RECISTv1.1Request of the regulatory authority,
Section 7 .1.3:
Stopping Rules
for Clinical 
DeteriorationClarification that the decrease in 
the ECOG represents a worsening 
of performance status from 
baseline.Request by the regulatory auth ority.
Section 8.1.3.1 Jensen references (2) have 
incorrect years (2014 changed to 
2015 and the 2016 changed to 
2017)Correct edtypos
Section
10.6.2 .1:
Rechallenge 
Following Liver 
Stopping 
Events that are 
Possibly 
Related to 
Study 
TreatmentModified the first bullet (addition
underlined) to read, “Investigator 
requests consideration of 
rechallenge with study treatment 
for a participant who is receiving 
compelling benefit (partial 
response or complete response)
with study treatment that exceeds 
risks, and no effective alternative 
therapy is available.
Add the following requirements:
The ALT at the time of   Request by the regulatory authority.
2018N362439_01 CONFIDENTIA L
207871
4Section # and 
NameDescription of Change Brief Rationale
rechallenge is <3x ULN 
The participant did not have 
additional risk factors for a fatal 
outcome following the initial 
injury including 
hypersensitivity ,jaundice, 
bilirubin >2x ULN , (direct 
bilirubin >35% of total 
bilirubin), or INR >1.5.
Section 11. 
ReferencesJensen references (2) have 
incorrect years (2014 chang ed to
2015 and the 2016 changed to
2017)Correct ty pos
2018N362439_0 1 CONFIDENTIA L
207871
5TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 3
1.PROTOCOL SUMMARY ........................................................................................ 10
1.1. Synopsis ..................................................................................................... 10
1.2. Schema ...................................................................................................... 13
1.3. Schedule of Activities (SoA) ........................................................................ 13
2.INTRODUCTION .................................................................................................... 22
2.1. Study Rationale .......................................................................................... 22
2.2. Background ................................................................................................ 23
2.3. Benefit/Risk Assessment ............................................................................ 26
2.3.1. Risk Assessment ......................................................................... 26
2.3.2. Benefit Assessment ..................................................................... 27
2.3.3. Overall Benefit: Risk Conclusio n.................................................. 28
3.OBJECTIVES AND ENDPO INTS ........................................................................... 28
3.1. Part 1: Dose Escalation of GSK3359609 in Combination with 
Tremelimumab ............................................................................................ 28
3.2. Part 2: Cohort Expansion of the RP2D Dose Comb ination vs. SOC 
in R/R HNSCC ............................................................................................ 29
4.STUDY DESIGN .................................................................................................... 30
4.1. Overall Design ............................................................................................ 30
4.1.1. Part 1: Dose Escalation of Tremelimumab and 
GSK3359609 ............................................................................... 31
4.1.1.1. Dose Limiting Toxicity ................................................. 32
4.1.1.2. Non-Limiting Toxicities ............................................... 33
4.1.1.3. Dose Escalation Decisions and Selection of 
Part 2 Dose ................................................................ 34
4.1.2. Part 2: Cohort Expansion of the RP2D Dose Combination 
vs. SOC ....................................................................................... 34
4.2. Scientific Rationale for Study Design .......................................................... 34
4.3. Justification for Dose .................................................................................. 35
4.3.1. GSK3359609 Dose Rationale ...................................................... 35
4.3.1.1. GSK3359609 Dosing Frequency ................................ 35
4.3.1.2. GSK3359609 Rationale for Fixed Dose ...................... 36
4.3.2. Tremelimumab Dose Rationale .................................................... 36
4.4. End of Stud y Definition ............................................................................... 37
4.4.1. Participant Completion ................................................................ .37
5.STUDY POPULATION ........................................................................................... 37
5.1. Inclusion Criteria ......................................................................................... 38
5.2. Exclusion Criteria ........................................................................................ 40
5.3. Lifestyle Considerations .............................................................................. 43
5.4. Screen Failures ........................................................................................... 43
6. STUDY INTERVENTION ........................................................................................ 43
6.1. Study Intervention(s) Administered ............................................................. 43
6.2. Preparation/Handling/Storage/Accountability .............................................. 44
2018N362439_0 1 CONFIDENTIA L
207871
66.3. Measures to Minimize Bias: Randomization and Blinding ........................... 45
6.4. Study Intervention Compliance ................................................................... 45
6.5. Concomitant Therapy .................................................................................. 45
6.5.1. Permitted Medications and Non -Drug Therapies .......................... 46
6.5.2. Prohibited Medications and Non -Drug Therapies ......................... 46
6.6. Dose Modification and Safet y Management Guidelines .............................. 47
6.6.1. General Guidelines for Immune -Related Adverse Events ............ 47
6.6.2. Dose Modification and Toxicity Management of Infusion-
Reactions Related to Immunotherapy Treatment ......................... 63
6.6.3. Dose Delay .................................................................................. 66
6.7. Intervention after the End of the Study ........................................................ 66
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/W ITHDRAW AL..................................................................... 67
7.1. Discontinuation of Study Intervention .......................................................... 67
7.1.1. Continuation of Treatment Upon Confirmed Disease 
Progression ................................................................................. 68
7.1.2. Liver Chemistry Stopping Criteria ................................................ 69
7.1.2.1. Study Intervention Restart or Rechallenge after 
Liver Stopping Criteria Met ......................................... 70
7.1.3. Stopping Rules for Clinical Deterioration ...................................... 70
7.2. Participant Discontinuation/W ithdrawal from the Study ............................... 71
7.3. Lost to Follow Up ........................................................................................ 71
8.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 72
8.1. Efficacy Assessments ................................................................................. 72
8.1.1. Tumor Imagi ng and Disease Assessments .................................. 72
8.1.1.1. Initial Tumor Imaging .................................................. 73
8.1.1.2. Tumor Imaging During the Study ................................ 73
8.1.1.3. End of Treatment Imaging .......................................... 74
8.1.2. Tumor Growth Kinetics ................................................................ 74
8.1.3. Patient Reported Outcomes (PRO) .............................................. 74
8.1.3.1. PROMIS Physical Function ........................................ 75
8.1.3.2. EORTC QLQ -C30 & HN35 ......................................... 76
8.1.3.3. FACT GP5 .................................................................. 76
8.1.3.4. PRO -CTCAE .............................................................. 76
8.1.3.5. EuroQOL Group EQ -5D 3 Level Version .................... 77
8.2. Safety Assessments ................................................................................... 77
8.2.1. Physical Examinations ................................................................ .77
8.2.2. Performance Status ..................................................................... 77
8.2.3. Vital Signs .................................................................................... 77
8.2.4. Electrocardiograms ...................................................................... 78
8.2.5. Echocardiograms ......................................................................... 78
8.2.6. Clinical Safety Laboratory Assessments ...................................... 78
8.3. Adverse Events and Serious Adverse Events ............................................. 79
8.3.1. Time Period and Frequency for Collecting AE and SAE 
Informat ion................................................................................... 79
8.3.2. Method of Detecting AEs and SAEs ............................................. 80
8.3.3. Follow -up of AEs and SAEs ......................................................... 80
8.3.4. Regulatory Reporting Requirements for SAEs ............................. 80
8.3.5. Pregnancy ................................................................................... 80
8.3.6. Cardiovascular and Death Events ................................................ 80
2018N362439_0 1 CONFIDENTIA L
207871
78.4. Treatment of Overdose ............................................................................... 81
8.5. Pharmacokinetics ....................................................................................... 81
8.5.1. Blood Sam ple Collection .............................................................. 82
8.5.2. Sample Analysis .......................................................................... 82
8.6. Pharmacodynamics .................................................................................... 82
8.7. Genetics ..................................................................................................... 82
8.8. Biomarkers ................................................................................................ .83
8.8.1. Blood Biomarkers ........................................................................ 83
8.8.2. Tumor Tissue Biomarkers ............................................................ 83
8.8.3. Immunogenicity Assessments ...................................................... 84
8.8.4. DNA/RNA Transcriptome and RNA expression Research ........... 84
8.8.5. Proteome Research ..................................................................... 84
8.9. Health Economics/Medical Resource Utilization and Health 
Economics .................................................................................................. 84
9.STATISTICAL CONSIDER ATIONS ........................................................................ 85
9.1. Statistical Hypotheses ................................................................................. 85
9.1.1. Part 1: Dose Escalation ............................................................... 85
9.1.2. Part 2: Cohort Expansion ............................................................. 85
9.2. Sample Size Determination ........................................................................ 85
9.2.1. Part 1: Dose Escalation ............................................................... 85
9.2.2. Part 2: Cohort Expansion ............................................................. 87
9.3. Populations for Analyses ............................................................................ 88
9.4. Statistical Analyses ..................................................................................... 89
9.4.1. Efficacy Analyses ......................................................................... 89
9.4.1.1. Overall Survival (OS) .................................................. 89
9.4.1.2. Overall Response Rate (ORR) ................................... 90
9.4.1.3. Disease Control Rate (DCR) ...................................... 90
9.4.1.4. Duration of Response (DOR) ...................................... 90
9.4.1.5. Progression Free Survival (PFS) ................................ 90
9.4.1.6. Time to Response (TTR) ............................................ 90
9.4.1.7. Predictive Probability of Phase 3 Success .................. 90
9.4.2. Safety Analyses ........................................................................... 91
9.4.2.1. Extent of Exposure ..................................................... 91
9.4.2.2. Adverse Events .......................................................... 91
9.4.2.3. Clinical Laboratory Evaluations .................................. 92
9.4.2.4. Other Safety Measures ............................................... 92
9.4.3. Other Analyses ............................................................................ 92
9.4.3.1. Pharmacokinetic Analyses .......................................... 92
9.4.3.2. Pharmacokinetic/Pharmacodynamic Analyses ........... 93
9.4.3.3. Immunogenicity Analyses ........................................... 93
9.4.3.4. Translational Research Analyses ............................... 93
9.4.3.5. Tumor Kinetic Analyses .............................................. 93
9.5. Interim Analyses ......................................................................................... 93
9.5.1. Part 1: Dose Escalation ............................................................... 93
9.5.2. Part 2: Cohort Expansion ............................................................. 94
10.SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ............................................................................................... 95
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ............................................................................................ 95
10.1.1. Regulatory and Ethical Considerations ........................................ 95
2018N362439_0 1 CONFIDENTIA L
207871
810.1.2. Financial Disclosure ..................................................................... 95
10.1.3. Informed Consent Process .......................................................... 95
10.1.4. Data Protection ............................................................................ 96
10.1.5. Dissemination of Clinical Study Data ........................................... 96
10.1.6. Data Quality Assurance ............................................................... 97
10.1.7. Source Documents ...................................................................... 98
10.1.8. Study and Site Closure ................................................................ 98
10.1.9. Publication Policy ......................................................................... 98
10.2. Appendix 2: Clinical Laboratory Tests ......................................................... 99
10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ..................................... 100
10.3.1. Definition of AE .......................................................................... 100
10.3.2. Definition of SAE ........................................................................ 101
10.3.3. Definition of Cardiovascular Events ........................................... 102
10.3.4. Recording and Follow -Up of AE and SAE .................................. 102
10.3.5. Reporting of SAE to GSK ........................................................... 104
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................ 106
10.4.1. Definition: W oman of Childbearing Potential (W OCBP) ............. 106
10.4.2. Contraception Guidance ............................................................ 107
10.4.3. Collection of Pregnancy Information: ......................................... 108
10.5. Appendix 5: Genetics ................................................................................ 110
10.6. Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments and Study Intervention Rechallenge Guidelines .................. 111
10.6.1. Liver Chemistry Stopping and Monitoring Criteria ...................... 111
10.6.1.1. ALT up to 2.5xULN at Baseline ................................ 111
10.6.1.2. Baseline ALT up to 5xULN for Participants with 
Documented Liver Metastases/Tumor 
Infiltration .................................................................. 113
10.6.1.3. Liver Chemistry Increased Monitoring Criteria 
with Continued Therapy ............................................ 115
10.6.2. Liver Safety Drug Restart or Re -Challenge Guideli nes.............. 115
10.6.2.1. Re-challenge Following Liver Stopping Events 
that are Possibly Related to Study intervention ......... 115
10.6.2.2. Re-challenge Following Transient Liver 
Stopping Events Not Related to S tudy 
intervention ............................................................... 117
10.7. Appendix 7: Guidelines for Assessment of Disease, Disease 
Progression and Response Criteria .......................................................... 119
10.7.1. Assessment Guidelines by RECIST 1.1 ..................................... 119
10.7.2. Guidelines for Evaluation of Disease by RECIST 1.1 ................. 120
10.7.3. Evaluation of Response by iRECIST .......................................... 120
10.8. Appendix 8: Creatinine Clearance Calculation Formulas .......................... 127
10.9. Appendix 9: ECOG Performance Status ................................................... 129
10.10. Appendix 10: Statistical Methods for Study Design ................................... 130
10.10.1. Bivariate CRM Method for Part 1 Dose Escalation ..................... 130
10.10.1.1. Description of the Bivariate Continual 
Reassessment Method ............................................. 130
10.10.1.2. Logistic Model for Bivariate CRM .............................. 130
10.10.2. Simulation Method for Part 2 Sample Size Estimatio n............... 131
10.11. Appendix 11: Abbreviations and Trademarks ............................................ 134
10.12. Appendix 12: Protocol Amendment History ............................................... 138
2018N362439_0 1 CONFIDENTIA L
207871
911.REFERENCES ..................................................................................................... 139
2018N362439_01 CONFIDENTIA L
207871
101. PROTO COL SUMMA RY
1.1. Synopsis
Protocol Title: A Phase I /II,Open -label , Two Part Study  of GSK3359609 in 
Combination with Tremelimumab in Participants with Selected, Advanced Solid Tumors
Short Title: GSK3359609 plus Tremelimumab for the Treatment of Advanced Solid 
Tumors
Rationale:   GSK3359609 is an inducible T cell co- stimulator ( ICOS)agonist antibody  
and tremelimumab is a cytotoxic T -lymphocy te-associated protein 4 (CTLA -4)
antagonist antibody . In nonclinical and clinical studies in a variet y of tumors, it has be en 
shown that I COS expression on T cells is upregulated after CTLA -4treatment.
Additionally , ICOS+CD4 T cells have been shown to have a positive association with 
response in t remelimumab treated chemotherap y-resistant malignant mesothelioma 
patients. It is hypothesized that the combination of these two agents will provide greater 
antitumoral response than either agent alone. The purpose of this study  is to evaluate if 
the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and 
provide s significant survival benefit to participants with relapsed/refractory  (R/R) Head 
and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical investigation .
Objectives and Endpoints:
PART 1
Objectives Endpoints
Primary
Determine safety, tolerability and the 
R2PD of GSK3359609 in combination 
with tremelimumab Frequency and severity of DLTs, AEs, 
AESI, SAEs and AE/SAE /DLT s leading to 
dose modifications/delays/withdrawals; 
changes in laboratory, vital signs, and 
ECG safety assessment parameters
Secondary
 Evaluate clinical activity of GSK3359609 
in combination with tremelimumab ORR, DCR
 Characterize the PK properties of 
GSK3359609 and tremelimumab when 
administered in combination Cmax, Cmin, AUC (0 -t) of GSK3359609 
and tremelimumab as data per mit
 Determine immunogenicity of 
GSK3359609 and tremelimumab when 
administered in combination Detection and characterization of ADA 
against GSK3359609 and/or 
tremelimumab
AEs = adverse events; SAEs = serious adverse events; DLTs = dose limiting toxicities ; AESI = adverse events of 
special interest; RP2D = recommended phase 2 dose; ECG = electrocardiogram; ORR = overall response rate; 
DCR = disease control rate; Cmax = m aximum observed concentration ; Cmin = minimu m observed 
concentration; AUC (0 -t) = area under the concentration -time curve over the dosing interval; ADA = anti -drug 
antibodies
2018N362439_01 CONFIDENTIA L
207871
11PART 2 
Objectives Endpoints
Primary
Evaluate clinical activity of GSK3359609 
in combination with tremelimumab
compared to SOC OS
Secondary
 Further evaluate the cli nical activity of 
GSK3359609 in combination with 
tremelimumab compared to SOC ORR, DCR, PFS, TTR, DoR
 Further evaluate the PK properties of 
GSK3359609 and tremelimumab when 
administered in combination Cmax, Cmin, AUC (0 -t)of GSK3359609 
and tremelimumab as data permit
 Further evaluate immunogenicity of 
GSK3359609 and tremelimumab when 
administered in combination ADA incidence 
 Further evaluate the safety and 
tolerability of GSK3359609 and 
tremelimumab when administered in 
combination Frequency and sever ity of AEs, AESI,
SAEs and AE/SAEs leading to dose 
modifications/delays/withdrawals; 
changes in laboratory, vital signs, and 
ECG safety assessment parameters
OS = overall survival; SOC = standard of care; ORR = overall response rate ; DCR = disease control rate; PFS = 
progression -free survival; TTR = time to response; DoR = duration of response; TCR = T cell receptor; ADA = 
anti-drug antibodies; AEs = adverse events; SAEs = serious adverse events; Cmax = m aximum observed 
concentration ; Cmin = minimum observed concentration; AUC ( 0-t) = area under the concentration -time curve 
over the dosing interval .
Overall Design:
This is a Phase I/II, open -label, 2 -part study  of GSK3359609 in combination with 
tremelimumab. As shown in Figure 1, Part 1 is dose escalation and will enroll
participants with advanced, selected solid tumors and Part 2 is randomized expansion and
will enrol l participants with R/R HNSCC who have disease progress ionafter receiving at 
least 1 platinum -based chemotherap y and at least 1 anti-PD-1/PD -L1 therapy , whether in 
combination or separately .In Part 2, participants will be stratified by  line of anti-PD-(L)1 
therap y(i.e., received in the first line or second line) .
Part 1 dose escalation will initiate with 8 mg GSK33 59609 and 75 mg tremelimumab
(termed dose level [DL ] 1), the planned lowest dose for each agent . The highest planned 
doses are 80 mg GSK3359609 and 225 mg tremelimumab. GSK3359609 will be 
administered every  3 weeks and tremelimumab will be administered eve ry 3 weeks for 6 
doses, followed b y ever y 12 weeks. Tremelimumab is to be administered first as an IV 
infusion over 60 minutes. GSK33596 09 will be administered as a 30 -minute IV infusion 
beginning at least 1 hour and no more than 2 hours following the end of the 
tremelimumab infusion. Dose escalation will occur using a zone -based approach; each 
2018N362439_01 CONFIDENTIA L
207871
12zone must clear for safety  prior to the next zone being opened to enrollment. Dose 
escalation will be guided by  the biv ariate Continuous Reassessment Method ( CRM )
model until the maximum tolerated dose ( MTD) or maximum administered dose ( MAD )
dose combination (s)aredetermined. Unplanned dose combinations within the range of 
the planned doses of each agent may  be investigated to support the identification of 
optimal d oses to administer in combination. Additionally , doses lower than planned of 
either agent may  be investigated. PK/pharmacody namic cohort (s)may be initiated at any  
DL(s), once safety  is cleared, with mandatory  paired tumor sample collections to inform 
on dose selection for Part 2 of the study . 
The severit y of all toxicities will be graded using National Cancer Institute -Common 
Toxicity  Criteria for Adverse Events (NCI -CTCAE) (version 5.0). The DLT observation 
period is 28 day s in length and begins on the day GSK3359609 and tremelimumab are
first administ ered to the participant .
A single dose combination will be selected as the recommended Phase 2 dose ( RP2D)
and carried forward from Part 1 into Part 2 . The totality  of data will be used to determine 
whethe r to proceed to Part 2 and which dose combination will be chosen as the RP2D.
Part 2 expansion is randomized andopen -label to evaluate the efficacy  of the selected 
RP2D dose combination compared to the Investigator’s choice of selected current 
standard of care ( SOC ) in the treatment of R/R HNSCC who have progressed after 
receiving at least 1 platinum -based chemotherap y and at least 1 anti -PD-1/PD -L1
therap y,whether in combination or separately . Randomization is 2:1 to the 
investigational and SOC arms, res pectivel y. Part2 will also characterize PK and 
pharmacod ynamic effects. Additional tumor ty pe cohorts may be added either as a single 
arm expansion or with an appropriate comparator if a signal is identified in Part 1, based 
on the totality  of the evidenc e and would be the subject of a future amendment. 
Disclosure Statement : Part 1 is a single group treatment part with 1 arm. Part 2 is a 
parallel group random treatment assignment part with 2 arm s. 
Number of Participants: Approximately  114 participants wi llbeenroll edin this study ; 
up to 24 in Part 1 and 90 in Part 2.
Intervention Groups and Duration: The study  is comprised of 3 periods (further details 
in the Schedule of Activities (SoA).
Screening: Participants may  sign the informed consent form up to 45 day sprior to first 
dose and screening procedures should be completed within 30 day s prior to first dose or
as described in the SoA .
Treatment :Study  intervention is defined as GSK3359609 in combination with 
tremelimumab and in Part 2, participants wi ll be randomized to study  intervention or 
SOC (Part 2 only ; Investigator’s choice of paclitaxel, docetaxel or cetuximab). 
Participants will receive study  intervention or SOC until disease progression, 
unacceptable toxicity  or death .
Follow -up:Participant s will be followed for survival and subsequent anticancer therap y 
once study  intervention/SOC has been discontinued .Note: Participants who discontinue 
2018N362439_01 CONFIDENTIA L
207871
13study  intervention/SOC prior to progression or prior to confirmed progression by  
iRECI ST will also be followed for progression or confirmation of progression by  
iRECI ST. 
The total duration of study  participation begins with the signing of the informed consent 
form (ICF) through the final protocol -defined follow -up assessment for survival and is 
estimated to be up to 4 years (~2 years on treatment and ~2 years in survival follow -up); 
however, participants deriving benefit may  be on study  intervention beyond 2 y ears. 
Data Monitoring Committee: There will not be a formal data monitoring committee for 
this stud y.The Dose Escalation and Selection Plan will describe the process for making 
dose escalation /selection decisions and responsible personnel.
1.2. Schema
Figure 1 Study  Design Schema
1.3. Schedule of A ctivities (SoA )
Protocol waivers or ex emptions are not allowed except for immediate safety  concerns. 
Therefore, adherence to the study  design requirements, including those specified in the 
Schedule of Activities, are essential and required for study  conduct.
The following points must be noted:
If assessments are scheduled for the same nominal time, THEN the assessments should 
occur in the following order:
1. 12 -lead ECG
2.Vital signs
3.Blood draws (e.g.,PK blood draws)
Note: Other assessments not listed may  occur at any  time; however, the timing of A LL 
the assessments must allow the blood draw to occur at the exact nominal time.
2018N362439_01 CONFIDENTIA L
207871
21Abbreviations: ADA = Anti-drug antibodies; AE = Adverse event; AESI = Adverse events of special interest; ANC = Absolute neutrophil count; CR = complete response; ECG = 
Electrocardiogram; ECOG PS = Eastern Cooperative Oncology Group performance status; EOI = End of infusion; EORTC QLQ -C30 and HN35 = European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire –Core 30 and head and neck 35 module; EQ -5D = EuroQOL Group EQ -5D; FACT GP5 = Functional Assessment of Cancer 
Therapy -General Physical Well Being Item 5; HIV = Human immunodeficiency virus; ICF = Informed consent form; iRECIST = Modified Response Evaluation Criteri a in Solid Tumors 
1.1 for immune -based therapeutics; MUGA = Multigated acquisition scan; PBMC = peripheral mononuclear cells;  PD = Progressive Disease; PK = Pharmacokinetics; PR = Partial 
response; PRO -CTCAE Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events; PROMIS PF = Patient -Reported Outcome Measurement 
Information System –Physical Function; Q = Every; RNA = Ribonucleic acid; SAE = Serious adverse event; SOC = Standard of care; TDV = Treatment Discontinuation Visit ; W = 
Week; WOCBP = Women of childbearing potential
2018N362439_01 CONFIDENTIA L
207871
222. INTRODUCTION
2.1. Stud y Rationale
GSK3359609 is an inducible T cell co -stimulator (ICOS) agonist antibody  and 
tremelimumab is a c ytotoxic T -lymphocy te-associated protein 4 (CTLA -4) antagonist 
antibody . In nonclinical and clinical studies in a variety  of tumors, it has been shown that 
ICOS expression on T cells is upregulated after CTL A-4treatment [ Fan, 2014; Fu, 2011; 
Tang , 2013]. Additionally, ICOS+CD4 T cells have been shown to have a positive
association with response in t remelimumab treated chemotherap y-resistant malignant
mesothelioma patients [Calabrò , 2013]. It is hy pothesized that the combination of these 
two agents will provide a significant antitumoral response . The purpose of this study  is to 
evaluate if the combination of GSK3 359609 and tremelimumab is safe and tolerable (Part 
1) and provides significant survival benefit to participants with relapsed/ refractory (R/R) 
Head and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical 
investigation (Part 2) .
Part 1
In Par t 1 of study  207871, study  intervention will be tested at escalating dose 
combinations in participants with advanced, selected solid tumors that are 
relapsed/refractory  to standard therapies to determine the best dose combination of 
tremelimumab and GSK335 9609. The selection of these solid tumors was based on 
evidence of their reported response to immune checkpoint therapies [ Swaika , 2015; 
Zamarin, 2015] and/or of exhibiting features indicating a greater likeli hood of 
susceptibility  to immune directed therapies, such as tumor mutation load or 
number/phenoty pe of tumor infiltrating l ymphocy tes [Powles , 2014].
Part 2
Head and neck cancers are the ninth most common malignancies in the world w ith over 
90% of these being squamous cell carcinomas [Gupta , 2016]. Although these patients are 
treated with potentially curative treatments, many develop recurrent or metastatic disease. 
This patient population continues to have a hi gh unmet medical need, as median overall 
survi val is less than 1 y ear [Argiris , 2017]. For recurrent, unresectable or metastatic 
disease without an option for radiation, platinum -based chemotherap y alone or in 
combination with other chemotherapeutic agents is also among the preferred first line 
treatment options [ NCCN, 2018]. While immunotherap y has been shown to prolong 
progression- free survival and increase the 1 -year overall survival rate over standard of 
care (SOC) single agent therapies [ Ferris , 2016 ] and is now recommended as second line 
therap y [NCCN , 2018], the prognosis for these patients remains poor. 
R/RHNSCC was chosen as a tumor type of interest in Part 2 of this study  due to the high 
unmet medical need in patients who have failed platinum -based chemotherapy and anti -
PD-(L)1 therap y. Several studies have indicated that infiltration with immune cells 
correlated with favourable clinical outcomes in HNSCC [ Mandal , 2016; Ferris , 2015]. 
ICOS and CTLA -4 expression has been seen on T cells in the in -silico analy sis of the 
TCGA database in a proportion of HNSCC surgically  resected tumor samples and 
2018N362439_01 CONFIDENTIA L
207871
23multiplex I HC based st udies have shown ICOS and CTL A-4 expression on TILS to a 
varying extent between HNSCC patients from surgically resected samples including both 
CD8 and CD4 T cells andboth conventional and regulatory  CD4 T cells [Kim, 2016]. 
The combina tion of an ICOS agonist antibody  with a CTL A4 blocking antibody  could 
enhance activation of the CD8 and CD4 T -conventional cells while controlling the T -reg 
suppressive effects and is therefore h ypothesized to have a significant antitumor effect in 
HNSCC .
The choice of chemotherapy  for R/RHNSCC following failure of first line therap y and 
failure of second line anti-PD-(L)1therapy is not well defined and is based on several 
factors, including previous chemotherap y exposure, performance status, and comorbid
conditions. Several single agent chemotherap y options existed as second line therap y for 
patients who are not appropriate for a platinum-containing regimen. These agents now 
fall into the third line post -approval of the anti -PD-(L)1 agents. In the United States and 
the EU, ASCO, NCCN and ESMO recommendations include best supportive care, 
clinical trials, and single agents including paclitaxel, docetaxel, 5- fluorouracil, 
methotrexate, cetuximab, ifosfamide, bleom ycin, gemcitabine, capecitabine, and 
vinorelbine [ NCCN , 2018; Mesia , 2013]. Methotrexate and bleomy cin have FDA 
approved indications for head and neck cancer; however, both agents are considered toxic 
in the setting of newer chemotherap y agents and methotrex ate had poor performance in 
the recent P hase III study [ Ferris , 2016]. Furthermore, the bleom ycin label contains the 
following language, “the response to bleom ycin is poorer in patients with previously 
irradiated head and neck cancer ”. This population is expected to be the majority  of 
participants in this study and thus bleomy cin will not be included in the SOC options in 
this study . The I nvestigator’s choice of SOC will cons ist of the following agents:
cetuximab (where it is approved for use as a single agent for recurrent HNSCC ), 
paclitaxel (which is incorporated into regimens in earl y lines of disease and is commonly  
used in late line as a single agent), and docetaxel (which appear sto be the most active 
agent in the platinum refrac tory setting, has approved indications as a single agent and 
has demonst rated activity in this setting ) [Ferris , 2016] .
2.2. Background
A model of cancer immunity  is described as a cy clic multistep process that functions to 
elicit an effe ctive antitumor response [ Chen , 2013]. Each step can be negatively  
regulated, thus providing the tumor with redundant mechanisms by  which to block an 
antitumor immune response. In some cases, tumors will be highl y dependent on a single
mechanism, and in these cases, there is the potential to achieve significant clinical 
activity  with a single agent immunomodulatory  therapy . However, it is expected that 
tumors often utilize redundant mechanisms to evade antitumor immune responses and in 
these cases, combination therapies are likel y required.
Robust antitumor responses including complete cure in some cancers have been achieved 
by modulating a patient’s immune sy stem. Antibodies targeting the checkpoint receptors 
or their cognate ligands en gaged in negative regulation of T cell responses, such as 
CTL A-4 and PD -1 (Programmed death receptor -1)/PD-L1(PD L igand ), have 
demonstrated efficacy  and are proven effective as anticancer immunotherapies in a broad 
2018N362439_01 CONFIDENTIA L
207871
24range of tumors including some solid tum ors otherwise considered poorl y immunogenic
[Chen, 2015; Brahmer , 2012; Topalian, 2012; Meng , 2017].
However ,the majorit y of tumors are non- responsive to this class of agents when given as 
monotherap y as these tumors may  possess features that enable them to evade immune 
surveillance, suppress immune reactivity , proliferate and survive within an inflammatory  
microenvironment . In addition, multiple mechanisms of immune suppression could exist
which may  prohibit effective antitumor immune responses. I n these instances, 
combination therapies will likely  be required. The clinical data generated by  the 
combination of ipilimumab (anti- CTLA -4) and nivolumab (anti -PD-1) in pat ients with 
metastatic melanoma is an example of the practice changing clinical benefit of such 
combinations [ Wolchok, 2013; Larkin, 2015]
In some patients, inhibition of negative immune checkp oint pathway s alone may  not 
elicit an effective antitumor response .To reinstate immunosurveillance, t reatment 
approaches may  require combinations with agents that provide co -stimulatory  signals or
target different processes within the immune cascade ; these regimens may  include 
chemotherap ieswhich possess advantageous immunological effects [Galluzzi, 2015] .
Immunomodulatory  agents that target other components of the cancer immunity  cycle are 
needed to expand the population of patie nts and range of tumor ty pes that may  respond to 
immunotherapy  as well as enhance the magnitude and duration of antitumor responses in 
patients whose tumors are alread y sensitive to current immunotherap y approaches. 
Ultimately , the aim is to improve patien t survival outcome in all disease settings 
including the advanced setting which is considered non- curative b y nature.
GSK3359609 is a humanized IgG4 anti-ICOS agonist monocl onal antibody [ Mayes,
2018 ] selected for its nanomolar (nM) binding to and agonist activity  in ICOS -expressing 
CD4+ and CD8+ effector T cells. GSK3359609 is specificall y engineered as an 
Immunoglobulin (Ig)G4 hinge -stabilized isoty pe, IgG4PE, to markedl y decrease binding 
affinity  of the Fc (Fragment cr ystallizable) region of the mAb to activating Fcγ receptors 
and C1q, and thereb y diminish the cytotoxic potential of GSK3359609 that would result 
in depletion of I COS -positive T cells through antibody -dependent or complement -
dependent cell mediated mecha nisms, respectively . Moreover, the IgG4PE isoty pe retains 
functional binding to the Fc inhibitor receptor, Fc RIIb, a feature described as critical 
for modulating antibody  agonist activity  [Li, 2011 ], which also may  be e ssential for 
optimal I COS agonist activity  and its associated antitumor effects in humans.
ICOS is a co -stimulatory  receptor belonging to the CD28/CTL A immunoglobulin super 
family  with expression restricted to T cells [ Hutloff , 1999]. I COS is weakl y expressed on 
resting TH17, follicular helper T and regulatory T (Treg) cells ,yet is highl y induced on 
CD4+ and CD8+ T cells upon T cell receptor (TCR) engagement and activation [ Paulos,
2010 ; Wakamatsu , 2013 ]. Upregulation of ICOS leads to both Th1 and Th2 cy tokine 
secretion and sustained effector T cell proliferation and function [ Sharpe , 2002]. A 
growing bod y of evidence supports the concep t that activating ICOS on CD4+ and CD8+ 
effector T cells has antitumor potential.
2018N362439_01 CONFIDENTIA L
207871
25The rationale for targeting ICOS in cancer has been established by  multiple lines of 
nonclinical and clinical evidence. Engagement of the I COS pathway  with an I COS -L-Fc 
fusion protein is shown to have potent antitumor activity  in multiple sy ngeneic mouse 
tumor models [ Ara, 2003]. 
GSK3359609 has been tested in combination with anti -
CTL A-4 monoclonal antibodies (mAb) (ipilimumab) in either ex -vivo human PBMC 
assay s or in a modified ML R assay . The GSK3359609 and anti -CTLA -4 combination 
resulted in a significant enhancement in IFN γproduction compared to either agent alone 
in both the PBMC assay  as well as the M LR assay. Refer to the GSK3359609 
Investigator’s Brochure (IB) [ GSK Document Number 2017N319717_01] for further 
details. 
Tremelimumab is a human immunoglobulin (Ig)G2 mAb that is directed against CTL A-
4; clu ster of differentiation [CD]152 , a cell surface rece ptor that is expressed primaril y on 
activated T cells and acts to inhibit their activation. Tremelimumab completely  blocks the 
interaction of human CTLA -
4 with CD80 and CD86, resulting in increased release of 
cytokines (interleukin [IL ]-2 and interferon [I FN]-γ) from human T cells, peripheral 
blood mononuclear cells and whole blood [Tarhini , 2008]. Tremelimumab is being 
developed b y AstraZeneca for use in the treatment of cancer. 
To date ,tremelimumab has been given to more than 1500 patients as part of ongoing 
studies either as monotherap y or in combination with other anticancer agents. Refer to the 
current tremelimumab IB[AstraZeneca , 2017] for a complete summary  of non -clinical 
and clin ical information including safety, efficacy  and pharmacokinetics.
Emerging data from patients treated with anti -CTLA -4 antibodies suggest a positive role 
of ICOS+ effector T cells in mediating an antitumor immune response. Patients with 
metastatic melanoma [Di Giacomo, 2013], urothelial [ Carthon, 2010], breast 
[Vonderheide , 2010] or prostate cancer [ Chen, 2009] who have increased absolute counts 
of circulating and tumor infiltrating CD4+ICOS+ and CD8+ICOS+ T cells after 
ipilimumab treatment have significantly  better treatment related outcomes than patients 
where little or no increases are observed. Importantly , it was shown that ipilimumab 
changes the ICOS+ T effector to Treg ratio, reversing an abundance of Tregs pre -
treatment to a significant abundance of T effectors vs. Tregs following treatment [ Liakou , 
2008; Vonderheide , 2010]. As evidenced by  the clinical data, ICOS+ T effector cells may  
be a positive predictive biomarker of ipilimumab response, and activation of this 
population of cells with an I COS agonist anti body  may  show enhanced clinical activity  
than either agent alone. As suggested in the literature [ Melero , 2013], the complimentary  
mechanisms of actions of CTL A
-4 blocking antibodies which inhibit the suppressive
action on T cells thus ‘taking off the brakes’ and activating them while combining with 
an ICOS agonist antibody  which further co-stimulates the activated T cells for enhanced 
effector function and proliferation has the potential to mount a more robust immune 
antitumor response.
As evident from the clinical efficacy  of antibodies directed against checkpoint inhibitors
indicated for the treatment of cancers, targeting immune checkpoint modulators is an 
established concept that has resulted in patients deriving t ransformational clinical benefit. 
The unique mechanistic profile of an anti- ICOS agonist antibody  provides an opportunity  
to investigate the antitumor potential of targeting a T cell co -stimulator in combin ation
2018N362439_01 CONFIDENTIA L
207871
26with other immune -targeted agents that regulate key  immune pathway s or immune cell 
populations as well as tumor targeted agents, either in development or already  in clinical 
use. The aim of this approach is to achieve s ynergistic antitumor responses that translate 
into improvement in patient surviva l.
2.3. Benefit/Risk A sses sment
GSK3359609 is being currentl y investigated in a Phase 1 study 204691 with doses 
ranging from 0.001 mg/kg to 3 mg/kg as monotherapy  and from 0.01 mg/kg to 3 mg/kg 
in combination with a PD -1 inhibitor. GSK 3359 609 has been generally well tolerated in 
the 204691 study  andthe majority  of AEs reported in participants receiving monotherapy  
were Grade 1 or Grade 2. More detailed information about the known and expected 
benefits and risks and reasonably  expected AEs is provided in the GSK 3359609 IB [GSK 
Document Number 2017N319717_01]. Risks with tremelimumab monotherap y include, 
but are not limited to: GI  effects (colitis, diarrh ea, enterocoli tis and intestinal 
perforation); endocrine disorders (h ypo and h yperthyroidism, hy pophy sitis and adrenal 
insufficiency );skin effects (rash, and pruritus); elevations in lipase and amylase and 
clinical manifestations of pancreatitis; other gastrointestinal events e.g. ,ulcerative colitis, 
dehy dration, nausea and vomiting; hepatic events including hepatitis, and liver enzy me 
elevations; pneumonitis and ILD; nervous s ystem events including encephalitis, 
peripheral motor and sensory  neuropathies, Guillain -Barre and proximal muscle 
weakness; cy topenias including thrombocy topenia, anemia and neutropenia; infusion-
related reactions, anaph ylaxis, and allergic reactions; renal events including renal failure, 
acute kidney  injury , nephritis, nephrotic sy ndrome, autoimmune nephritis and electrol yte 
abnormalities such as h ypokalemia; a utoimmune diseases including autoimmune arthritis, 
Sjogren ’s syndrome and giant cell temporal arteritis; hy pergl ycemia and diabetes 
mellitus; and py rexia. However, w hile treme limumab has been used extensively  with a 
clearl y defined toxicity  profile, the da ta at the doses and schedule studied in the study  is 
limited. Therefore ,the combination of GSK3359609 and tremelimumab could have an 
unknown tox icity profile. More detailed information about the known and expected 
benefits and risks and reasonably  expected AEs areprovided in the tremelimumab IB
[AstraZeneca , 2017].
2.3.1. Risk A ssessment
The risk assessment and mitigation strategy  for GSK3359609 in combination with 
tremelimumab in this protocol is outlined in Table 1. 
Table 1 Risk A ssessment and Mitigation Strategy
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Immune- related AEsInflammatory AEs such as 
diarrhea/colitis, pneumonitis, 
nephritis, and hepatotoxicity are 
well established as treatment 
emergent AEs with immune -
modulating agents, and are 
consistent with the immune -Participant s with the following 
medical history are ineligible for
this study
oToxicity ( Grade 3) related to 
prior immunotherapy leading 
to study intervention
discontinuation 
2018N362439_01 CONFIDENTIA L
207871
27Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
stimulatory mechanism of action 
of these agents.oActive autoimmune disease 
(refer to Section 5.2)
oSevere hypersensitivity to 
another mAb
Established management 
algori thms for irAEs
Refer to Section 6.6.1 for further 
details on the identification, 
evaluation, and management of 
toxicities with a potential immune 
etiology.
Hypersensitivity reactionRisk for infusion reactions and 
hypersensiti vity is inherent to 
many mAbs [ Brennan ,2010]Participant s with history of 
severe hypersensitivity to 
another mAb or to the 
chemotherapies under 
investigation including any 
ingredient used in the formulation 
are inel igible for this study 
Refer to Section 6.6.2 for further 
details on management of 
infusion reactions.
Severe cytokine release 
syndrome (sCRS)ICOS is a costimulatory 
receptor that can stimulate 
proliferation and activation of T 
cells
GSK3359609 is an ICOS 
agonist that can co -stimulate T 
cellactivation in the context of 
TCR signal.Refer to Section 6.6.2 for further 
details on management of CRS.
Immune complex diseaseImmune complex formation and 
deposition findings in nonclinical 
safety studies (refer to the 
individual IBs)Clinical laboratory safety 
assessments and 
immunogenicity testing
Abbreviations: AE= adverse event; CRS=cytokine release syndrome; ICOS=inducible T cell co-stimulator; 
IB=Investigator ’s brochure; mAb=monoclonal antibody; TCR= T cell receptor
2.3.2. Benefit A ssessment
This is a Phase I/IIopen -label study  of GSK3359609 in combination with tremelimumab
conducted in participants with select advanced solid tumors that are relapsed/refract ory to 
standard therapies. Both GSK3359609 and tremelimumab monotherapies and the 
combination of the two targets have demonstrated preclinical activity ; however, whether 
the combination of GSK3359609 and tremelimumab together clinicall y will have a 
2018N362439_01 CONFIDENTIA L
207871
28greater antitumoral response is unknown. T herefore , any potential beneficial effect for an 
individual participant attributable to combination therap y with GSK3359609 and 
tremelimumab is unknown. 
2.3.3. Overall Benefit: Risk Conclusion
Data from nonclinical models sugge st the combination of anti -ICOS agonist and anti -
CTL A-4 antibodies has the potential for enhanced anti tumor activity  through 
complementary  mechanisms (refer to Section 2.2). M easures are taken to minimize the 
risks to participa nts participating in th isstudy  (e.g., frequent safet y anddisease 
assessments). Therefore, the potential risks identified in association with GSK3359609 as 
a combination therap y with tremelimumab are justified by  the anticipated benefits that 
may be affor ded to participants with relapsed/refractory  solid tumors. The participants in 
this study have exhausted other standard therapy  options resulting in a great unmet 
medical need for alternate therapies. Thus, the risk to these participants is justified when 
weighed against the potential benefits of combination therapy.
3. OBJECTIVES A ND ENDPO INTS
3.1. Part 1: Dose Escalation of GSK3359609 in Combination with 
Tremelimumab
Objectives Endpoints
Primary
Determine safety, tolerability and the
RP2D of GSK3359609 in combination 
with tremelimumab Frequency and severity of DLTs, AEs, 
AESI, SAEs and DLT/ AE/SAEs leading to 
dose modifications/delays/withdrawals; 
changes in laboratory, vital signs, and 
ECG safety assessment parameters
Secondary
 Evaluate clinical activity of G SK3359609 
in combination with tremelimumab ORR, DCR
 Characterize the PK properties of 
GSK3359609 and tremelimumab when 
administered in combination Cmax, Cmin, AUC (0 -t) of GSK3359609 
and tremelimumab as data permit
 Determine immunogenicity of 
GSK3359609 and tremelimumab when 
administered in combination Detection and characterization of ADA 
against GSK3359609 and/or 
tremelimumab
Exploratory
 Evaluate clinical activity of GSK3359609 
in combination with tremelimumab PFS, OS ,TTR, DoR
 Evaluate pharmacodynam icchanges in 
markers of target engagement ,immune 
cell profiles, immune activation and 
function or tumor biology post treatment  Immunophenotyping and functional 
analysis
 Other biomarkers such as gene 
2018N362439_01 CONFIDENTIA L
207871
29Objectives Endpoints
compared to that at screening expression changes, relev ant transcripts, 
TCR diversity, and/or soluble analytes
AEs = adverse events; SAEs = serious adverse events ; DLTs = dose limiting toxicities ;AESI = adverse events of 
special interest; RP2D = recommended phase 2 dose; ORR = overall response rate; DCR = d isease control rate; 
Cmax = m aximum observed concentration ; Cmin = minimum observed concentration; AUC (o -t) = area under the 
concentration -time curve over the dosing interval; ADA = anti -drug antibodies; PFS = progression -free survival; OS = 
overall survival; TTR = time to response; DoR = duration of response; TCR = T cell receptor.
3.2. Part 2: Cohort Expansion of the RP2D Dose Combination vs. 
SOC in R/R HNSCC
Objectives Endpoints
Primary
Evaluate clinical activity of GSK3359609 
in combination with tremelim umab
compared to SOC OS
Secondary
 Further evaluate the clinical activity of 
GSK3359609 in combination with 
tremelimumab compared to SOC ORR, DCR, PFS, TTR, DoR
 Further evaluate the PK properties of 
GSK3359609 and tremelimumab when 
administered in combin ation Cmax, Cmin, AUC (0 -t) of GSK3359609 
and tremelimumab as data permi t
 Further evaluate immunogenicity of 
GSK3359609 and tremelimumab when 
administered in combination ADA incidence 
 Further evaluate the safety and 
tolerability of GSK3359609 and 
tremel imumab when administered in 
combination Frequency and severity of AEs, AESI,
SAEs and AE/SAEs leading to dose 
modifications/delays/withdrawals; 
changes in laboratory, vital signs, and 
ECG safety assessment parameters
Exploratory 
 Examine potential relationships between 
anticancer activity and changes in 
markers of target engagement immune 
cell profiles, immune activation and 
function or tumor biology post treatment 
compared to that at screening Immunophenotyping and functional 
analysis, anticancer activit y parameters
 Other b iomarkers such as gene 
expression changes, relevant transcripts, 
TCR diversity, and/or soluble analytes
 Evaluate other measures of antitumor 
activity Evaluation of tumor growth kinetic 
parameters which may be measured by 
the following methods: including, but not 
limited to, RECIST 1.1, uni-dimensional, 
2018N362439_01 CONFIDENTIA L
207871
30Objectives Endpoints
bi-dimensional, and volumetric tumor 
measurements
 Explore relationship between antitumor 
activity, PK parameters, 
pharmacodynamic activity and other 
participant characteristics Antitumor activity (CR, PR, SD, PD), 
tumor kinetic parameters, PK 
parameters, pharmacodynamic activity, 
and other pa rticipant characteristics as 
data permit
 Examine potential relationships between 
anticancer activity and various 
biomarkers 
 Evaluate potential markers of sensitivity
and/or resistance to the treatment Target expression, immune phenotypes, 
HPV positivity for HNSCC tumors, TCR 
(T cell receptor) sequencing , genetic 
polymorphisms in the target or other 
related gene expression and/or tumor 
mutational burd en
 Evaluate disease and treatment related 
symptoms and impact on function and 
health -related quality of life Health -related quality of life as measured 
by the EORTC -QLQ -C30 and HN35, 
PROMIS -PF, and EQ -5D
 Evaluate participant -reported tolerability  PRO -CTCAE and FACT GP5
OS = overall survival; SOC = standard of care; ORR = overall response rate; DCR = disease control rate; ; PFS = 
progression -free survival; TTR = time to response; Cmax = m aximum observed concentration ; Cmin = minimum 
observed concentration ; AUC ( 0-t) = area under the concentration -time curve over the dosing interval ; DoR = 
duration of response; TCR = T cell receptor; ADA = anti -drug antibodies; AEs = adverse events; SAEs = serious 
adverse events; RECIST = r esponse evaluation criteria in so lid tumors ; PK = pharmacokinetic; EORTC QLQ -C30
and HN35 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire –Core 
30 and head and neck cancer 35 module ; EQ-5D = = EuroQOL Group EQ -5D; FACT GP5 = Functional 
Assessmen t of Cancer Therapy –General Physical Well Being Item 5; PROMIS PF = Patient -Reported Outcome 
Measurement Information System –Physical Function; Impression of Change ; PRO -CTCAE = Patient Reported 
Outcomes –Common Terminology Criteria for AEs
4. STUDY DESI GN
4.1. Overall Design
This is a Phase I/II, open -label, 2 -part study  of GSK3359609 in combination with 
tremelimumab. As illustrated in Figure 1in Section 1.2, Part 1 is dose escalation and will 
enroll participants with advanced, selected solid tumors and Part 2 is randomized 
expansion and will enroll participants with R/RHNSCC who have progressed after 
receiving at least 1 platinum -based chemotherap y and at least 1 anti -PD-1/PD-L1
therap y, whether in comb ination or separately .
Study  intervention will be defined as treatment with GSK3359609 and tremelimumab, 
given in combination. In Part 2 participants will be randomized at a ratio of 2:1 to either 
the study  intervention or SOC , respectivel y.
The study  is comprised of 3 periods: screening (assessments up to 30 prior to first dose ), 
treatment (until disease progression, unacceptable toxicity  or death) , and follow -up. The 
total duration of study  participation begins with the signing of the informed consent for m 
2018N362439_01 CONFIDENTIA L
207871
31(ICF) through the final protocol -defined follow -up assessment for survival and is 
estimated to be up to 4 years (~2 years on treatment and ~2 years in survival follow -up); 
however, participants deriving benefit may  be on study  intervention bey ond 2 y ears. 
4.1.1. Part 1: Dose Escalation of Tremelimumab and GSK3359609
In Part 1 dose escalation, eligible participants will receive GSK3359609 in combination 
with tremelimumab at a defined dosing schedule (see Section 6.1). Part 1 will ini tiate 
with 8 mg GSK3359609 and 75 mg tremelimumab (termed dose level [DL] 1) , the 
planned lowest doses for each agent. The highest planned doses are 80 mg GSK3359609 
and 225 mg tremelimumab (termed DL6) . GSK3359609 will be administered every  3 
weeks and tr emelimumab will be administered every  3 weeks for 6 doses, followed b y 
every  12 weeks. Tremelimumab is to be administered first as an IV infusion over 60 
minutes. GSK3359609 will be administered as a 30- minute IV infusion beginning at least 
1 hour and no m ore than 2 hours following the end of the tremelimumab infusion. As 
shown in Figure 1, dosing will begin at DL1 and continue using zone -based dose 
escalation rules whereb y each zone must be cleared for safety  prior to opening the next 
zone of DL s. 
DL1 and DL2 will enroll one participant each to obtain preliminary  safety  data that will 
inform the toxicity  probability model; these DLs will be expanded to enroll at least two 
additional participants if a Grade 2 or above toxicity  attributable to either agent or a Dose 
Limiting Toxicity  (DLT) is observed. DL3, DL4, DL 5, and DL6 will enroll as full safet y 
cohorts, i.e. ,3 to 9 participants will be enroll ed for each DLguided b y the bivariate CRM 
model [ Neuenschwander , 2008 ; Neuenschwander , 2014 ] until the MTD or MAD dose 
combinations are determined. Unplanned DLswithin the range of the planned doses of 
each agent may  be investigated to support the identificatio n of optimal doses to 
administer in combination. Additionally , doses lower than planned of either agent may  be 
investigated. If a participant withdraws from the study  before the completion of the 28 -
day DLT evaluation period for reasons other than DL T, the n the participant may be 
replaced.
In the absence of DLTs, the dose escalation rules are deterministic. Participant allocation 
in this stage is determined entirely b y the preferred dose order. If DLTs are observed, a 
bivariate CRM model will be used to guide dose recommendations. This model will 
provide posterior probability  of observing a DLT at all dose combination levels based on 
emerging DLT data and prior information. In addition to the zone -based escalation rule, 
dose escalation will follow two rules. First, if the next preferred DLhas excessive risk of 
toxicity , then that DLcannot be assigned. Instead, a new participant will be assigned to 
the highest preferred DLwithout such risk of toxicity . It is noted that the recommended 
DLshould not be in a zone if “lower” zones have not been “cleared ”. Second, if one DL
emerges as having a much higher chance of having a DLT rate in the target toxicity  
interval (DLT rate between 16% and 33%), that DLwill be opened for enrol lment. This 
latter situation occurs rarely  with the sample size anticipated in this study . Thus, the most 
common use of the model is to eliminate allocation to potentially  unsafe doses in 
combination .Details of the bivariate CRM method areprovided in Appendix 10.
Dose recommend ations based on the bivariate CRM analy sis will be used as guidance for 
the data review team . To ensure safet y of participants, additional participants may be 
2018N362439_01 CONFIDENTIA L
207871
32enroll ed at a current DLat the discretion of the data review team, even though a hig her 
dose is recommended b y CRM analy sis.
PK/pharmacod ynamic cohort(s) may  be initiated at any  DL(s), once safet y is cleared, 
with mandatory  paired tumor sample collections to inform on dose selection for Part 2 of 
the study . In DL s enrolling more than 1 pa rticipant, treatment will be administered at 
least three day s apart between the first two participants enrolled; the third and any  
subsequent participants will be administered treatment at a minimum of 24 hours apart. 
This staggered approach allows for an initial assessment of safet y in a participant accrued 
to a dose level before initiating the next participant’s treatment. 
A single dose combination will be selected as the recommended Phase 2 dose ( RP2D)
and carried forward from Part 1 into Part 2 . The totality  of data, including 
safet y/tolerability , PK, pharmacod ynamic , and efficacy  will be used to determine whether 
to proceed to Part 2 and which dose combination will be chosen as the RP2D.
At the time of each dose escalation decision for which the bivari ate CRM model would 
be implemented , the Fixed and Adaptive Clinical Trial Simulator (FACTSTMversion 6.1 
or above )will be used . The recommended dose will be the dose with the highest posterior 
probability  of lying in the target toxicity interval with the additional requirement that the 
sum of the posterior probabilities of the DLT rate in the excessive toxicity  or 
unacceptable toxicity range is less than 25 %(see details in Section 10.10.1 ).
4.1.1.1. Dose Limiting Toxicity
The severit y of all toxicities will be graded using the NCI-CTCAE ( version 5.0) [NCI, 
2017]. The DLT observation period is 28 day s in length and begins on the day  
GSK3359609 and tremelimumab are first administrated to the participant.
A DLT is defined as an AE that meets at least one of the criteria listed in Table 2 and is 
considered b y the Investigator to be clinicall y relevant and attributed (probably, or 
possibly ) to the study  intervention during the 28-d ayDLT observation period. An AE 
considered related to the underly ing disease under study  is not defined as a DL T.
2018N362439_01 CONFIDENTIA L
207871
33Table 2 Dose -Limiting Toxicity  Criteria
Toxicity DLT Definition
Hematologic Febrile neutropenia 
Grade 4 neutropenia of >7 days in duration or requiring G- CSF
Grade 4 anemia 
Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia
Non-
hematologicGrade 4 toxicity
Grade 3 pneumonitis 
Any ≥ Grade 2 pneumonitis that does not resolve to ≤ Grade 1 within 3 days 
of the initiation of maximal supportive care
Grade 3 toxicity that does not resolve to Grade 1 or baseline within 3 days 
despite optimal supportive carea
Any Grade 2 ocular toxicit y requiring systemic steroids, or any ≥ Grade 3 
ocular toxicity
Other Any other toxicity considered to be dose -limiting which in the judgment of the 
Investigator and Medical Monitor that occurs within or beyond four weeks will 
be considered in the selecti on of the dose to recommend for expansion 
cohorts
a. Suggested toxicity management guidelines are described in Section 6.6.1 and may include systemic 
corticosteroids for immune -related toxicities; if systemic cort icosteroids use delays administration of the second 
dose (s)of study intervention and the event does not otherwise meet the DLT criteria for non -hematologic toxicity, 
the dose delay will not be considered a DLT.
If a participant experiences a DLT during the DLT observation period, the participant
may resume dosing at the same or lower dose level provided the toxicity did not meet 
study  treatment discontinuation criteria and following approval by  the Sponsor.
4.1.1.2. Non-Limiting Toxicities
The following toxicities have been deemed to be non -limiting for the purposes of this 
study . These toxicities will not be taken into account for dose escalation decisions unless, 
in the opinion of the investigator and the Medical Monitor, they  represent a DL T.
Grade 3 and Grade 4 clinically  asymptomatic laboratory  abnormalities (e.g., 
amylase or lipase)
Grade 3 endocrine disorder (th yroid, pituitary , and/or adrenal insufficiency ) that is 
managed with or without sy stemic corticosteroid therapy  and/or hormone 
replacement therap y and the participant is asymptomatic
Grade 3 nausea, vomiting, or fatigue that resolves to ≤Grade 1 within 7 days with 
optimal supportive care
Grade 3 and Grade 4 infusion- related reactions (I RRs) in participants not 
receiving proph ylaxis for I RRs 
Grade 3 inflammatory  reaction attributed to a local antitumor response (e .g., 
inflammatory reaction at sites of metastatic disease, ly mph nodes, etc)
2018N362439_01 CONFIDENTIA L
207871
344.1.1.3. Dose Escalation Decisions and Selection of Part 2 Dose
A data review team , consisting (at a minimum) of the participating Investigator (s), 
Medical Monitor, pharmacokineticist, and statistician, will be responsible for determining 
whether dose escalation during Part 1 should continue as planned and for determining the 
Part 2 dose. Prior to the dose escalation /selection decision, the data review team will
review available relevant data on all AEs including non- DLTs , laboratory  assessments 
and other safet y evaluations, as well as available PK and pharmacod ynamic data. The 
dose escalation/selection decisions and rationale will be documented in writing with 
copies maintained at each study  site and in the master study  files at GlaxoSmithKline 
(GSK). Further details may  be found in the Dose Escalation and Selection Plan. 
4.1.2. Part 2: Cohort Expansion of the RP2D Dose Combination vs. SOC
In Part 2, eligible participants will be randomized 2:1 to open -label GSK3359609 plus 
tremelimumab at the RP2D (n 60) or a SOC single -agent therap y of the Investigator’s 
choice to include paclitaxel, docetaxel or cetuximab (n 30) . See Section 6.1for detai ls. 
Part 2 will employ  a Bayesian anal ysis to estimate thepredictive probability  of observing 
a significant improvement of
OS in a hy pothetical future Phase 3 trial enroll ing345
participants ( 230 participants for investigational RP2D dose combination and 115 
participants for SOC ), based on the treatment effect difference in OS between the two 
arms in Part 2 .
4.2. Scientific Rationale for Study  Design
The combination of GSK3 359609 and tremelimumab was selected based on
complementary mechanisms of action and anticipated robust antitumor activity .
Eligibility  criteria require that participants have disease that has progressed after standard 
therapies or are otherwise unsuitable for standard therapies, and the criteria are intended 
to minimize the risk of adverse reactions to treatment with immunotherapies .These 
participants have an unmet medical need .
In Part 1, dose escalation will be performed using bivariate CRM model to optimize the 
allocation of participants to dose combinations with a 16 -33% DLT frequency .The DLT 
criteria are based on t ypical oncology  rules with additional modifications for toxicities 
expected for the individual agents in the combination .
In Part 2, the cohort expansion design provides efficiencies in the evaluation of 
anticancer activity  of the investigational dose combination when compared with the SOC .
The GSK3359609/treme limumab combination regimen will subsequently  graduat e to 
separate Phase 3confirmatory  studies if the prespecified probability  threshold is met at 
the final anal yses.
2018N362439_01 CONFIDENTIA L
207871
354.3. Justification for Dose
4.3.1. GSK3359609 Dose Rationale
Preliminary PK data from study  204691 was utilized to develop a population PK model 
and estimate median steady -state peak and trough exposures at different fixed doses. The 
8, 24, 80, and 240 mg dose corresponds to an approximate 0.1, 0.3, 1, and 3 mg/kg dose 
assuming median bod y weight of 80 kg as described in Section 4.3.1.2 .
The functional effect of GSK3359609 has been characterized in several in vitro
experiments y ielding diff erent activity  coefficients depending on cell t ype, co -stimulation 
status, and cy tokines analy sed. The ICOS receptor occupancy  (RO) based on CD 4+or 
CD8+T cell s at an y given sy stemic exposure of GSK3359609 can be predicted by  
employ ing the in vitro potenc y values generated from different binding/activation assays 
in the range of 0.09 to 4.14 µg/mL  as listed in Table 3.
Sufficiently  high CD4+ RO is expected at peak exposures (89% to >99% RO) as well as 
at trough exposures (69% to > 99% RO) at steady -state with a GSK3359609 dose of
80mg. 
Collectively , based on the safet y and exposure data from the Phase 1 stud y and the 
predicted target engagement, 8, 24, and 80 mg doses are proposed to be evaluated in 
combination with tremelimumab i n this study . No drug-drug interaction related changes 
are expected in GSK3359609 PK with tremelimumab co -administration. Additionally , 
doses lower than the planned lowest 8 mg dose may  be investigated based on emerging 
data.
Table 3 Projected CD4+Receptor Occupancy from Population PK Predicted 
Median Steady -state Peak and Trough Exposures of GSK3359609 
based on in vitro potency  estimates .
Dose
(mg)Cmax
(g/mL)C
(g/mL)RO based on K d
[0.09  g/mL]
(%)RO based on T -
cell binding 
[0.989 g/mL] (%)RO based on IFN 
release (bound) 
[4.14  g/mL] (%)
At 
CmaxAt CAt 
CmaxAt CAt 
CmaxAt C
8 3.47 0.919 97.5 91.1 77.8 48.2 45.6 18.2
24 10.3 2.73 99.1 96.8 91.3 73.4 71.4 39.8
80 34.7 9.23 99.7 99.0 97.2 90.3 89.3 69.0
240 103.6 27.3 99.9 99.7 99.1 96.5 96.2 86.8
Refer to GSK3359609 IB [GSK Document Number 2017N319717 _01] for further 
details. 
4.3.1.1. GSK3359609 Dosing Frequency
The sy stemic half -life of GSK3359609 is approximately  25 day s based on the 
preliminary  population PK anal ysis of exposure data from ongoing study 204691. The 
existing GSK3359609 Q3W regimen in the ongoing clinical study  is also consistent with 
2018N362439_01 CONFIDENTIA L
207871
36the Q3W dosing regimen ty pical with IgG4 based monoclonal antibody  therapies. Thus, 
GSK33596 09 will be dosed Q3W in combination with tremelimumab. 
4.3.1.2. GSK3359609 Rationale for Fixed Dose
Therapeutic monoclonal antibodies are often dosed based on body -size due to the concept 
that this reduces inter -participant variability  in drug exposure. However, b ody-weight 
dependency  of PK parameters does not alway s explain the observed variability  in the 
exposure of monoclonal antibodies [ Zhao , 2017]. The advantage of bod y-weight based 
versus fixed dosing in this study  was evaluated through p opulation PK modelling and 
simulation efforts. A preliminary  population PK model was developed from monotherapy  
dose escalation (data up to doses of 1 mg/kg; n 19 participants). 
Simulations were performed by considering body weight distribution similar to that 
observed in the preliminary  dataset. At the 5thpercentile of body  weight (40 47 kg), there 
was a 70 -100% increase in median steady -state AUC(0 -); GSK3359609 exposures 
higher than these increases have been evaluated in the Phase 1 study  204691 with the 
3mg/kg dose regimen. At the 95thpercentile of body weight (107 118 kg), there was a 
23-32% decrease in median steady -state AUC(0 -) as compared to the median 80 kg 
exposure providing adequate RO with the minimal lowering of exposure. A similar 
outcom e is expected for stead y-state C maxand trough concentrations between body  
weight -based and fixed dosing. 
Overall, these preliminary  population PK simulations indicate that using fixed dosing 
would result in a similar range of exposures as that of body  weight-based dosing. Also, 
fixed dosing offers the advantage of reduced dosing errors, reduced drug wastage, 
shortened preparation time, and improve d ease of administration. Thus, switching to a 
fixed dose based on a reference bod y weight of 80 kg is reasona ble and appropriate.
4.3.2. Tremelimumab Dose Rationale
Tremelimumab is an Ig G2 mAb against human CTL A-4. In clinical studies, 
Tremelimumab exhibited dose -proportional PK following IV infusion following single 
IV doses of 0.1 to 15 mg/kg.Refer to tremelimumab IB [AstraZeneca , 2017] for further 
details.
The current study  will administer tremelimumab as a flat dose regimen of 75 mg and 
225 mg approximating the 1 mg/kg and 3 mg/kg regimens already  evaluated in multiple 
tremelimumab mono- and combination therap y studies. Tremelimumab has also been 
evaluated at a 10 mg/kg dose in combination with durvalumab, an anti -PD-L1 antibod y, 
where tremelimumab was administered as 10 mg/kg Q4W for 6 cy cles followed by  
10mg/kg Q12W [ Antonia , 2016]. The dosing regimen for the proposed doses in this 
study  is Q3W for the first six doses and Q12W thereafter. This Q3W dosing frequency  
for tremelimumab matches the GSK3359609 Q3W dosing frequency  providing greater 
patient convenience. T he overall t remelimumab systemic exposures with the highest 
proposed 225 mg regimen (225 mg Q3W for 6 cycles followed b y 225 mg Q12W) in the 
current stud y are expected to be well below the exposures observed with 10 mg/kg 
regimen (10 mg/kg Q4W for 6 cy clesfollowed b y 10mg/kg Q12W) studied as 
2018N362439_01 CONFIDENTIA L
207871
37monotherap y and combination therap y. No drug -drug interaction related changes are 
expected in GSK3359609 PK with tremelimumab co- administration.
4.4. End of Study  Definition
The end of the stud y is defined as the date of the completion of the last part icipant’s 
required follow -up visit or contact after stud y intervention/SOC discontinuation, death, or 
final visit or contact following discontinuation for any reason.
4.4.1. Participant Completion
For Part 1 , dose escalation ,partici pants will be considered as having comple tedthe study  
ifthey:
complete screening assessments, and receive at least two doses of study  
intervention or receive one dose but experience a DL T, and are observed during 
the 28- dayDLT observation period, and the follow -up visit for safet y(if 
required), or 
complete screening assessments and have died while receiving stud y intervention
or during the follow -up period for safety
For Part 2 , the dose e xpansion partof the study , participants will be considered as having 
comple tedthe study  ifthey:
complete the screening assessments, and receive at least one dose of stud y 
intervention or SOC , and discontinue study  intervention or SOC for reasons other 
than lost to follow -up or non -compliance , and complete the follow -up visit for 
safet y (if required), and are followed until death, or
complete screening assessments and have died while receiving stud y intervention
or SOC or during the post -study  follow -up period for safety
Document the cause of death in the eCRF.
A part icipant will be considered to have withdrawn from the study  if the participant has 
not died and is lost to follow- up, has withdrawn consent, at the investigator’s discretion is 
no longer being followed or if the study  is closed/terminated.
5. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrol lment criteria, also 
known as protocol waivers or exemptions, is not permitted.
2018N362439_01 CONFIDENTIA L
207871
385.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following crite ria 
apply :
1. Capable of giving signed informed consent/assent which includes compliance with 
the requirements and restrictions listed in the ICF and in this protocol.
2.Male or female, aged 18 y ears or older.
3.Body weight ≥ 30 kg.
4.Histological or cy tological documentation of an invasive malignancy  that was 
diagnosed as locall y advanced/metastatic or relapsed/refractory and is of one of the 
following tumor t ypes: 
a.Part 1:
i.Cutaneous Melanoma
ii.Head and Neck Squamous Cell Carcinoma (HNSCC )(oral cavity , 
larynx, orophary nx, hypophary nx, nasal cavit y/paranasal sinuses)
iii.Non-Small Cell L ung Cancer (Squamous and Non -squamous)
iv.Urothelial carcinoma of the upper and lower urinary  tract
v. Clear Cell Renal Carcinoma
vi.Castrate Resistant Prostate Adenocarcinoma 
b.Part 2:
Head and Neck Squamous Cell Carcinoma (oral cavity , lary nx, phary nx, 
paranasal sinu ses)
5.Part 1 only : Disease that has progressed after standard therapy  for the specific tumor 
type, or for which standard therap y has proven to be ineffective, intolerable, or is 
considered inappropriate, or if no further standard therap y exists , or where standard 
therap y is refused . May be anti-PD-1/anti -PD-L1experienced or naïve. 
6.Part 2 only : Disease that has progressed after receiving pla tinum -based chemotherap y 
(unless medicall y contraindicated or discontinued due to toxicity ) and anti-PD-1/anti -
PD-L1 therapy (in combination or as separate lines of therap y in either sequence).
7.Measurable disease per response evaluation criteria in solid tumors (RECI ST)version 
1.1 guidelines . Palpable lesions that are not measurable b y radiographic or 
photographic evaluations may  not be utilized as the only  measurable lesion. Any  
measurable lesion biopsied at Screening cannot be followed as a target/index lesion 
unless agreed upon b y GSK.
8.Eastern Cooperative Oncology  Group (ECOG) Performance Status (PS) score of 0 or 
1.
9.Adequate organ function as defined in Table 4.
2018N362439_01 CONFIDENTIA L
207871
39Table 4 Definitions of Adequate Organ Func tion
System Laboratory Values
Hematologica
Absolute neutrophil count 1.5x109/L
Absolute lymphocyte count 800/mm3
Hemoglobin 9 g/dL
Platelets 100x109/L
Hepatic
Albumin 2.5 g/dL
ALT 2.5xUpper Limit of Normal ( ULN)or 
≤5xULN for participants wit h 
documented liver metastases
Total bilirubin Bilirubin ≤1.5xULN (isolated bilirubin 
≤1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin 
<35%)
Renal
Calculated CrClb30mL/min
Cardiac
Ejection fractionc ≥50%
a. Participants may be transfused or receive growth factor treatment to meet minimum hematologic values up to 7 
days prior to determining eligibility
b. Calculated CrCl is required to be calculated using one of the formulas described in Appendix 8 .Either formula is 
acceptable and must be used consistently for each participant throughout the study.
c. Multigated acquisition scan (MUGA) is acceptable if ECHO is not available ; if measured with ECHO or MUGA, the 
same modality must be used for all subs equent evaluations (refer to Section 8.2.5 ). 
10.A female participant is eligible to participate if she is not pregnant (see Appendix 4), 
not breastfeeding, and at least one of the following conditions apply :
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 4; 
or,
b.A WOCBP who agrees to follow the contraceptive guidance in Appendix 4
while receiving stud y intervention and for at least 1 80 day s after the last dose 
of study  intervention. Note: If the participant is randomized to the SOC
regimen only , then the duration of contraception after the last dose of SOC
should be based on the package insert and Institutional guidelines . 
11.A male participant mu st agree to use a highl y effective contraception as detailed in 
Appendix 4of this protocol while receiving stud y intervention and for at least 180 
days after the last dose of study  intervention and refrain from donating sperm during 
this period . Note: If the participant is randomized to the SOC regimen onl y, then the 
duration of contraception after the last dose of SOC should be based on the package 
insert and Institutional guidelines.
12.Agree to collection of tumor tissue:
2018N362439_01 CONFIDENTIA L
207871
40a.Part 1 and P art 2: Archival tumor tissue collected any  time from the initial 
diagnosis of invasive malignancy ; a fresh tumor biopsy  will be required if 
archival specimen is unavailable prior to first dose .
b.Part 1 PK/pharmacod ynamic cohort (s): Archival tissue as noted in point (a)
above. Paired tumor biopsies: t umor tissue collected an y time after completion 
of dosing of the last therapy  and prior to first dose and an on- treatment biopsy .
c.Part 2: A minimum of 15 participant s from each arm will be required to 
provide pa ired tumor biopsies (in addition to the archival tissues as noted in 
point (a) above): tumor tissue collected an y time after completion of dosing of 
the last therap y and prior to first dose andan on -treatment biopsy .
5.2. Exclusion Criteria
Participants are ex cluded from the study  if any  of the following criteria apply :
1. Received prior treatment with the following therapies; calculation is based on date of 
last therap y to date of first dose of study  intervention or SOC :
a.CTL A-4(including tremelimumab) or ICOS -directed therapies at an y time .
b. ≥4 lines of prior anticancer treatment:
i.In participants that relapse or progress within 1 y ear from the 
beginning of adjuvant or concurrent therapy, the adjuvant/concurrent 
therap y is considered first line therap y
c.Systemic anticancer therapy  or investigati onal therapy  within 30 day s, or 5
half-lives, whichever is shorter; at least 14 day s must have elapsed between 
the date of the last prior therap y to the date of first dose of study  intervention
or SOC .
2.Prior radiation therap y: permissible if at least one n on-irradiated measurable lesion is 
available for assessment per RECI ST v1.1 or if a solitary  measurable lesion was 
irradiated, objective progression is documented . At least 14 day s must have elapses 
between the date of the last dosage of radiation and the first dose of stud y 
intervention/SOC .
3.Invasive malignancy  or history  of invasive malignancy  other than disease under study  
within the last two y ears, except as noted below:
a.Any other invasive malignancy  for which the participant was definitively  
treated, has been disease -free for ≤2 years and in the opinion of the 
Investigator and Medical Monitor will not affect the evaluation of the effects 
of the study  intervention or SOC on the currentl y targeted malignancy , may be 
included in this clinical study .
2018N362439_01 CONFIDENTIA L
207871
41b.Curatively  treated non- melanoma skin cancer or successfull y treated in- situ 
carcinoma
4.Toxicity  from previous anticancer treatment that includes:
a.≥Grade 3 toxicity  considered related to prior immunotherapy  and that led to 
treatment discontinuation .
b.Toxicity  related to prior treatme nt that has not resolved to ≤Grade 1 (except 
alopecia, vitiligo , hearing loss, endocrinopathy managed with replacement 
therap y, and peripheral neuropath y which must be ≤Grade 2) .
5.Central nervous s ystem (CNS) metastases, with the following exception: Partic ipants 
with previously  treated CNS metastases who are clinically  stable and had no 
requirement for steroids during at least 14 day s prior to first dose of study  
intervention or SOC . 
Note : Participant s with carcinomatous meningitis or leptomeningeal spread are 
excluded regardless of clinical stability .
6.Major surgery  28 day s of first dose of study  intervention or SOC .
Note: Tracheostomy  is not considered major surgery .
7.Autoimmune disease (current or history ) or sy ndrome that required s ystemic 
treatment wit hin the past 2 y ears. Replacement therapies which include physiological 
doses of corticosteroids for treatment of endocrinopathies (i.e., adrenal insufficiency ) 
are not considered s ystemic treatments .
8.Recent history  (within 24 weeks) of gastrointestinal ob struction that required surgery , 
acute diverticulitis, inflammatory  bowel disease, or intra -abdominal abscess.
9.Receiving s ystemic steroids (≥10mg oral prednisone or equivalent) or other 
immunosuppressive agents within 7 day s prior to first dose of study  intervention or 
SOC .
Note: Steroids as premedication for hy persensitivity  reactions (e .g., computed 
tomograph y [CT] scan premedication) are permitted. 
10.Prior allogeneic/autologous bone marrow or solid organ transplantation .
11.Received live -virus vaccine within 30 days from start of study  intervention or SOC .
Note: Seasonal influenza vaccines for injection are generally  killed virus vaccines 
and are allowed; however, intranasal influenza vaccines (for example , FluMist ™) 
are live attenuated vaccines and are not allowed.
12.Current or history  of idiopathic pulmonary  fibrosis, pneumonitis (for past, participant 
is excluded if steroids were required), in terstitial lung disease or organizing 
pneumonia
2018N362439_01 CONFIDENTIA L
207871
42Note: Post-radiation changes in the lung and/or asy mptomatic radiation -induced 
pneumonitis not requiring treatment may  be permitted if agreed upon by the 
Investigator and Medical Monitor .
13.Recent history  (with in 24 weeks) of uncontrolled, sy mptomatic ascites, pleural or 
pericardial effusions.
14.History  or evidence of cardiac abnormalities within the 24 weeks prior to enroll ment 
which include:
a.Serious uncontrolled cardiac arrhy thmia or clinically  significant 
elect rocardiogram abnormalities including second degree (Ty pe II) or third 
degree atrioventricular block.
b.Cardiomy opath y, myocardial infarction, acute coronary s yndromes (including 
unstable angina pectoris), coronary  angioplasty , stenting, or by pass grafting .
c.Symptomatic pericarditis .
15.Current unstable liver or biliary  disease per Investigator assessment defined by  the 
presence of ascites, encephalopathy , coagulopathy , hypoalbuminemia, esophageal or 
gastric varices, persistent jaundice, or cirrhosis. NOTE: Stable chronic liver disease 
(including Gilbert ’s syndrome or as ymptomatic gallstones) is acceptable .
16.Active infection requiring s ystemic therapy .
17.Known human immunodeficiency  virus infection; positive test for hepatitis B active 
infection (presence of hepatitis B surface antigen) or hepatitis C active infection; refer 
toTable 16 for additional details .
18.History  of severe hy persensitivity  to monoclonal antibodies , the Standard of Care 
agents, including an y ingredient used in the formulation, based on which treatment 
the participant is to receive .
19.Any serious and/or unstable pre -existing medical (aside from malignancy ), 
psychiatric disorder, or other conditions that could interfere with participant’s safet y, 
obtaining informed consent or c ompliance to the study  procedures, in the opinion of 
the Investigator .
20.For participants receiving SOC : Requires therapy with a medication that may  alter the 
PK of the SOC agent (e.g., strong inducers or inhibitors of CYP3A4 for participants 
receiving docetaxel or paclitaxel ) during the stud y treatment period. Please refer to 
the package insert for the agent the participant is to receive. 
21.For participants receiving SOC: Any  contraindication, per the package insert and/or 
Institutional guidelines, to the treatment the participant is to receive. 
2018N362439_01 CONFIDENTIA L
207871
435.3. Lifest yle Considerations
Participants should refrain from donating blood while participating in this study .
Participants should maintain a normal diet unless modifications are required to manage 
an AE such as diarrhea , nausea, or vomiting. For participants receiving SOC, the 
Investigator should refer to the applicable package insert and/or Institutional guidelines 
for foods to avoid during the study  treatment period (e.g., grapefruit, star fruit and 
pomegranate are kno wn CYP3A4 inhibitors and should not be consumed while receiving 
docetaxel or paclitaxel ). 
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are never subsequently  assigned a randomization numb er.A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure 
participants to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory au thorities. Minimal 
information includes demograph y, screen failure details, eligibility  criteria, and any  
SAE s.
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened. Rescreened participants must be assigned a new unique participant 
number that is different from the initial number.
6. STUDY INTERVENTION
6.1. Stud y Intervention( s)Administered
GSK3359609 and tremelimumab will be provided to sites by  the study  Sponsor . 
Investigator’s choice of SOC in Part 2 ( paclitaxel , docetaxel or cetuximab) will be 
provided b y the site per standard of care.
The route of administration for all agents is IV, thus they  should be administered to 
participants at each study site under medical supervision of an Investigator or designe e
(see Table 5).
Tremelimumab is to be administered first as an IV infusion over 60 minutes . 
GSK3359609 will be administered as a 30 -minute IV infusion beginning at least 1 hour 
and no more than 2 hours following the end of the tremelimumab infusion. Infusion time 
of each may  be adjusted based on infusion-related reactions.
Standard of care agents should be administered as per local and Institutional guidelines
(Table 6 ).Participants may receive necessary premedication regimens according to the 
approved product label or standard practice (i.e., corticosteroids , antihistamines, etc ).
2018N362439_01 CONFIDENTIA L
207871
44Table 5 Description and A dministration of Study  Interventions
Study Intervention
Product Name: GSK3 359609 Tremelimumab
Product 
DescriptionHumanized anti -ICOS agonist IgG4 
mAbHumanized anti -CTLA -4IgG2 mAb
Dosage form 
/strength:10mg/mL solution 20mg/mL solution
Planned dosage 
level(s):Part 1 : Dose escalation GSK3359609/tremelimumab: 8 mg/75 mg; 
8mg/225 mg; 24 mg/75 mg; 24 mg/225 mg; 80 mg/75 mg; 80 mg/225 mg
Part 2 : RP2D determined from Part 1
Route of 
Administration IV infusion IV infusion
Dosing 
instructions/
Frequency:Administer diluted product/ Q3W Administer diluted product/ Q3W for 6 
doses then Q12W thereafter
Manufacturer GSK MedImmune
Table 6 Standard of Care A gents
Product Name : Docetaxel Paclitaxel Cetuximab
DescriptionMicrotubule stabilizer/
small moleculeMicrotubule stabilizer/
small moleculeRecombina nt, 
human/mouse 
chimeric anti -EGFR 
mAb
Dosage form/strengthRefer to package 
insertRefer to package 
insertRefer to package 
insert
Dosage /frequency75mg/m2
administered once 
every 3 weeks80mg/m2
administered once 
weeklyAdminister a l oading 
dose of 4 00mg/m2
followed by 
250mg/m2once 
weekly
Route of 
administrationIV infusion IV infusion IV infusion
6.2. Preparation/Handling/Storage/A ccountability
Refer to the Study  Reference Manual (SRM) for instructions on the preparation of 
investigational study  interventions (both GSK3359609 and tremelimumab) .Standard of 
Care agents should be prepared and handled per local and Institutional guidelines.
The Investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit f or each study  intervention received and an y 
discrepancies are reported and resolved before use of the study  intervention.
2018N362439_01 CONFIDENTIA L
207871
45Only  participants enroll ed in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with 
access limited to the Investigator and authorized site staff.
The Investigator , institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance ( i.e., receipt, reconciliation, and final disposition records).
Further guidanc e and information for the final disposition of unused study  
intervention are provided in the SRM .
Under normal conditions of handling and administration, study  intervention is not 
expected to pose significant safety risks to site staff . Take adequate prec autions to 
avoid direct ey e or skin contact and the generation of aerosols or mists. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or 
GSK study  contact.
A Material Safety Data Sheet (MSDS)/equivalent document de scribing occupational 
hazards and recommended handling precautions either will be provided to the 
Investigator, where this is required b y local laws, or is available upon request from 
GSK.
6.3. Measures to Minimize Bias: Randomization and Blinding
In Part 2 of the study , once determined to be eligible for the study , all participants will be 
centrall y randomized using an Interactive Voice/Web Response Sy stem (IVRS/I WRS) . 
Before the stud y is initiated, the telephone number and call -in directions for the IVRS
and/or the log in information and directions for the I WRS will be provided to each site. 
This is an open -label study ; however, participants will be randomized to study  
intervention or SOC in Part 2 of the stud yusing an IVRS/I WRS to reduce potential bias.
6.4. Stud y Intervention Compliance
Study  intervention swill be intravenousl y administered to participants at the site . 
Administration will be documented in the source documents and reported in the CRF.
6.5. Concomitant Therapy
Participant s will be instructed to inform t he Investigator prior to starting any  new 
medications from the screening visit until discontinuation of study  intervention. Any 
permitted concomitant medication(s), including non- prescription medication(s) and 
herbal product(s), taken during the stud y will be recorded in the eCRF. The minimum 
requirement for reporting is drug name, dose, dates of administration, and the reason for 
medication.
Questions regarding concomitant medications must be directed to GSK for clarification.
2018N362439_01 CONFIDENTIA L
207871
46If changes are made to the list of permitted/prohibited medications in the future , formal 
documentation will be provided by  GSK and stored in the study  file. Any such changes 
will be communicated to the investigative sites byletter.
For participants randomized to SOC, r efer to the dr ug interaction information in the 
product package inserts for precautions and prohibited concomitant medications related 
to the SOC chosen by  the I nvestigator. 
6.5.1. Permitted Medications and Non -Drug Therapies
All participant s should receive full supportive ca re during the treatment course of the 
study , including transfusion of blood and blood products, and treatment with antibiotics, 
antiemetics, antidiarrheals, and analgesics, as appropriate. Seasonal flu vaccine is 
permitted as an injection only , i.e., intra -nasal flu vaccine is not permitted . Elective 
palliative surgery  or radiation may  be permitted on a case -by-case basis in consultation 
with GSK Medical Monitor.
The following medications are permitted as indicated:
a.Bisphosphonates and receptor activator of nuclear factor- kappaB ligand (RANKL) 
inhibitors (e.g., denosumab): Participant s are required to have been on a stable dose 
for at least 4 weeks prior to receiving first dose of study  intervention. Prophy lactic 
use in participant s without evidence or histo ry of bone metastasis is not permitted, 
except for the treatment of osteoporosis.
b. Growth factors: Initiation of growth factors is not permitted during the first 4 weeks 
of study  intervention , unless clinically  indicated for toxicity  management and agreed 
upon by  the Investigator and the GSK Medical Monitor.
c.Steroids: Participant s with pre- existing conditions requiring steroids are permitted to 
continue taking up to a maximum of 10 mg of prednisone or equivalent provided the 
participant has been on a stable dose for at least 28 day s before first dose of study  
intervention; see exclusion criteria in Section 5.2forfurther requirements. Steroids 
used for premedication of SOC and hy persensitivity  reactions (e.g., CT scan 
premedication) are permitted .
d.Treatment with cannab inoids prescribed b y a Phy sician are permitted.
6.5.2. Prohibited Medications and Non- Drug Therapies
The following medications are prohibited before the first dose of study  intervention /SOC
(seeSection 5.2for specific time requirements) and during the stud y treatment period :
a.Anticancer therapies other than those referred to as study  intervention that include ,
but are not limited to chemotherap y, immunotherapy, biologic therap y, hormonal 
therap y (other than ph ysi ologic replacement), surgery , and radiation therapy  (other 
than palliative intervention as described in Section 6.5.1)
b.Any investigational drug(s) other than those referred to a s study  intervention
c.Live vaccines such as intra-nasal flu vaccine (s ee exclusion criteria in Section 5.2for 
further details).
2018N362439_01 CONFIDENTIA L
207871
47d.For participants receiving SOC, an y medication that may alter the PK of the SOC 
agent (e.g., strong inducers or inhibitors of CYP3A4 for participants receiving 
docetaxel or paclitaxel ) as per the package insert and/or Institutional guidelines.
6.6. Dose Modification and Safety Management Guidelines
Distinct safety  management guidelines, including dose modification algorithms, are 
provided in this section for participant s treated with the combination of GSK3359609 and 
tremelimumab .
Please note : In instances where the Investigator is directed to permanentl y discontinue 
study  intervention per Table 7, this is mandatory for tremelimumab and at the discretion 
of the Investigator for GSK3359609. However, GSK3356909 may  only be restarted if the 
event resolves to ≤ Grade 1 within 14 day s AND has been stable at ≤ Grade 1 for at least 
7 day s and requires approval from the Medical Monitor. 
Refer to SOC prescribing information or standard practice guidelines for the management 
of AEs or potential safety -related issues. 
All AEs are to be graded according to NCI -CTCAE (version 5.0) [ NCI, 201 7]. All dose 
modifications and the reason(s) for the dose modification must be documented in the 
eCRF.
6.6.1. General Guidelines for Immune -Related A dverse Events
AEs associated with immunotherap y treatment may be immune -mediated. T hese 
immune -related AEs (irAEs) may  occur shortly  after the first dose ,several months after 
the last dose of treatment, or during the treatment course, and may  affect more than one 
body  system simultaneously . Therefore, earl y recognition of and initiation of treatment 
for these events is critical to reduce potential complications. 
For suspected irAEs, ensure adequate evaluation to confirm the etiology  or exclude other 
causes. Additional procedures or tests such as, but not limited to, bronchoscopy , 
endosc opy, or skin biopsy  may  be included as part of the evaluation. Based on the 
severit y of irAEs, withhold or permanentl y discontinue treatment and administer 
corticosteroids. Dose modification and toxicity management guidelines for irAEs 
associated with immu notherapies are provided in Table 7, though irAEs may  occur in 
nearl y all organs, some of them not noted in the guidelines . Note : This guidance does not 
apply  to participants randomized to SOC in Part 2.
Before ad ministration of study  intervention , investigators are to review a participant’s 
AEs, concomitant medications, and clinical evaluation results, e.g., vital signs, laboratory  
results, ECG, ECOG PS, phy s ical examination findings, responses, etc. as outlined i n the 
Schedule of Activities (Section 1.3) to monitor for new or worsening irAEs and ensure 
continues dosing is appropriate. 
Adverse Events of Special Interest (AESI)
AESI  are defined as events of potential imm unologic etiology , including irAEs . Such 
events recentl y reported after treatment with other immune modulatory therapy include 
2018N362439_01 CONFIDENTIA L
207871
48colitis, uveitis, hepatitis, pneumonitis, diarrhea, endocrine disorders, and specific 
cutaneous toxicities, as well as other even ts that may  be immune mediated. 
Table 7 Dose Modification and Toxicity  Management Guidelines for Immune -
related AEs
General Instructions for dose modifications:
Grade 1 No dose modifications
Grade 2 Hold study intervention until Grade 2 resolution to Grade ≤1. 
If toxicity worsens, then treat as Grade 3 or Grade 4. 
Study intervention can be resumed once event stabilizes to Grade ≤1 after completion of steroid 
taper.
Participants with endocrinopathies who may require prolonged or continued steroid replacement 
can be retreated with study intervention on the following conditions:
 The event stabilizes and is controlled.
 The participant is clinically stable as per Investigator clinical judgement.
 Doses of prednisone are at ≤10mg/day o r equivalent.
Consider whether study intervention should be permanently discontinued in events with high 
likelihood for morbidity and/or mortality (e.g., myocarditis, or other similar events even if they are 
not currently noted in the guidelines) when they do not rapidly improve to Grade <1 upon 
treatment with systemic steroids and following full taper.
Grade 3 Depending on the individual toxicity, study intervention may be permanently discontinued. Please 
refer to guidelines below.
Note: For Grade ≥3 asymptomatic amylase or lipase levels, hold study intervention, and if 
complete work up shows no evidence of pancreatitis, study intervention may be continued or 
resumed.
Note: Study intervention should be permanently discontinued in Grade 3 events with high 
likelihood for morbidity and/or mortality –e.g., myocarditis, or other similar events even if they 
are not currently noted in the guidelines.
Grade 4 Permanently discontinue study intervention.
Note: There are some exceptions to permanent disc ontinuation of study drug for Grade 4 events 
(e.g., hyperthyroidism, hypothyroidism, Type 1 diabetes mellitus).
Additionally, permanently discontinue study intervention for the following conditions:
 Inability to reduce corticosteroid to a dose of ≤10 mg of prednisone per day (or equivalent) within 12 weeks 
after last dose of study intervention.
 Recurrence of a previously experienced Grade 3 treatment -related AE following resumption of dosing.
General Instructions for toxicity management :
It ispossible that events with an inflammatory or immune -mediated mechanism could occur in nearly all organs, some 
of them not noted specifically in these guidelines. Whether specific irAEs (and/or laboratory indicators of such events) 
are noted in these guide lines or not, participants should be thoroughly evaluated to rule out any alternative etiology 
(e.g., disease progression, concomitant medications, and infections) to a possible immune -mediated event. In the 
absence of a clear alternative etiology, all suc h events should be managed as if they were immune related. General 
recommendations follow.
 Symptomatic and topical therapy should be considered for low grade (Grade 1 or 2, unless otherwise 
specified) events. 
 For persistent (>3 to 5 days) low -grade (Grade 2) or severe (Grade ≥3) events, promptly start prednisone 1 
to 2mg/kg/day PO or IV equivalent.
 Some events with high likelihood for morbidity and/or mortality (e.g., myocarditis, or other similar events even 
if they are not currently noted in the guideli nes) should progress rapidly to high dose IV corticosteroids 
(methylprednisolone at 2 to 4 mg/kg/day) even if the event is Grade 2, and if clinical suspicion is high and/or 
there has been clinical confirmation. Consider, as necessary, discussing with the M edical Monitor, and 
promptly pursue specialist consultation.
 If symptoms recur or worsen during corticosteroid tapering (28 days of taper), increase the corticosteroid 
dose (prednisone dose [e.g., up to 2 to 4 mg/kg/day PO or IV equivalent]) until stabiliz ation or improvement 
of symptoms, then resume corticosteroid tapering at a slower rate (>28 days of taper).
 More potent immunosuppressives such as TNF inhibitors (e.g., infliximab) (also refer to the individual 
2018N362439_01 CONFIDENTIA L
207871
49sections of the irAEs for specific type of im munosuppressive) should be considered for events not 
responding to systemic steroids. Progression to use of more potent immunosuppressives should proceed 
more rapidly in events with high likelihood for morbidity and/or mortality (e.g., myocarditis, or othe r similar 
events even if they are not currently noted in the guidelines) when these events are not responding to 
systemic steroids.
 With long -term steroid and other immunosuppressive use, consider need for Pneumocystis jirovecii
pneumonia (PJP, formerly kn own as Pneumocystis carinii pneumonia) prophylaxis, gastrointestinal 
protection, and glucose monitoring.
 Discontinuation of study intervention is not mandated for Grade 3/Grade 4 inflammatory reactions attributed 
to local tumor response (e.g., inflammatory reaction at sites of metastatic disease and lymph nodes). 
Continuation of study intervention in this situation should be based upon a benefit -risk analysis for that 
participant.
Specific Immune -Related AEs:
Immune -related 
AEsSeverity grade 
(CTCAEv 5.0) or 
conditions Dose Modification / 
General Guidance Toxicity Management
Pneumonitis / 
Interstitial Lung 
Disease (ILD)Any Grade Monitor participants for signs and 
symptoms of pneumonitis or ILD (new 
onset or worsening shortness of breath 
or cough). Part icipants should be 
evaluated with imaging and pulmonary 
function tests, including other diagnostic 
procedures as described below.
Initial work- up may include clinical 
evaluation, monitoring of oxygenation via 
pulse oximetry (resting and exertion), 
laborato ry work -up, and high -resolution 
CT scan.
Grade 1
(asymptomatic, 
clinical or 
diagnostic 
observations only; 
intervention not 
indicated)No dose modifications 
required. However, 
consider holding study 
intervention dose as 
clinically appropriate and 
during diagnostic work- up 
for other etiologies.Monitor and closely follow up in 2 to 4 
days for clinical symptoms, pulse 
oximetry (resting and exertion), and 
laboratory work -up and then as clinically 
indicated.
Consider Pulmonary and Infectious 
disease consult.
Grade 2
(symptomatic; 
medical 
intervention 
indicated; limiting 
instrumental 
activities of daily 
living [ADLs])Hold study intervention 
until Grade 2 resolution to 
Grade ≤1.
If toxicity worsens, then 
treat as Grade 3 or 
Grade 4.
If toxicity improves to 
Grade ≤1, then the 
decision to reinitiate 
study intervention will be 
based upon treating 
physician’s clinical 
judgment and after 
completion of steroid 
taper.Monitor symptoms daily and consider 
hospitalization.
Promptly start systemic steroids (e.g., 
prednisone 1 to 2 mg/kg/day PO or IV 
equivalent).
Reimage as clinically indicated.
If no improvement within 3 to 5 days, 
additional workup should be conside red 
and prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day 
started
If still no improvement within 3 to 5 days 
despite IV methylprednisolone at 2 to 
4mg/kg/day, promptly start 
immunosuppressive therapy such as 
TNF inhibitors (e.g., infliximab at 
5mg/kg every 2 weeks). Caution: It is 
important to rule out sepsis and refer to 
infliximab label for general guidance 
before using infliximab.
Once the participant is improving, 
2018N362439_01 CONFIDENTIA L
207871
50gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics,
antifungals, or anti- PJP treatment.
Consider pulmonary and infectious 
disease consult.
Consider, as necessary, discussing with 
Medical Monitor.
Grade 3 or 4
(Grade 3: severe 
symptoms; limiting 
self-care ADL; 
oxygen indicated)
(Grade 4: life -
threatening
respiratory 
compromise; 
urgent intervention 
indicated [e.g., 
tracheostomy or 
intubation])Permanently discontinue 
study intervention.Promptly initiate empiric IV 
methylprednisolone 1 to 4 mg/kg/day or 
equivalent.
Obtain Pulmonary and Infectious 
disease consult; consider, as necessary, 
discussing with Medical Monitor.
Hospitalize the participant.
Supportive care (e.g., oxygen).
If no improvement within 3 to 5 days, 
additional workup should be considered 
and prompt treatment with additional 
immunosuppressiv e therapy such as 
TNF inhibitors (e.g., infliximab at 
5mg/kg every 2 weeks dose) started. 
Caution: rule out sepsis and refer to 
infliximab label for general guidance 
before using infliximab.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Diarrhea / Colitis Any Grade Monitor for symptoms that may be 
related to diarrhea/enterocolitis (e.g., 
abdominal pain, cramping, or changes in 
bowel habits such as incr eased 
frequency over baseline or blood in 
stool) or related to bowel perforation 
(e.g., sepsis, peritoneal signs, and 
ileus).
Participants should be thoroughly 
evaluated to rule out any alternative 
etiology (e.g., disease progression, other 
medications, or infections), including 
testing for clostridium difficile toxin, etc.
Steroids should be considered in the 
absence of clear alternative etiology, 
even for low -grade events, to prevent 
potential progression to higher grade 
event.
Monitor for symptoms that m ay be 
related to diarrhea/enterocolitis 
(abdominal pain, cramping, or changes 
in bowel habits such as increased 
frequency over baseline or blood in 
stool) or related to bowel perforation 
(such as sepsis, peritoneal signs, and 
ileus).
Participants should be thoroughly 
evaluated to rule out any alternative 
etiology (e.g., disease progression, other 
2018N362439_01 CONFIDENTIA L
207871
51medications, or infections), including 
testing for clostridium difficile toxin, etc.
Steroids should be considered in the 
absence of clear alternative etiology, 
even for low -grade events, to prevent 
potential progression to higher grade 
event.
Use analgesics carefully; they can mask 
symptoms of perforation and peritonitis.
Grade 1
(Diarrhea: stool 
frequency of <4 
over baseline per 
day)
(Colitis: 
asymptomatic; 
clinical or 
diagnostic 
observations only)No dose modifications. Monitor closely for worsening symptoms.
Consider symptomatic treatment, 
including hydration, electrolyte 
replacement, dietary changes (e.g., 
American Dietetic Association colitis 
diet), and loper amide. Use probiotics as 
per treating physician’s clinical 
judgment.
Grade 2
(Diarrhea: stool 
frequency of 4 to 6 
over baseline per 
day) 
(Colitis: abdominal 
pain; mucus or 
blood in stool)Hold study intervention 
until resolution to Grade 
≤1.
If toxicity worsens, then 
treat as Grade 3 or 
Grade 4.
If toxicity improves to 
Grade ≤1, then study 
intervention can be 
resumed after 
completion of steroid 
taper.Consider symptomatic treatment, 
including hydration, electrolyte 
replacement, dietary changes (e.g., 
American Dietetic Association colitis 
diet), and loperamide and/or 
budesonide.
Promptly start prednisone 1 to 
2mg/kg/day PO or IV equivalent.
If event is not responsive within 3 to 5 
days or worsens despite prednisone at 1 
to 2mg/kg/day PO or IV equivalent, GI 
consult should be obtained for 
consideration of further workup, such as 
imaging and/or colonoscopy, to confirm 
colitis and rule out perforation, and 
prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day 
started.
If still no improvement within 3 to 5 days 
despite 2 to 4 mg/kg IV 
methylprednisolone, promptly start 
immunosuppressives such as infliximab 
at 5mg/kg once every 2 weeks. Caution: 
it is important to rule out bowel 
perforation and refer to infliximab label 
for general guidance before using
infliximab.
Consider, as necessary, discussing with 
Medical Monitor if no resolution to Grade 
≤1 in 3 to 4 days.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Grade 3 or 4
(Grade 3 diarrhea: 
stool frequency of 
≥7 over baseline Grade 3
Permanently discontinue if 
toxicity does not improve 
to Grade ≤1 within 14 Promptly initiate empiric IV 
methylprednisolone 2 to 4mg/kg/day or 
equivalent.
Monitor stool frequency and volume and 
2018N362439_01 CONFIDENTIA L
207871
52per day; Grade 4 
diarrhea: life 
threatening 
consequences)
(Grade 3 colitis: 
severe abdominal 
pain, change in 
bowel habits, 
medical 
intervention 
indicated, 
peritoneal signs; 
Grade 4 colitis: life -
threatening 
consequences, 
urgent intervention 
indicated)days; study intervention 
can be resumed after 
completion of steroid 
taper.
Grade 4
Permanently discontinue 
study intervention. maintain hydration.
Urgent GI consult and imaging and/or 
colonoscopy as appropriate.
If still no improvement within 3 to 5 days 
of IV methylprednisolone 2 to 
4mg/kg/day or equivalent, prom ptly start 
further immunosuppressives (e.g., 
infliximab at 5 mg/kg once every 2 
weeks). Caution: Ensure GI consult to 
rule out bowel perforation and refer to 
infliximab label for general guidance 
before using infliximab.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Hepatitis 
(elevated liver 
function tests 
[LFTs])Any grade Monitor and evaluate LFTs: AST, AST, 
alkaline phosphatase, bilirubin.
Evaluate f or alternative etiologies (e.g., 
viral hepatitis, disease progression, 
concomitant medications). 
Grade 1
(AST or ALT >ULN 
and ≤3.0xULN 
and/or bilirubin > 
ULN and 
≤1.5xULN)No dose modifications. If 
event worsens, treat as 
Grade 2.Continue LFT monitoring per protocol.
Grade 2
(AST or 
ALT >3.0xULN and 
≤5.0xULN and/or 
bilirubin >1.5xULN 
and ≤3.0xULN)Refer to Section 7.1.1 for 
stopping criteria and 
required follow up. 
ONLY if labs do not meet 
stopping criteria:
Study inter vention 
should be held until 
Grade 2 resolution to 
Grade ≤1. 
If toxicity improves to 
Grade ≤1 or baseline, 
resume study 
intervention after 
completion of steroid 
taper.
If toxicity worsens, then 
treat as Grade 3 or 4. Regular and frequent checking of LFTs
(e.g., every 1 to 2 days) until elevations 
of these are improving or resolved.
If no resolution to Grade ≤1 in 1 to 2 
days, consider, as necessary, 
discussing with Medical Monitor.
If event is persistent (>3 to 5 days) or 
worsens, promptly start prednison e 1 to 
2mg/kg/day PO or IV equivalent.
If still no improvement within 3 to 5 days 
despite 1 to 2 mg/kg/day of prednisone 
PO or IV equivalent, consider additional 
work up and start prompt treatment with 
IV methylprednisolone 2 to 4 mg/kg/day.
If still no improvement within 3 to 5 days 
despite 2 to 4 mg/kg/day of IV 
methylprednisolone, promptly start 
immunosuppressives (i.e., 
mycophenolate mofetil). Discuss with 
Medical Monitor if mycophenolate 
mofetil is not available. Infliximab 
should NOT be used.
Once th e participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Grade 3 or 4
(Grade 3: AST or 
ALT >5.0xULN and Refer to Section 7.1.1 for 
stopping criteria and 
required follow up. Promptly initiate empiric IV 
methylprednisolone at 1 to 4 mg/kg/day 
or equivalent.
2018N362439_01 CONFIDENTIA L
207871
53≤20.0xULN and/or 
bilirubin >3.0xULN 
and ≤10.0xULN)
(Grade 4: A ST or 
ALT >20xULN 
and/or 
bilirubin >10xULN)If still no improvement with in 3 to 5 days 
despite 1 to 4 mg/kg/day 
methylprednisolone IV or equivalent, 
promptly start treatment with 
immunosuppressive therapy (i.e., 
mycophenolate mofetil). Discuss with 
Medical Monitor if mycophenolate is not 
available. Infliximab should NOT be 
used.
Perform hepatology consult, abdominal 
workup, and imaging as appropriate.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Nephritis or renal 
dysfuncti on
(elevated serum 
creatinine)Any Grade Consult with nephrologist.
Monitor for signs and symptoms that 
may be related to changes in renal 
function (e.g., routine urinalysis, 
elevated serum BUN and creatinine, 
decreased creatinine clearance, 
electrolyte i mbalance, decrease in urine 
output, or proteinuria).
Participants should be thoroughly 
evaluated to rule out any alternative 
etiology (e.g., disease progression or 
infections).
Steroids should be considered in the 
absence of clear alternative etiology 
even for low -grade events (Grade 2), in 
order to prevent potential progression to 
higher grade event.
Grade 1
(Serum creatinine 
> 1 to 1.5 x 
baseline; > ULN to 
1.5xULN)No dose modifications. Monitor serum creatinine weekly and 
any accompanying symptoms.
oIf creatinine returns to baseline, 
resume its regular monitoring per 
study protocol.
oIf creatinine worsens, depending on 
the severity, treat as Grade 2, 3, or 
4.
Consider symptomatic treatment, 
including hydration, electrolyte 
replacement, and diuretics.
Grade 2
(serum creatinine 
>1.5 to 3.0 x 
baseline; >1.5 to 
3.0 x ULN)Hold study intervention 
until resolution to Grade 
≤1 or baseline. 
If toxicity worsens, then 
treat as Grade 3 or 4.
If toxicity improves to 
Grade ≤1 or baseline, 
then resume study 
intervent ion after 
completion of steroid 
taper.Consider symptomatic treatment, 
including hydration, electrolyte 
replacement, and diuretics.
Carefully monitor serum creatinine every 
2 to 3 days and as clinically warranted.
Consult nephrologist and consider renal 
biopsy if clinically indicated.
If event is persistent (>3 to 5 days) or 
worsens, promptly start prednisone 1 to 
2mg/kg/day PO or IV equivalent.
If event is not responsive within 3 to 5 
days or worsens despite prednisone at 1 
to 2mg/kg/day PO or IV equival ent, 
2018N362439_01 CONFIDENTIA L
207871
54additional workup should be considered 
and prompt treatment with IV 
methylprednisolone at 2 to 4 mg/kg/day 
started.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
When event returns to baseline, resume 
study intervention and routine serum 
creatinine monitoring per study protocol.
Grade 3 or 4
(Grade 3: serum 
creatinine >3.0 x 
baseline; >3.0 to 
6.0 x ULN; Grade 
4: serum creatinine 
>6.0 x ULN)Permane ntly discontinue 
study intervention.Carefully monitor serum creatinine on 
daily basis.
Consult nephrologist and consider renal 
biopsy if clinically indicated.
Promptly start prednisone 1 to 
2mg/kg/day PO or IV equivalent.
If event is not responsive withi n 3 to 5 
days or worsens despite prednisone at 1 
to 2mg/kg/day PO or IV equivalent, 
additional workup should be considered 
and prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day 
started.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Rash
(excluding bullous 
skin formations)Any Grade Monitor for signs and symptoms of 
dermatitis (rash and pruritus).
IF THERE IS ANY BULLOUS 
FORMATION, THE MEDIC AL 
MONITOR SHOULD BE CONTACTED 
AND STUDY DRUG DISCONTINUED.
Grade 1 No dose modifications. Consider symptomatic treatment, 
including oral antipruritics (e.g., 
diphenhydramine or hydroxyzine) and 
topical therapy (e.g., urea cream).
Grade 2 For persisten t (>1 to 2 
weeks) Grade 2 events, 
hold scheduled study 
intervention until resolution 
to Grade ≤1 or baseline.
If toxicity worsens, then 
treat as Grade 3.
If toxicity improves to 
Grade ≤1 or baseline, 
then resume 
intervention after 
completion of steroid 
taper.Obtain dermatology consult.
Consider symptomatic treatment, 
including oral antipruritics (e.g., 
diphenhydramine or hydroxyzine) and 
topical therapy (e.g., urea cream).
Consider moderate -strength topical 
steroid.
If no improvement of rash/skin lesions 
occurs within 3 to 5 days or is worsening 
despite symptomatic treatm ent and/or 
use of moderate strength topical steroid, 
consider, as necessary, discussing with 
Medical Monitor and promptly start 
systemic steroids such as prednisone 1 
to 2mg/kg/day PO or IV equivalent.
Consider skin biopsy if the event is 
persistent for >1 to 2 weeks or recurs.
Grade 3 or 4 Grade 3 Consult dermatology.
2018N362439_01 CONFIDENTIA L
207871
55Hold study intervention 
until resolution to Grade 
≤1 or baseline.
If temporarily holding the 
study intervention does not 
provide improvement of 
the Grade 3 skin rash to 
Grade ≤1 or baseline 
within 30 days, the n 
permanently discontinue 
study intervention.
Grade 4
Permanently discontinue 
study intervention.Promptly initiate empiric IV 
methylprednisolone 1 to 4 mg/kg/day or 
equivalent.
Consider hospitalization.
Monitor extent of rash [Rule o f Nines].
Consider skin biopsy (preferably more 
than 1) as clinically feasible.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Consider, as necessary, discussing with 
Medical Monitor.
Endocrinopathy
(e.g., 
hyperthyroidism, 
hypothyro idism, 
Type 1 diabetes 
mellitus, 
hypophysitis, 
hypopituitarism, 
and adrenal 
insufficiency; 
exocrine event of 
amylase/lipase 
increased also 
included in this 
section)Any Grade Consider consulting an endocrinologist 
for endocrine events.
Consider, as necess ary, discussing with 
Medical Monitor.
Monitor participants for signs and 
symptoms of endocrinopathies. Non -
specific symptoms include headache, 
fatigue, behavior changes, changed 
mental status, vertigo, abdominal pain, 
unusual bowel habits, polydipsia, 
polyuria, hypotension, and weakness.
Participants should be thoroughly 
evaluated to rule out any alternative 
etiology (e.g., disease progression 
including brain metastases, or 
infections).
Depending on the suspected 
endocrinopathy, monitor and evaluate 
thyroid function tests: TSH, free T3 and 
free T4 and other relevant endocrine 
and related labs (e.g., blood glucose and 
ketone levels, HgA1c).
For modest asymptomatic elevations in 
serum amylase and lipase, 
corticosteroid treatment is not indicated 
as long as the re are no other signs or 
symptoms of pancreatic inflammation.
If a participant experiences an AE that is 
thought to be possibly of autoimmune 
nature (e.g., thyroiditis, pancreatitis, 
hypophysitis, or diabetes insipidus), the 
investigator should send a bloo d sample 
for appropriate autoimmune antibody 
testing.
Grade 1 
(including those 
with asymptomatic 
endocrinopathy)No dose modifications. Monitor participant with appropriate 
endocrine function tests.
For suspected 
hypophysitis/hypopituitarism, consider 
consultation of an endocrinologist to 
guide assessment of early -morning 
ACTH, cortisol, TSH and free T4; also 
consider gonadotropins, sex hormones, 
2018N362439_01 CONFIDENTIA L
207871
56and prolactin levels, as well as 
cosyntropin stimulation test (though it 
may not be useful in diagnosing earl y 
secondary adrenal insufficiency).
If TSH < 0.5xLLN, or TSH >2xULN, or 
consistently out of range in 2 
subsequent measurements, include free 
T4 at subsequent cycles as clinically 
indicated and consider consultation of 
an endocrinologist.
Grade 2
(includi ng those 
with symptomatic 
endocrinopathy)For Grade 2 
endocrinopathy other than 
hypothyroidism and Type 
1 diabetes mellitus, hold 
study intervention dose 
until participant is clinically 
stable.
If toxicity worsens, then 
treat as Grade 3 or 
Grade 4.
Study i ntervention can be 
resumed once event 
stabilizes and after 
completion of steroid 
taper.
Participants with 
endocrinopathies who may 
require prolonged or 
continued steroid 
replacement (e.g., adrenal 
insufficiency) can be 
retreated with study 
intervention on the 
following conditions:
The event stabilizes and 
is controlled.
The participant is 
clinically stable as per 
investigator or treating 
physician’s clinical 
judgement.
Doses of prednisone are 
≤10mg/day or 
equivalent.Consult endocrinologist to guide 
evalua tion of endocrine function and, as 
indicated by suspected endocrinopathy 
and as clinically indicated, consider 
pituitary scan.
For all participants with abnormal 
endocrine work up, except those with 
isolated hypothyroidism or Type 1 DM, 
and as guided by an endocrinologist, 
consider short term corticosteroids (e.g., 
1 to 2 mg/kg/day methylprednisolone or 
IV equivalent) and prompt initiation of 
treatment with relevant hormone 
replacement (e.g., hydrocortisone, sex 
hormones).
Isolated hypothyroidism may be treated 
with replacement therapy, without study 
intervention interruption, and without 
corticosteroids.
Isolated Type 1 diabetes mellitus (DM) 
may be treated with appropriate diabetic 
therapy, without study intervention 
interruption, and without corticosteroi ds.
Once participants on steroids are 
improving, gradually taper 
immunosuppressive steroids (as 
appropriate and with guidance of 
endocrinologist) over ≥28 days and 
consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
For participants with no rmal endocrine 
workup (laboratory assessment or MRI 
scans), repeat laboratory 
assessments/MRI as clinically indicated.
Grade 3 or 4 For Grade 3 or 4 
endocrinopathy other than 
hypothyroidism and Type 
1 diabetes mellitus, hold 
study intervention dose 
until endocrinopathy 
symptom(s) are controlled. 
Study intervention can be 
resumed once event 
stabilizes and after 
completion of steroid 
taper.
Participants with Consult endocrinologist to guide 
evaluation of endocrine function and, as 
indicated by suspected endocrinopathy 
and as clinically indicated, consider 
pituitary scan. Hospitalization 
recommended.
For all participants with abnormal 
endocrine work up, except those with 
isolated hypothyroidism or Type 1 DM, 
and as guided by an endocrinologist, 
promptly initiate empiric IV 
methylprednisolone 1 to 2 mg/kg/day or 
equivalent, as well as relevant hormone 
2018N362439_01 CONFIDENTIA L
207871
57endocrinopathies who may 
require prolonged or 
continued steroid 
replacement (e.g., adrenal 
insuffic iency) can be 
retreated with study 
intervention on the 
following conditions:
The event stabilizes and 
is controlled.
The participant is 
clinically stable as per 
investigator or treating 
physician’s clinical 
judgement.
Doses of prednisone are 
≤10mg/day or 
equivalent.replacement (e.g., hydrocortisone, sex 
hormones).
For adrenal crisis, severe dehydration, 
hypotension, or shock, immediately 
initiate IV corticosteroids with 
mineralocorticoid activity.
Isolated hypothyroidism may be treated 
with replacement therapy, without study 
intervention interruption, and without 
corticosteroids.
Isolated Type 1 diabetes mellitus may 
be treated with appropriate diabetic 
therapy, without study intervention 
interruption, and without corticosteroids.
Once participants on steroids are 
improving, gradually taper 
immunosuppressive steroids (as 
appropriate and with guidance of 
endocrinologist) over ≥28 days and 
consider prophylactic antibiotics, 
antifungals, and anti- PJP treatment.
Neurotoxicity
(to include but not 
be limited to limbic 
encephalitis and 
autonomic 
neuropathy, 
excluding 
Myasth enia Gravis 
and Guillain -Barre)Any Grade Participants should be evaluated to rule 
out any alternative etiology (e.g., 
disease progression, infections, 
metabolic syndromes, or medications).
Monitor participant for general 
symptoms (headache, nausea, verti go, 
behavior change, or weakness).
Consider appropriate diagnostic testing 
(e.g., electromyogram and nerve 
conduction investigations).
Perform symptomatic treatment with 
neurological consult as appropriate.
Grade 1 No dose modifications. See “Any Grade” recommendations 
above.
Grade 2 For acute motor 
neuropathies or 
neurotoxicity, hold study 
intervention dose until 
resolution to Grade ≤1.
For sensory 
neuropathy/neuropathic 
pain, consider holding 
study intervention dose 
until resolution to Grade 
≤1.
If toxicity worsens, then 
treat as Grade 3 or 4.
Study intervention can be 
resumed once event 
improves to Grade ≤1 and 
after completion of steroid 
taper.Consider, as necessary, discussing with 
the Medical Monitor.
Obtain neurology consult.
Sensory neuropathy/n europathic pain 
may be managed by appropriate 
medications (e.g., gabapentin or 
duloxetine).
Promptly start systemic steroids 
prednisone 1 to 2 mg/kg/day PO or IV 
equivalent.
If no improvement within 3 to 5 days 
despite 1 to 2 mg/kg/day prednisone PO 
or IV equivalent, consider additional 
workup and promptly treat with 
additional immunosuppressive therapy 
(e.g., IV immunoglobulin therapy [ IVIG]).
Grade 3 or 4 Grade 3
Hold study intervention
dose until resolution to 
Grade ≤1.Consider, as necessary, discussing with 
Medical Monitor.
Obtain neurology consult.
Consider hospitalization.
2018N362439_01 CONFIDENTIA L
207871
58Permanently discontinue 
study intervention if Grade 
3 irAE does not resolve to 
Grade ≤1 within 30 days.
Grade 4
Permanently discontinue 
study intervention.Promptly initiate empiric IV 
methylprednisolone 1 to 2 mg/kg/day or 
equivalent.
If no improvement within 3 to 5 days 
despite IV corticosteroids, consider 
additional workup and promptly treat 
with additional immu nosuppressants 
(e.g., IVIG).
Once stable, gradually taper steroids 
over ≥28 days.
Peripheral 
neuromotor 
syndromes
(such as Guillain -
Barre and 
myasthenia gravis)Any Grade The prompt diagnosis of immune -
mediated peripheral neuromotor 
syndromes is important, since certain 
participants may unpredictably 
experience acute decompensations that 
can result in substantial morbidity or in 
the worst case, death. Special care 
should be taken for certain sentinel 
symptoms that may predict a more 
severe outcome, such as prominent 
dysphagia, rapidly progressive 
weakness, and signs of respiratory 
insufficiency or autonomic instability.
Participants should be evaluated to rule 
out any alternative etiology (e.g., 
disease progression, infections, 
metabolic syndromes or medications). It 
should be noted t hat the diagnosis of 
immune -mediated peripheral 
neuromotor syndromes can be 
particularly challenging in participants 
with underlying cancer, due to the 
multiple potential confounding effects of 
cancer (and its treatments) throughout 
the neuraxis. Given the importance of 
prompt and accurate diagnosis, it is 
essential to have a low threshold to 
obtain a neurological consult.
Neurophysiologic diagnostic testing 
(e.g., electromyogram and nerve 
conduction investigations, and “repetitive 
stimulation” if myastheni a is suspected) 
are routinely indicated upon suspicion of 
such conditions and may be best 
facilitated by means of a neurology 
consultation.
It is important to consider that the use of 
steroids as the primary treatment of 
Guillain -Barre is not typically con sidered 
effective. Participants requiring 
treatment should be started with IVIG 
and followed by plasmapheresis if not 
responsive to IVIG.
Grade 1 No dose modifications. Consider, as necessary, discussing with 
the Medical Monitor.
Care should be taken to monitor 
participants for sentinel symptoms of a 
2018N362439_01 CONFIDENTIA L
207871
59potential decompensation as described 
above.
Obtain a neurology consult.
Grade 2 Hold study intervention 
dose until resolution to 
Grade ≤1.
Permanently discontinue 
study intervention if it does 
not resolve to Grade ≤1 
within 30 days or if there 
are signs of respiratory 
insufficiency or autonomic 
instability.Consider, as necessary, discussing with 
the Medical Monitor.
Care should be taken to monitor 
participants for sentinel symptoms of a 
potential decompensation as described 
above.
Obtain a neurology consult
Sensory neuropathy/neuropathic pain 
may be managed by appropriate 
medications (e.g., gabapentin or 
duloxetine).
MYASTHENIA GRAVIS:
Steroids may be successfully used to 
treat myasthenia gravis. It is impo rtant to 
consider that steroid therapy (especially 
with high doses) may result in transient 
worsening of myasthenia and should 
typically be administered in a monitored 
setting under supervision of a consulting 
neurologist.
Participants unable to tolerate steroids 
may be candidates for treatment with 
plasmapheresis or IVIG. Such decisions 
are best made in consultation with a 
neurologist, considering the unique 
needs of each participant.
If myasthenia gravis -like neurotoxicity is 
present, consider starting A chE inhibitor 
therapy in addition to steroids. Such 
therapy, if successful, can also serve to 
reinforce the diagnosis.
GUILLAIN- BARRE:
It is important to consider here that the 
use of steroids as the primary treatment 
of Guillain -Barre is not typically 
considered effective.
Participants requiring treatment should 
be started with IVIG and followed by 
plasmapheresis if not responsive to 
IVIG.
Grade 3 or 4
(severe or life -
threatening events)Grade 3
Hold study intervention 
dose until resolution to 
Grade ≤1.
Permanently discontinue 
study intervention if Grade 
3 irAE does not resolve to 
Grade ≤1 within 30 days 
or if there are signs of 
respiratory insufficiency or 
autonomic instability.
Grade 4
Permanently discontinue 
study intervention.Consider, as necessary, d iscussing with 
Medical Monitor.
Recommend hospitalization.
Monitor symptoms and obtain 
neurological consult.
MYASTHENIA GRAVIS:
Steroids may be successfully used to 
treat myasthenia gravis. They should 
typically be administered in a monitored 
setting under supervision of a consulting 
neurologist.
Participants unable to tolerate steroids 
may be candidates for treatment with 
2018N362439_01 CONFIDENTIA L
207871
60plasmapheresis or IVIG.
If myasthenia gravis -like neurotoxicity 
present, consider starting A chE inhibitor 
therapy in addition to steroid s. Such 
therapy, if successful, can also serve to 
reinforce the diagnosis.
GUILLAIN- BARRE:
It is important to consider here that the 
use of steroids as the primary treatment 
of Guillain -Barre is not typically 
considered effective.
typically considered effe ctive.
Participants requiring treatment should 
be started with IVIG and followed by 
plasmapheresis if not responsive to 
IVIG.
Myocarditis Any Grade Discontinue drug 
permanently if biopsy-
proven immune -mediated 
myocarditis.The prompt diagnosis of immune -
mediated myocarditis is important, 
particularly in participants with baseline 
cardiopulmonary disease and reduced 
cardiac function. 
Consider, as necessary, discussing with 
the Medical Monitor.
Monitor participants for signs and 
symptoms of myocarditis (new onset or 
worsening chest pain, arrhythmia, 
shortness of breath, peripheral edema). 
As some symptoms can overlap with 
lung toxicities, simultaneously evaluate 
for and rule out pulmonary toxicity as 
well as other causes (e.g., pulmonary 
embolism, congestive heart failure, 
malignant pericardial effusion). A 
Cardiology consultation should be 
obtained early, with prompt assessment 
of whether and when to complete a 
cardiac biopsy, including any other 
diagnostic procedures.
Initial work- up should include clinical
evaluation, BNP, cardiac enzymes, 
ECG, echocardiogram (ECHO), 
monitoring of oxygenation via pulse 
oximetry (resting and exertion), and 
additional laboratory work -up as 
indicated. Spiral CT or cardiac MRI can 
complement ECHO to assess wall 
motion abnormali ties when needed.
Participants should be thoroughly 
evaluated to rule out any alternative 
etiology (e.g., disease progression, other 
medications, or infections).
Grade 1
(asymptomatic with 
laboratory (e.g., 
BNP) or cardiac 
imaging 
abnormalities)No dose modifications 
required unless clinical 
suspicion is high, in which 
case hold study 
intervention dose during 
diagnostic work- up for Monitor and closely follow up i n 2 to 4 
days for clinical symptoms, BNP, cardiac 
enzymes, ECG, ECHO, pulse oximetry 
(resting and exertion), and laboratory 
work -up as clinically indicated.
Consider using steroids if clinical 
2018N362439_01 CONFIDENTIA L
207871
61other etiologies. If study 
intervention is held, 
resume after complete 
resolution to Grade 0.suspicion is high.
Grade 2, 3 or 4
(Grade 2: 
Symptoms with 
mild to moderate 
activity or exertion)
(Grade 3: Severe 
with symptoms at 
rest or with minimal 
activity or exertion; 
intervention 
indicated)
(Grade 4: Life -
threatening 
consequences; 
urgent
intervention 
indicated (e.g., 
continuous IV 
therapy or 
mechanical 
hemodynamic 
support))Grade 2
Hold study intervention 
dose until resolution to 
Grade 0. If toxicity rapidly 
improves to Grade 0, then 
the decision to reinitiate 
study intervention will be 
based upon treating 
physician’s clinical 
judgment and after 
completion o f steroid 
taper. If toxicity does not 
rapidly improve, 
permanently. D iscontinue 
study intervention.
Grade 3 or 4
Permanently discontinue 
study intervention.Monitor symptoms daily, hospitalize.
Promptly start IV methylprednisolone 2 
to 4mg/kg/day or equivalent after 
Cardiology consultation has determined 
whether and when to complete 
diagnostic procedures including a 
cardiac biopsy.
Supportive care (e.g., oxygen).
If no improvement within 3 to 5 days 
despite IV methylprednisolone at 2 to 
4mg/kg/day, prompt ly start 
immunosuppressive therapy such as 
TNF inhibitors (e.g., infliximab at 
5mg/kg every 2 weeks). Caution: It is 
important to rule out sepsis and refer to 
infliximab label for general guidance 
before using infliximab.
Once the participant is improving , 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, or anti- PJP treatment.
Myositis / 
Polymyositis 
(“Poly/myositis”)Any Grade Monitor participants for signs and 
symptoms of poly/myositis. Typically, 
muscle weakne ss/pain occurs in 
proximal muscles including upper arms, 
thighs, shoulders, hips, neck and back, 
but rarely affects the extremities 
including hands and fingers; also ,
difficulty breathing and/or trouble 
swallowing can occur and progress 
rapidly. Increased general feelings of 
tiredness and fatigue may occur, and 
there can be new -onset falling, difficulty 
getting up from a fall, and trouble 
climbing stairs, standing up from a 
seated position, and/or reaching up.
If poly/myositis is suspected, a 
Neurology consultation should be 
obtained early, with prompt guidance on 
diagnostic procedures. Myocarditis may 
co-occur with poly/myositis; refer to 
guidance under Myocarditis. Given 
breathing complications, refer to 
guidance under Pneumonitis/ILD. 
Given possibility o f an existent (but 
previously unknown) autoimmune 
disorder, consider Rheumatology 
consultation.
Consider, as necessary, discussing with 
the Medical Monitor.
Initial work- up should include clinical 
evaluation, creatine kinase, aldolase, 
2018N362439_01 CONFIDENTIA L
207871
62LDH, BUN/creatinine, erythrocyte 
sedimentation rate or C -reactive protein 
level, urine myoglobin, and additional 
laboratory work -up as indicated, 
including a number of possible 
rheumatological/antibody tests (i.e., 
consider whether a rheumatologist 
consultation is indicated a nd could guide 
need for rheumatoid factor, antinuclear 
antibody, anti- smooth muscle, 
antisynthetase [such as anti- Jo-1], 
and/or signal -recognition particle 
antibodies). Confirmatory testing may 
include electromyography, nerve 
conduction studies, MRI of the muscles, 
and/or a muscle biopsy. Consider 
Barium swallow for evaluation of 
dysphagia or dysphonia.
Participants should be thoroughly 
evaluated to rule out any alternative 
etiology (e.g., disease progression, other 
medications, or infections).
Grade 1
(mild pain)No dose modifications. Monitor and closely follow up in 2 to 4 
days for clinical symptoms and initiate 
evaluation as clinically indicated.
Consider Neurology consult.
Consider, as necessary, discussing with 
the Medical Monitor.
Grade 2
(moderat e pain 
associated with 
weakness; pain 
limiting 
instrumental ADLs)Hold study intervention 
dose until resolution to 
Grade ≤1.
Permanently discontinue 
study intervention if it 
does not resolve to 
Grade ≤1 within 30 days 
or if there are signs of 
respiratory i nsufficiency.Monitor symptoms daily and consider 
hospitalization.
Obtain Neurology consult, and initiate 
evaluation.
Consider, as necessary, discussing with 
the Medical Monitor.
If clinical course is rapidly progressive 
(particularly if difficulty breathi ng and/or 
trouble swallowing), promptly start IV 
methylprednisolone 2 to 4 mg/kg/day 
systemic steroids along with receiving 
input from Neurology consultant 
If clinical course is not rapidly 
progressive, start systemic steroids 
(e.g., prednisone 1 to 2 mg/kg/day PO or 
IV equivalent); if no improvement within 
3 to 5 days, continue additional work up 
and start treatment with IV 
methylprednisolone 2 to 4 mg/kg/day
If after start of IV methylprednisolone at 
2 to 4 mg/kg/day there is no 
improvement within 3 to 5 days, 
consider start of immunosuppressive 
therapy such as TNF inhibitors (e.g., 
infliximab at 5 mg/kg every 2 weeks). 
Caution: It is important to rule out sepsis 
and refer to infliximab label for general 
guidance before using infliximab.
Once the particip ant is improving, 
2018N362439_01 CONFIDENTIA L
207871
63gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, or anti- PJP treatment.
Grade 3 or 4
(pain associated 
with severe 
weakness; limiting 
self-care ADLs; 
severe or life -
threatening events)Grade 3
Hold study intervention 
dose until resolution to 
Grade ≤1.
Permanently discontinue 
study intervention if Grade 
3 irAE does not resolve to 
Grade ≤1 within 30 days 
or if there are signs of 
respiratory insufficiency.
Grade 4
Permanently discontinue 
study inter vention.Monitor symptoms closely; recommend 
hospitalization.
Obtain Neurology consult, and complete 
full evaluation.
Consider, as necessary, discussing with 
the Medical Monitor.
Promptly start IV methylprednisolone 2 
to 4mg/kg/day systemic steroids along
with receiving input from Neurology 
consultant.
If after start of IV methylprednisolone at 
2 to 4 mg/kg/day there is no 
improvement within 3 to 5 days, 
consider start of immunosuppressive 
therapy such as TNF inhibitors (e.g., 
infliximab at 5 mg/kg every 2 weeks). 
Caution: It is important to rule out sepsis 
and refer to infliximab label for general 
guidance before using infliximab.
Consider whether participant may 
require IVIG, plasmapheresis.
Once the participant is improving, 
gradually taper steroids over ≥28 days 
and consider prophylactic antibiotics, 
antifungals, or anti- PJP treatment.
6.6.2. Dose Modification and Toxicity  Management of Infusion -
Reactions Related to Immunotherapy  Treatment
Infusion reactions are a well-documented AE associated with the admini stration of 
monoclonal antibodies (mAbs). Infusion reactions ty picall y develop within 30 minutes to 
2 hours after initiation of drug infusion, although sy mptoms may  be delay ed for up to 48 
hours . The incidence of infusion reactions varies by  mAb agent, and there are multiple 
mechanisms known to lead to infusion -related reactions including both IgE -dependant 
anaph ylactic and non -IgE dependent an aphylactoid hy persensitivities. Cytokine release 
syndrome, and when severe, cy tokine “storm”, has been identified a s a sequela of the 
immune sy stem activation associated with infusion reactions.
Infusion reactions may  affect any  organ s ystem in the body . Most are mild in severit y, 
although severe and even fatal reactions occur. As a group, infusion reactions (including
both cy tokine -mediated and allergic) usuall y occur during or within a few hours of drug 
infusion. Occasionall y, a reaction may occur one to two days after administration. The 
NCI-CTCAE (version 5.0) [NCI, 201 7]for grading adverse reac tions during 
chemotherap y administration has a scale for grading the severit y of infusion reactions and 
separate grading scales for allergic reactions and anaph ylaxis. While use of these separate 
grading scales may  be useful for classify ing the nature of a n infusion reaction for 
research purposes, they  are less useful for clinical care, since it may not be obvious if the 
participant is having an allergic infusion reaction or a non -allergic infusion reaction. 
2018N362439_01 CONFIDENTIA L
207871
64Clinically , infusion reactions may present with flushing, itching, urticaria, and/or 
angioedema, repetitive cough, sudden nasal congestion, shortness of breath, chest 
tightness, wheeze, sensation of throat closure or choking, and/or change in voice quality , 
faintness, tach ycardia (or less often brad ycardia), hy potension, hy pertension and/or loss 
of consciousness, nausea, vomiting, abdominal cramping, and/or diarrhea, sense of 
impending doom, tunnel vision, dizziness, and/or seizure, severe back, chest, and pelvic 
pain. See Table 9 and Table 10for dose modification and treatment guidance for 
GSK3359609 and tremelimumab infusion r eaction s, respectivel y.
To better understand the underly ing etiology  of these events, serum try ptase, C -reactive 
protein (CRP) , ferritin, and a cy tokine panel should be drawn during the occurrence of an 
infusion reaction/CRS of any  grade as outlined in Table 8. The serum try ptase , CRP and 
ferritin panels m aybe performed at the Investigator’s designated local laboratory , if 
available . The serum cy tokine panel will be performed at a GSK designated laboratory . 
These data will aid in the classify ing (albeit retrospectivel y) the etiology of the AE .
Table 8 Biomarker Panel
Biomarker Relationship to Adverse Event
Serum tryptaseaIgE-related infusion reaction (Allergic/anaphylaxis) 
[Schwartz, 2006]
Serum CRPa Elevated in CRS [ Lee, 2014 ]
Serum ferritina Elevated in CRS [[ Lee, 2014 ]
Plasma cytokine panelb
(IFN-γ*^, TNF- α*^, IL -2*, IL -4, IL-5*, IL -6*^, IL- 8*, IL -10*, IL-
12p70, IL -13, and IL -17)*  Reported to be elevated in CRS [ Lee, 2014 ]
^ Consistently reported as elevated in CRS [ Lee, 
2014]
CRP=C -reactive protein; CRS= Cytokine release syndrome; IFN -g = Interferon gamma; TNF -a = Tumor necrosis factor 
alpha; IL = Interleukin. 
a. Performed by Investigator designated local laboratory if available; otherwise performed by GSK designated 
laboratory
b. Performed by GSK designated laboratory
These guidelines are suggestions . Investigators and site staff may  also follow their site 
standard operating procedures for the treatment of these events.
2018N362439_01 CONFIDENTIA L
207871
65Table 9 Immunotherapy  Infusion Reaction Dose Modification and Treatment 
Guidelines for GSK3359609
NCI-CTCAE Grade Treatment Premedication at 
Subsequent Dosing
Grade 1
Mild reaction; infusion interruption not 
indicated; intervention not indicatedIncrease monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opinion of the 
Investigator .None
Grade 2
Requires therapy or infusion interruption 
but responds pr omptly to symptomatic 
treatment (e.g., antihistamines, NSAIDs, 
narcotics, IV fluids); prophylactic 
medications indicated for ≤24 hrsStop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Increase monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opinion of the 
Investigator .
If symptoms resolve within 1 hour of stopping 
drug infusion, the infusion may be restarted 
at 50% of the original infusion rate (e.g. ,from 
100 mL/hr to 50 mL/hr) . Otherwise dosing will 
be held until symptoms resolve and the 
participant should be pre -medicated for the 
next scheduled dose.
Participant s who develop Grade 2 toxicity 
despite adequat e premedication should be 
permanently discontinued from further study 
drug treatmentParticipant may be pre -
medicated 1.5h (± 30 
minutes) prior to infusion 
of GSK3359609 with:
Diphenhydramine 50 mg 
PO(or equivalent dose of 
antihistamine).
Acetaminophen 50 0-
1000 mg PO(or 
equivalent dose of 
analgesic).
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly responsive to 
symptomatic medication and/or brief 
interruption of infusion); recurrence of 
symptoms following initial improvement; 
hospitalization indicate d for other clinical 
sequelae (e.g., renal impairment, 
pulmonary infiltrates)
Grade 4:
Life-threatening; pressor or ventilatory 
support indicatedStop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
Epinephrine**
IV flui ds
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Increase monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opinion of the 
Investigator .
Hospitalization may be indicated .
**In cases of anaphylaxis, epinephrine should 
be used immediately.
Participant is permanently discontinued from 
further study drug treatment.No subsequent dosing
Appropriate resuscitation equipment should be available at the bedside and a physician rea dily available during the 
period of drug administration.
For further information, please refer to the NCI-CTCAE v5.0[NCI, 2017]
2018N362439_01 CONFIDENTIA L
207871
66Table 10 Immunotherapy  Infusion Reaction Dose Modification and Treatment 
Guidelin esfor Tremelimumab
NCI-
CTCAE 
GradeTreatment Premedication at 
Subsequent Dosing
Any 
GradeManagement per Institutional standard at the discretion of investigator .
Monitor participant s for signs and symptoms of infusion -related reactions 
(e.g., fever and/ or shaking chills, flushing and/or itching, alterations in heart 
rate and blood pressure, dyspnea or chest discomfort, skin rashes etc) and 
anaphylaxis (e .g.,generalized urticaria, angioedema, wheezing, 
hypotension, tachycardia) .
Grade 1 The infusion r ate of tremelimumab may be decreased by
50% or temporarily interrupted until resolution of the event .
Acetaminophen and/or antihistamines may be administered per Institutional 
standard at the discretion of the investigator .Consider premedication 
per Institutional standard 
prior to subsequent doses
Grade 2 The infusion rate of tremelimumab may be decreased 50% or temporarily 
interrupted until resolution of the event (up to 4 hours) .
Subsequent infusions may be given at 50% of the initial infusion rate .
Acetaminophen and/or antihistamines may be administered per Institutional 
standard at the discretion of the investigator .Consider premedication 
per Institutional standard 
prior to subsequent doses
Grade 3/4 Permanently discontinue.
Manage severe infusion -related reactions per I nstitutional standards (e .g.,
IM epinephrine, followed by IV diphenhydramine and ranitidine, and IV 
glucocorticoid) .
6.6.3. Dose Delay
For GSK3359609 in combination with tremelimumab , if there is a dose delay  between 1
and 7 day s, the proce dures at the original scheduled visit (including dosing) should be 
performed as soon as possible. Subsequent visits will follow as originall y scheduled. If 
the delay  is 8 day s, the visit and dose(s) will be considered missed. The procedures at 
the next sc heduled visit should be performed as originall y scheduled , and subsequent 
visits will continue to follow Q3W. For all dose delay s, disease assessments should 
continue as per Section 8.1.1.2 . Participant s with infusion delay s greater than three weeks 
due to toxicity  should discontinue study  intervention unless the treating Investigator and 
Sponsor/Medical Monitor agree there is strong evidence supporting continued treatment. 
For participant s requiring elective surgery  or radiatio n therap y, every effort should be 
made to wait one to two weeks after the last dose of study  intervention before performing 
surgery  or starting radiation. Study  intervention should not be administered again until 
one to two weeks after recovery  from surger y or radiation (refer to Section 6.5.1 for 
details on permitted medications and non -drug therapies).
For participants randomized t o receive SOC, Investigators should follow the applicable 
package insert and/or Institutional guidelines for dose delays. Protocol -defined 
assessments (e.g., safet y assessments, disease assessments) should continue as outlined in 
the SoA , Section 1.3
6.7. Intervention after the End of the Study
The study  partici pants will not receive an y additional treatment from GSK after 
permanent discontinuation of study  intervention . The Investigator is responsible for 
2018N362439_01 CONFIDENTIA L
207871
67ensuring that consideration is given to the post -study  care of the participant’s medical 
condition.
7. DISCONTI NUA TION OF STUDY INTERVENTION A ND 
PARTICIPA NT DISCONTI NUA TION/WITHDRA WAL
7.1. Discontinuation of Study  Intervention
Participants will receive study  intervention or SOC for the scheduled period as indicated 
in the SoA , unless one of the following events occurs e arlier: 
disease progression (as determined by iRECI ST)
death
unacceptable toxicity , including meeting stopping criteria for liver chemistry  
abnormalities , QTc prolongation or clinical deterioration 
In addition, study  intervention or SOC may be permanent ly discontinued for any  of the 
following reasons:
Deviation(s) from the protocol
Request of the participant or proxy  (withdrawal of consent by  participant or 
proxy)
Discretion of the Investigator
Participant is lost to follow-up
Closure or termination of the study
Study  intervention must be permanently  discontinued in the case of pregnancy
A participant may  withdraw consent at any  time; no further assessments will be required 
and the Investigator must document this in the site study  records.
All participan ts who discontinue from study  intervention or SOC (earl y or permanent) for 
any reason will have safety  assessments at the time of discontinuation and during follow-
up as specified in the SoA.
All participant s who permanently  discontinue study  intervention or SOC without disease 
progression will be followed for progression according to the protocol -defined on-
treatment disease assessment schedule until one or more of the following occur:
a new anticancer therapy  is initiated
disease progression
death
Participants permanentl y discontinuing study  intervention after progression by  RECI ST 
1.1 but prior to confirmed progression b y iRECI ST should be followed to confirm 
progression (see Table 18 ).
2018N362439_01 CONFIDENTIA L
207871
68All participants who permanently  discontinue study  intervention or SOC for an y reason 
will be followed for survival and new anticancer therap y (including radiotherap y) ever y 
12 weeks until death, termination of the overall study  or an arm b y the Sponsor. The 
every  12-week schedule should begin once the study  intervention/SOC has been 
discontinued. If participants are unable or unwilling to attend clinic visits during follow -
up, contact to assess survival may  be made via another form of communication (e.g., 
telephone, email, etc.).
Early disconti nuation of GSK3359609 and tremelimumab (early discontinuation will not 
per se constitute permanent discontinuation) may  be considered for participants who have 
attained a confirmed complete response per RECIST 1.1 and who received study  
intervention for at least 24 weeks and had at least two treatments of GSK3359609 bey ond 
the date when the initial CR was declared; these participants will undergo disease 
assessments at a frequency  of 12 weeks. These participants may  be permitted to resume 
study  intervention upon disease progression following consultation with the Investigator 
and GSK Medical Monitor and upon written consent by  the participant . If study  
intervention is restarted, participants will be required to resume assessments outlined in 
the SoA in Section 1.3.See Section 7.1.1 for specific conditions under which a 
participant may  continue study  intervention beyond disease progression.
If the stud y is terminated by the Sponsor for reasons unrelate d to safet y, and a participant 
is currentl y active in the study, receiving study intervention, and is deriving benefit from 
that intervention without evidence of disease progression in the opinion of the 
Investigator, the participant may  continue to receiv e study  intervention upon agreement 
between the Sponsor and Investigator.
7.1.1. Continuation of Treatment Upon Confirmed Disease Progression
Participants who have confirmed disease progression (unequivocal disease progression)
by RECI ST 1.1 may continue study  intervention at the discretion of the Investigator with 
approval from the Medical Monitor, and upon separate written consent of the participant. 
Continuation on study  intervention with confirmed disease progression is contingent 
upon the following conditions:
participant has documented clinical benefit
absence of clinical signs or sy mptoms indicating clinically  significant disease 
progression
no decline in ECOG performance status
absence of rapid disease progression or threat to vital organs or critical anato mical 
sites (e.g., CNS metastasis, respiratory  failure due to tumor compression, or spinal 
cord compression) requiring urgent alternative medical intervention
no significant, unacceptable, or irreversible toxicities related to stud y intervention
2018N362439_01 CONFIDENTIA L
207871
697.1.2. Liver Chem istry Stopping Criteria
Liver chemistry stopping and increased monitoring criteria have been designed to 
assure participant safety  and evaluate liver event etiology .
Discontinuation of study  intervention for abnormal liver tests is required when a 
participant meets one of the conditions outlined in the algorithm in Figure 2or for 
participant s with documented liver metastases in Figure 3.
Figure 2 Liver Chemistry  Stopping Criteria –Liver Stopping Event A lgorithm
for Participants with A LT up to 2.5 X ULN at Baseline

2018N362439_01 CONFIDENTIA L
207871
70Figure 3 Liver Chemistry  Stopping Criteria –Liver Stopping Event A lgorithm 
for Participants with documented liver metastases with A LT up to 5 
X ULN at Baseline
The details on follow -upprocedures are outlined in Section 10.6.
7.1.2.1. Study  Intervention Restart or Rechallenge after Liver Stopping Criteria 
Met
Study  intervention restart or rechallenge is not allowed after liver chemistry stopping 
criteria are met b y any participant in this study  unless:
GSK Medical Governance approval is granted .
Ethics and/or I RB approval is obtained, if required, and
Separate consent for treatment restart/rechallenge is si gned b y the participant.
Refer to Section 10.6 for additional information.
7.1.3. Stopping Rules for Clinical Deterioration
To adequatel y assess the antitumor effect of immunotherapeutic agents, it is reasonable to 
allow participants experiencing apparent progression as defined by  RECI ST 1.1
guidelines to continue to receive treatment until progression is confirmed at the next 
imaging assessment at least 4 weeks later as indicated by  iRECI ST guidelines. 
Nevertheless, these considerations should be balanced b y clinical judgment as to whether 
2018N362439_01 CONFIDENTIA L
207871
71the participant is clinically  deteriorating and unlikely  to receive any  benefit from 
continued study  intervention .
In cases where deterioration was assessed to have occurred after a c linical event that, in 
the Investigator ’s opinion, is attributable to disease progression and is unlikely  to reverse 
with continued study  intervention or managed b y supportive care (e.g., bisphosphonates 
and/or bone directed radiotherap y, thoracentesis, or paracentesis for accumulating 
effusions), study  intervention should be discontinued . In these cases, the decision to 
continue treatment must be discussed with the Sponsor’s Medical Monitor . Examples of 
events that may , in the Investigator ’s opinion, indic ate a lack of clinical benefit include, 
but are not limited to, the following:
Worsening of ECOG PS from baseline byat least 2 points 
Skeletal related events defined by  the following:
opathologic bone fracture in the region of cancer involvement
ocancer related surgery  to bone, and/or 
ospinal cord or nerve root compression
Development of new CNS metastases
Any setting where the initiation of new antineoplastic therapy  has been deemed 
beneficial to the participant even in the absence of any  such documente d clinical 
event.
7.2. Participant Discontinuation /Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the Investigator for safety , behavioral, 
compliance o r administrative reasons. This is expected to be uncommon.
If the subject voluntaril y discontinues from study  intervention due to toxicity , ‘adverse 
event’ will be recorded as the primary  reason for permanent discontinuation in the eCRF.   
At the time of discontinuation from the study intervention or SOC , if possible, a
treatment discontinuation visit should be conducted, as shown in the SoA. See the SoA 
for data to be collected at the time of study  intervention /SOC discontinuation and follow -
up and for an y further evaluations that need to be completed.
7.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assign ed visit 
2018N362439_01 CONFIDENTIA L
207871
72schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study .
Before a participant is deemed lost to follow up, the Investigator or designee must make 
every  effort to regain contact with the participant (wher e possible, 3 telephone calls and, 
if necessary , a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant’s 
medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study are handled as part of Appendix 1 .
8. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and their timing are summarized in the SoA. 
Protocol waivers or exemptions are not allowed .
Immediate safety  concerns should be discussed with the Sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study  intervention .
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The Investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical mana gement ( e.g., 
blood count) and obtained before signing of ICF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol- specified criteria and was 
performed within the time frame defined in the SoA.
The maximum amount of blood collected from each participant from screening 
through Week 10, including an y extra assessments that may  be required, will not 
exceed 480 mL.If a participant completes 2 years of study  intervention and all 
required assessments, no more than 850 mL of blood will be collected. 
oRepeat or unscheduled samples may be taken for safet y reasons or for tec hnical 
issues with the samples.
8.1. Efficacy  Assessments
8.1.1. Tumor Imaging and Disease A ssessments
RECI ST 1.1 will be used in the assessment of disease burden (target and non -target 
lesions determination) at screening and as the primary measure of tumor response 
endpoints. iRECIST will be used by  the Investigator to assess tumor response and 
progression and make treatment decisions. 
2018N362439_01 CONFIDENTIA L
207871
73A description of the adaptations and iRECI ST process is provided in Appendix 7 , with 
additional details in the iRECI ST publication [ Seymour , 2017]. A summary  of imaging 
and treatment requirements after first radiologic evidence of progression isprovided in 
Table 18 and illustrated as a flowchart in Figure 4in Appendix 7 . 
Tumor images will be obtained and transmitted to a central imaging ve ndor for potential 
central review . The process for tumor imaging and transmission to the central imaging 
vendor are detailed in the Imaging Manual . Tumor imaging is strongl y preferred to be 
acquired b y IV/oral contrast enhanced CT. When CT with iodina ted c ontrast is 
contraindicated or when mandated by  local practice , MRI may  be used. MRI  is the 
preferred modality  for imaging the brain and spine. The same imaging modality , ideall y 
the same scanner, scanning technique and the use of contrast should be used fo r a 
participant throughout the study  to optimize reproducibility  and accuracy  of assessment 
of existing and new tumor burden. 
Note s: 
1.Imaging must include the chest, abdomen, and pelvis.
2.Brain imaging should be conducted, if clinically indicated, at scree ning and 
throughout the stud y for evaluation of brain metastases. MRI  is preferred however 
CT imaging with IV contrast is acceptable if MRI is medically  contraindicated. 
3.Bone scans are optional for participants with a history of bone metastases or for 
those participants with new bone pain. An y supplemental imaging done to support a 
positive or negative bone scan, such as plain X- rays that may  be acquired for 
correlation, should be submitted to the central imaging vendor.
All bone scan abnormalities at scr eening that could indicate metastases should be 
evaluated b y X-ray, CT, or MRI  to determine if they  represent malignant lesions. I f a 
bone scan was performed within 6 weeks prior to the first dose it does not need to be 
repeated (in the absence of new or w orsening clinical sy mptoms suggesting bone 
involvement). Ty pically  bone scanning will be performed using bone scintigraph y; 
however, positron emission tomograph y (PET) scan ([18F] -fluorodeox yglucose or [18F] -
fluoride) is acceptable, providing coverage is s ufficient to evaluate total spine, clavicle, 
ribs, pelvis and long bones.
8.1.1.1. Initial Tumor Imaging
Initial tumor imaging at scree ning must be performed within 30 days prior to Day  1. 
Tumor imaging performed as part of routine clinical management is acceptable for use as 
screening tumor imaging if it is of diagnostic quality , is performed within 30 days prior to 
Day 1and can be assessed by  the central imaging vendor . 
8.1.1.2. Tumor Imaging During the Study
The first on- study  imagin g assessment must be performed 9 weeks after the first dose of 
study  intervention or SOC . Subsequent tumor imaging must be performed every  6weeks 
until W eek 5 2and every  12 weeks thereafter . Imaging timing should follow calendar 
days and should not be adjusted for dosing delay s. Imaging should continue to be 
2018N362439_01 CONFIDENTIA L
207871
74performed until confirmed disease progression is identified by  the Investigator , per 
iRECI ST (Appendix 7 ). 
Objective response (CR or PR) must be confirmed by  a repeat imaging assessment. 
Tumor imaging to confirm PR or CR must be performed at least 4 weeks after the first 
indication of a response is observed. Participants will then return to regular scheduled 
imaging, starting with the next scheduled imaging time point. Participants who receive 
additional imaging for confirmation do not need to undergo the next scheduled tumor 
imaging if it is less than 4 weeks later and tumor imaging may  resume at the subsequent 
scheduled imaging time point. 
Per iRECI ST, disease progression should be confirmed by  the site at least 4 weeks and up 
to 8 weeks after site -assessed first radiologic evidence of PD . Participants who have 
unconfirmed PD may continue study  intervention at the discretion of the Investigator
until progression is confirmed by  the site, provided they  have met the c onditions detailed 
inAppendix 7 .
8.1.1.3. End of Treatment Imaging
Disease assessments at the TDV and during follow -up should be performed as outlined in 
Section 7.1.
8.1.2. Tumor Grow th Kinetics
To evaluate the effect of study  intervention on the growth rate of individual tumor 
lesions, pre -baseline images (within 6 months before the baseline scan) will be requested 
to support exploratory  investigation of tumor growth kinetics . Up to 3 pre -baseline scans 
may be request ed and submitted . Only  those participants who consent to this collection 
will have their pre -baseline images submitted to the central vendor for these anal yses.
8.1.3. Patient Reported Outcomes (PRO)
Planned time points for all assessments related to PROs are lis ted in the SoA and will 
apply  to Part 2 of the study  only.PRO assessments will be administered based on the 
availability  of appropriate translated versions.   Cancer can have a profound impact on 
patients’ health related quality  of life (HRQL); both the symptoms of the disease as well 
as the tolerability  profile of treatments impact HRQL . The patient -reported outcomes 
(PRO) in this study  (Table 11) aim to measure changes in HNSCC symptoms (EORTC -
HN35 ), physical func tioning (PROMI S-PF), and sy mptomatic side effects and 
tolerability  (PRO -CTCAE and FACT- G Item 5) . Cancer related HRQL will be measured 
with the EORTC -QLC-C30 and EQ -5D- 3L. 
2018N362439_01 CONFIDENTIA L
207871
75Table 11 PRO Outcomes Assessed in Study  207871
Instrument Role Rationale & Overview
EORTC QLQ -C30 
EORTC QLQ -HN35Disease specific 
HRQoLThe current standard in disease -specific instruments for assessing cancer 
(specific type as well) HRQoL in clinical trials . A modular system of 
instruments consisting of the co re 30 items ( C30)and HN35 module.
PROMIS –PF Physical 
Function in 
Cancer Physical function can be affected by both disease symptoms and 
treatment- related adverse events, and needs to be evaluated separately . 
Physical function questions will be selecte d from the PROMIS PF item 
bank .
FACT GP5 Symptomatic 
AEs (Global)Single question from the well -established FACT -G (V4), to assess overall 
tolerability from participant ’s perspective 
PRO -CTCAE Symptomatic 
AEs (Specific)A standard and flexible approach to describe and evaluate symptomatic 
adverse events as they are experienced and reported by participants
themselves. 
EQ-5D-3L Health Status The EQ -5D is a generic instrument for describing and valuing health . It is 
based on a descriptive system that def ines health in terms of 5 
dimensions:  Mobility, Self -Care, Usual Activities, Pain/Discomfort, and 
Anxiety/Depression. 
EORTC QLQ -C30 and HN35 = European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire –Core 30 and head an d neck cancer 35module ; FACT GP5 = Functional Assessment of Cancer 
Therapy –General Physical Well Being Item 5; PROMIS PF = Patient -Reported Outcome Measurement Information 
System – Physical Function; Impression of Change ; PRO -CTCAE = Patient Reported Ou tcomes –Common 
Terminology Criteria for AEs; EQ-5D-3L = EuroQOL Group EQ -5D 3 Level Version .
Completion of PRO Questionnaires
PRO questionnaires are to be administered at the beginning of the visits specified in the 
SoA in the order presented in the elect ronic device. To avoid biasing responses, the 
participant s should not be told the results of diagnostic tests prior to completing the 
questionnaires. Adequate time must be allowed to complete all items on the 
questionnaires, and if necessary , the participa ntmust be encouraged to complete any  
missing items.
8.1.3.1. PROMIS Phy sical Function
PROMI S (Patient Reported Outcome Measurement I nformation Sy stem) is a set o f self -
report measurement tools developed b y the US National I nstitutes for Health (NIH) 
[Rose, 2014]. The PROMIS Ph ysical Function item bank is a domain -based item bank 
developed using modern psy chometric theory , containing questions assessing phy sical 
function across a range of baseline functional status.
The most rece nt version of the PROMI S Phy sical Function Item Bank (version 2.0) 
contains 165 items that assess a range of abilities . There also exists a 45- Item PROMI S-
Cancer Item Ba nk (PROMI S Ca Bank version 1.1) [Jensen , 2015;Jensen , 201 7]
containing a subset of items that may  be relevant to patients with cancer . Participants 
enroll ed will self- complete a subset of PROMI S Phy sical Function items.
	
	
 	



D+*+/+-+ 
#H
H>/; I(/8
	<
/%>$$	>	$$	?W2W@$$	8	 	&	$8	
			>$$	''	$	$'$$8 $$	$'$$'$
; -!!=9	<
/%	&'W2	 &	
'$$8'	>	$$	?<
/%W2W%#@	&$$ 		$	'	
$&		'$$'&$		&	&$W 2$&	$9
	W2W%#$	'&		'	'$ (			'9
$
>	$$	$'$ 	'&	$'&	&$ $	&$8	'	9
		$'	 '$'	?$'		&$ '$'8$$(	@
&&'	?$8		0(&$$8$@8 	W2
'	"$8	$	&?	$&$	$	' $$$	
$'$$$'$	@9
			'E ''	&		<
/%W$2$	W	 $$	$ 
$	&''		'$$'&		&$$		$	W2W%# ;4I-!!!=9
$
'&$		(	&$$	&'	--$8	$	&9
&	 	&&	
		'E''	$'$$'$8	$8$ $8		?	
&	@		''$	$8'$''	.$$ &	$'$$$
	&		$8'8	9
D+*+/+/+ "8
	F%?:	$7@$*+$	&'&$$8		>	 $$($	$7
$&W2&$)$'3	4	$8'$F&$3	4	 $8<&$3	
4	$8F'$3	4	$8; %	-!!=9
$'$		$		$
$	$&''				( $	$	'$'
$	'$$?	.&	C
:
1&$	'	$ @$	8		
$?$8$8&$$	(	$@9
	F% $	&$$8	$	&&	F%$'	 		&	
	$			'	&		''	$	9	 	'	$$		($ +
	$	& '	8		'	8$8& N O
N O9$$	&$	$8$'			(		$ $	&	
&	$'$H		'$(	9
D+*+/+=+ "#>
	$	/		
'&	:	$	%&&	&$8 %$	$<
?/
%%<@$$			'&	&			(		 	(	
&&$'.$'$$$	''	'$$'$; 4'*#-7=9	/

%%<	$8			'&$	%&&	& $8%$	$
< ?%%<@		.$'< 	$8$''	 $9	/

%%<$'	$	&$-*7$	&			$8+,& &$'.$'$$	
&	%%<9/
%%<($		&$'		.$ 	
	'$$(		$8&&$'	&	$			'$ ''	'$$'$9
	
			$	&		'	&	/
%%<:	 $-9#
	&$
$	&$$		9CCI
CCI
2018N362439_01 CONFIDENTIA L
207871
778.1.3.5. EuroQOL Group EQ -5D 3 Level Version
EQ-5D is a standardized measure of health status developed by  the EuroQol Group in 
order to provide a simple, generic measure of health for clinical and economic appraisal 
[EuroQol , 1990]. The EQ -5D is applicable t o a wide range of health conditions and 
treatments and provides a simple descriptive profile and a single index value for health 
status that can be used in the clinical and economic evaluation of health care . The EQ -
5D-3L descriptive sy stem comprises the f ollowing 5 dimensions: mobility , self -care, 
usual activities pain/discomfort and anxiety /depression. Each dimension has 3 levels: no 
problems, some problems, extreme problems. The respondent is asked to indicate his/her 
health state b y selecting the most a ppropriate statement in each of the 5 dimensions. The 
EQ VAS records the respondent’s self -rated health on a vertical, visual analogue scale 
where the endpoints are labelled ‘Best imaginable health state’ and ‘Worst imaginable 
health state’. This information can be used as a quantitative measure of health outcome as 
judged b y the individual respondents.
8.2. Safet y Assessments
Planned time points for all safety  assessments are provided in the SoA . These s hould be 
performed and assessed pre-dose on dosing day s. These are required at a minimum and 
may be performed more frequentl y as clinically appropriate (e.g., for weekly dosing of 
SOC agents). Additional time points for safet y testing may  be added during the course of 
the study  based on newl y available data to en sure appropriate safet y monitoring.
8.2.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory , gastrointestinal, and neurological s ystems . Height and weight 
will also be measured and re corded.
A brief ph ysical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular s ystem, and abdomen (liver and spleen). Weight will also be measured 
and recorded. 
Height will be recorded at Screening only.
Investigators sho uld pay  special attention to clinical signs related to previous serious 
illnesses.
8.2.2. Performance Status
Performance status will be assessed using the ECOG scale (Appendix 9 ).
8.2.3. Vital Signs
Vital signs will be m easured after 5 minutes of r est and will include temperature, s ystolic 
and diastolic blood pressure, pulse rate , respiratory  rate and oxy gen saturation via pulse 
oximetry . Blood pressure should be taken in the same position throughout the study  and 
captured in the eCRF. 
Vital signs will be measured more frequently  if warranted by  clinical condition of 
the participant. 
2018N362439_01 CONFIDENTIA L
207871
78If a participant develops fever and infusion related reaction or cy tokine release 
syndrome is suspected, refer to management guidelines (Section 6.6and 
subsections ).
8.2.4. Electrocardiograms
Single 12-lead ECG will be obtained using an ECG machine that automatically  calculate s 
the heart rate and measures thePR, QRS, QT, and QTcFintervals; manual calculation of 
QTcF is permitted . In addition to t he times indicated in the SoA, an ECG may be 
repeated as clinicall y indicated . 
8.2.5. Echocardiograms
Echocardiograms (ECHO) will be performed locally  at screening to assess cardiac 
ejection fraction for study  eligibility , as specified in the SoA (Section 1.3). Additional 
ECHO assessments may  be performed if clinicall y warranted . The evaluation of the 
echocardiograph y should include an evaluation for left ventricular ejection fraction 
(LVEF ) and both right and left- sided valvular lesi ons. Multigated Acquisition Scan 
(MUGA) can be used in lieu of ECHO (if not feasible ) in the assessment of LVEF; the 
same modality  should be used in any  subsequent assessments .
8.2.6. Clinical Safety  Laboratory  Assessments
Refer to Appendix 2forthe list of protocol -required laboratory  tests to be performed and 
to the SoA for the timing and frequency . All protocol -required safety  laboratory  
assessments will be performed at the institution’s local laboratory . Reference ranges for 
all safet y parameters must be provided to the site by the laboratory responsible for the 
assessments . The results of each test must be recorded in the eCRF. If additional non-
protocol specified laboratory  assessments are performed at the institution’s local 
laboratory  and result in a change in participant management or are considered clinically  
significant b y the Investigator (for example, SAE or AE or dose modification) the results 
must also be recorded in the eCRF .
Laboratory  results obtained during S creening should be used to determine eligibility  
criteria . In situations where laboratory  results are outside the permitted range, the 
Investigator may opt to retest the participant and the subsequent screening result, if 
within range, may  be used to confi rm eligibility .
For all other protocol- required blood and tissue sample collections, l aboratory requisition 
forms must be completed and samples must be clearly  label ledwith the participant 
number, protocol number, site/center number, and visit date . Detai ls for the preparation 
and shipment of samples that are required to be tested by  a central laboratory  will be 
provided b y the laboratory and are detailed in the laboratory manual. Refer to the SRM 
for appropriate processing and handling of samples to avoid duplicate and/or additional 
blood draws . 
The Investigator must review the laboratory report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the e CRF. The 
laboratory  reports must be filed w ith the source documents. Clinically  significant 
abnormal laboratory  findings are those which are not associated with the underly ing 
2018N362439_01 CONFIDENTIA L
207871
79disease, unless judged b y the Investigator to be more severe than expected for the 
participant ’s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 30 day safter the last dose of stud y intervention should 
be repeated until the values return to normal or baseline or are no longer considered 
signif icantl y abnormal by the Investigator or Medical Monitor . If such values do not 
return to normal/baseline within a period of time judged reasonable b y the Investigator , 
the etiology  should be identified and the Sponsor notified.
8.3. Adverse Ev ents and Serious A dverse Events
The definitions of an AE or SAE can be found in Appendix 3 .
The Investigator and an y qualified designees are responsible for detecting, documenting, 
and reporting events that meet the definition of an AE or SAE and remai n responsible for 
following up AEs that are serious, considered related to the study  intervention , SOC or 
the study , or that caused the participant to discontinue the study  intervention or SOC (see 
Section 7). 
8.3.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All AESI sand SAEs will be collected from the start of treatment until 90 day s after the 
last dose of study  intervention or SOC at the time points specified in the SoA (Section
1.3). However, an y AESI or SAEs assessed as related to study participation (e.g., study  
intervention , protocol -mandated procedures, invasive tests, or change in existing therapy ) 
or related to a GSK product will be recorded from the time a participant consen ts to 
participate in the stud y. If subsequent anticancer treatment is initiated during the 90 -day 
follow -up period, AESI s and SAEs must continue to be collected and documentation of 
the subsequent anticancer treatment will be recorded in the eCRF.
All AEs will be collected from the start of stud y intervention or SOC until 30 day s after 
discontinuing study  intervention or SOC at the time points specified in the SoA (Section
1.3.
Medical occurrences that begin before the start of study  intervention /SOC but after 
obtaining informed consent will be recorded on the Medical History /Current Medical 
Conditions section of the eCRF not the AE section.
All SAE swill be recorded and reported to the Sponsor or designee immediately  and 
under n o circumstance should this exceed 24 hours, as indicated in Appendix 3 . The 
Investigator will submit any  updated SAE data to the Sponsor within 24 hours of it being 
available.
Investigators are not obligated to activel y seek AEs or SA Esafter the conclusion of the 
study  particip ation. However, if the Investigator learns of any  SAE, including a death, at 
any time after a participant has been discharged from the study , and he/she considers the 
event to be reasonabl y related to the study  intervention /SOC or study  participation, the 
Investigator must promptly  notify  the Sponsor .
2018N362439_01 CONFIDENTIA L
207871
808.3.2. Method of Detecting AEsand SA Es
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AE and/or SAE. Open- ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence . 
8.3.3. Follow-up of AEsand SA Es
After the initial AE/SAE report, the Investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs and non-serious AESI (as defined in 
Section 6.6.1 )will be followed until the event is resolved, stabilized, otherwise
explained, or the participant is lost to follow -up (as defined in Section 7.3). Further 
information on follow- up procedures is given in Appendix 3 .
8.3.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  the Investigator to the Sponsor of anSAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of 
a study  intervention under clinical investigation are met. 
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The Sponsor will comply with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and Investigator s.
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions ( SUSAR) according to local regulatory  requirements and Sponsor policy  and 
forwarded to Investigator s as necessary .
An Investigator who receives an Investigator safety  report describing a SAE or other 
speci fic safet y information ( e.g., summary  or listing of SAE s) from the Sponsor will 
review and then file it along with the Investigator’s Brochure and will notify  the 
IRB/IEC, if appropriate according to local requirements.
8.3.5. Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of male 
participants will be collected after the start of study  intervention and until 180 day s after 
the last dose of study  intervention .
If a pregnancy  is reported, the Investigator should inform GSK within 24 hours of
learning of the pregnancy  and should follow the procedures outlined in Appendix 4.
Abnormal pregnancy  outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAEs.
8.3.6. Cardiovascular and Death Events
For an y c ardiovascular events detailed in Appendix 3 and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF will 
2018N362439_01 CONFIDENTIA L
207871
81be require d to be completed . These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non- cardiovascular death. 
The CV e CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms . The CV information shoul d be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death eCRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
8.4. Treatment of Overdose
An overdose of GSK3359609 is defined as administration of a dose that is at least 50% 
greater than the intended dose. An overdose of tremelimum ab is defined as 
administration of a dose that is greater than the protocol- defined dose.
In the event of an overdose of either GSK3359609 or tremelimumab the Investigator
must :
1.Contact the Medical Monitor immediately .
2. C losely  monitor the participant for AEs/SAEs and laboratory  abnormalities for at 
least 130 day s.
3.Obtain a sample for PK analy sis within 28 day s from the date of the last dose of study  
intervention if requested by  the Medical Monitor (determined on a case- by-case 
basis).
4.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the eCRF.
Decisions regarding dose interruptions or modifications will be made by  the Investigator
in consultation with the Medical Monitor based on the clinical evaluation of the 
participant .
There is no specific antidote for overdose with either GSK3359609 or tremelimumab . In 
the event of a suspected overdose, it is recommended that the appropriate supportive 
clinical care be instituted as dictated b y the participant ’s clinical status.
Refer to the instructions in the approved product labels in the event of an overdose of 
docetaxel, paclitaxel or cetuximab. Contact the Medical Monitor immediately and closel y 
monitor the participant for AEs/SAEs.
8.5. Pharmacokinetics
Planned time points for all ph armacokinetics assessments are listed in Table 12and in the 
SoA.
2018N362439_01 CONFIDENTIA L
207871
828.5.1. Blood Sample Collection
The actual date and time of each blood sample collection will be recorded. The timing of 
PK samples may  be altered and/or PK samples may  be obtained at additional time points 
to ensure adequate PK monitoring. 
Details on PK blood sample collection, processing, storage, and shipping procedures are 
provided in the SRM/laboratory  manual. Windows for sample collection are provided in 
the SRM.
Table 12 Blood sample collection schedule for PK and A DA
Sample Times for Plasma Lev els of GSK3359609
 Pre-dose on treatment visits at Weeks 1, 2, 4, 7, 10, 13 , 16, 19, 25, then every 12 weeks.
 End of Infusion in Week s 1, 19and 2 5
 End of Infusion +4 hours in Week 1
 Additional PK samples to be collected at every pharmacodynamic sample which is collected on the non -
treatment visits
Sample Times for Serum Levels of Tremelimumab
 Pre-dose on treatment visits at Weeks 1, 2, 4 , 7, 10, 1 3, 16, then every 12 weeks.
 End of Infusion in Week 1
 End of Infusion +4 hours in Week 1
 Additional PK samples to be collected at every pharmacodynamic sample which is collected on the non -
treatment visits
Samples Times for Serum Anti-Drug Antibody Samp les G SK3359609
 Pre-dose on treatment visits at Weeks 1, 4, 7, 10, 13, 16, 19, 22, 25,every 12 weeks. 
 At the Treatment Discontinuation Visit.
 On non -treatment visit days draw at any time .
 For participants with a p ositive ADA at the last visit, draw one additi onal sample at 6 months after the last 
dose. 
Samples Times for Serum Anti-Drug Antibody Samples Tremelimumab 
 Pre-dose on treatment visits at Weeks 1, 4, 7, 10, 13, 16 then every 12 weeks.
 At the Treatment Discontinuation Visit.
 On non -treatment visit d ays draw at any time .
 For participants with a p ositive ADA at the last visit, draw one additional sample at 6 months after the last 
dose .
8.5.2. Sample A nalysis
PK analy sis will be performed on samples as indicated in the SoA and Table 12. 
Concentrations of the study  interventions will be determined using validated bioanaly tical 
methodologies. 
8.6. Pharmacody namics
Pharmacod ynamic parameters evaluated in this study are presented in Section 8.8on 
biomarkers .
8.7. Gene tics
A6mL  blood sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analy sis component of the study. Participation is 
2018N362439_01 CONFIDENTIA L
207871
83optional. Participants who do not wish to participate in the genetic research may still 
participate in the stud y.
In the event of DNA extraction failure, a replacement genetic blood sample may  be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the orig inal consent.
See Appendix 5for information regarding genetic research. Details on processes for 
collection, shipment and destruction of these samples can be found in the laboratory  
manual/ SRM .
8.8. Biomarkers
8.8.1. Blood Biomarkers
Blood sampl es for biomarkers will be collected as whole blood, plasma, and serum . 
Whole blood may be utilized to assess receptor occupancy  by GSK3359609 and 
tremelimumab , immune cell number s, phenot ype, activation and function. Additionally , 
whole blood will be used to isolate PBMCs and then preserved and stored for flow 
cytometry  of additional cell ty pes, subsequent functional anal ysis or genetic anal ysis and 
their relationship to clinical responses, and changes in response to treatment . PBMCs 
may also be evaluated for genomic (DNA) and gene expression (RNA) or protein 
alterations to determine treatment -related changes in immune -related signatures. Plasma 
and serum samples may be used for anal ysis of circulating soluble factors in relation to T 
cellactivation, cfDNA, exosomes and circulating proteins . Factors to be analy zed may  
include but are not limited to cy tokines, chemokines, soluble receptors, cfDNA , 
antibodies against tumor, self -tumor mutations, gene expression ; genetic analy sis (DNA, 
RNA or protein) or viral antigens. 
If predictive biomarkers are identified in the blood samples, these samples may  be used 
for the development of a diagnostic test.
8.8.2. Tumor Tissue Biomarkers
In Part 1 and Part 2, for all participants, archival tumor tissue will be required (or a fr esh 
biopsy  if no archival is available). Fr esh paired biops ies(defined as a pre-treatment 
sample, collected an y time after end of previous therap yand prior to first dose of study  
intervention/SOC , and an on- treatment sample collected at W eek 7) are recom mended, 
but not mandatory , EXCEPT as noted below:
In the PK/Pharma codynamic cohort(s), paired biopsies are required .
In Part 2, a minimum of 15 participants in each arm will be required to provide 
paired biopsies Additional participants may  be requested for paired biopsies if 
>30% of the 15 paired tissue samples are not evaluable.
For all participants in this study , a fresh biops y is recommended at the time of disease 
progression or response confirmation.
2018N362439_01 CONFIDENTIA L
207871
84These tissues will be evaluated b y immunohistoche mistry (IHC) or other potential
methods for expression of phenoty pic and functional immune cell markers. For some 
participants with cancer types that may  be virall y mediated , for e.g., HNSCC of the 
orophary nx, these tissues may be utilized to assess the HP V (human papilloma virus) 
status either by  a p16 IHC or other HPV testing methods. Additionally , tumor tissue may  
be utilized for DNA and/or RNA sequencing for exploratory  biomarker evaluations 
including but not limited to T cell diversity  (TCR diversity ),mutational load , DNA 
polymorphisms (target, Fc receptor etc.), tumor antigen- specific T cell assessments as 
well as expression of RNA and protein changes. These samples may  also be evaluated for 
predictive measures of response to include in the biomar ker-selected population . If a 
predictive biomarker is identified, these tissues may be used for the development of a 
diagnostic test. Other biomarkers may  be evaluated as determined by  additional data .
Details for the samples collection, processing, storage an d shipment will be provided in 
the SRM.
8.8.3. Immunogenicity  Assessment s
Antibodies to GSK3359609 and t remelimumab (ADA) will be evaluated in serum
samples collected from all participants acco rding to the SoA and Table 12. The actual 
date and time of each blood sample collection will be recorded. The timing of ADA
samples may be altered and/or ADA samples may  be obtained at additional time points to 
ensure adequate ADA monitoring.’
Serum samples will be screened for antibodies binding to GSK3359609 and to 
tremelimumab and the titer of confirmed positive samples will be reported. Other 
analyses may  be performed to verify  the stability  of antibodies to GSK3359609 and to 
tremelimumab and/or further characterize the immunogenicity  ofGSK33596 09 and of 
tremelimumab .
The detection and characterization of antibodies to GSK3359609 and to tremelimumab
will be performed using a validated assay  method for each either by or under the 
supervision of the Sponsor .Antibodies may  be further characterized and/or evaluated for 
their ability  to neutralize the activity  of the study  intervention s, GSK 3359609 an d 
tremelimumab . 
8.8.4. DNA /RNA  Transcriptome and RNA  expression Research
Samples for the assessments of blood biomarkers and tumor biomarkers are described in 
Section 8.8.1 and in Section 8.8.2 , respectivel y.
8.8.5. Proteome Research
See Section 8.8.1 for information on proteome research.
8.9. Health Economics /Medical Resource Utilization and Health 
Economics
The PROs used in this study  are presented in Section 8.1.3 and subsections.
2018N362439_01 CONFIDENTIA L
207871
859. STATISTICA L CONSIDER ATIONS
9.1. Statistical Hy potheses
9.1.1. Part 1: Dose Escalation 
With respect to the primary  objectives and endpoints, no specific statistical hypotheses 
are being tested in Part 1. The primary  focus will be on determining the recommended
dose for further exploration , the safet yprofile and the PK profile .
9.1.2. Part 2: Cohort Expansion
The primary  endpoint for Part 2 is OS and primary anal ysis is to perform Bayesian 
predictive probability  of Phase 3 study  success based on survival data. 
The hypotheses about the overall survival of the study  intervention (RP2D dose 
combination) and SOC are detailed below.
The null hy pothesis is:
H0: There is no difference in overall survival between the study  intervention and the SOC
The alternative hy pothesis is:
HA:The study  intervention improves overall survival over the SOC
9.2. Sample Size Determination
A maximum of 114 participants will be enrolled into the study . Up to 24 participant s will 
beenroll ed in Part 1 dose escalation and 90 participants will be enroll ed in Part 2 dose 
expansion. 
9.2.1. Part 1: Dose Escalation
The total number of participant s to be enroll ed in Part 1 will depend on the numbe r of 
participant s needed to characterize the individual dose cohorts for determination of the 
MTDs or MADs . With the pre -specified maximum sample size of 24 participants,
simulations were conducted to determine the average sample size and percentage of tim es 
each dose would be selected under three different scenarios, assuming the bivariate CRM 
dose recommendations are followed, e.g.,an increasing toxicity  scenario, a low toxicity  
scenario, and a threshold toxicity  scenario. For each scenario, 1000 clinica l trials were 
simulated . The average sample sizes over the 1000 clinical trials simulated under the 
three scenarios were 20.2, 22.7, and 22.7, respectively . Details of the scenarios are 
provided in Table 14. The dose combination s in the table are the pre- selected dose
combination s that are projected to be used in the study . The actual dose combination s 
used during the conduct of the study  may  be different.
For the simulations, the selected reference doses were 24mg for GSK3359609 and 75 mg 
for tremelimumab. The priors for each pair of parameters (α, β) for the toxicity  model for 
2018N362439_01 CONFIDENTIA L
207871
86each drug are specified via a bivariate normal distribution (as in the single drug CRM), 
with a separate mean and 
standard deviation (s.d.) for ln(α)and ln(β), and a correlation 
term. Th e parameters (s.d.) of the model are
ln(1)-3 (10), ln( 1) 1(10), 
ln(2)-3 (10), ln( 2) 1(10), 
ρ1 ρ20.1
where ln()and ln( ) for each drug are 
assumed to be distributed as bivariate normal
with correlation ρ. The prior for the interaction term η is assumed to follow the standard 
normal distribution N(0,1).
In addition, t he prior DLT information collected from former clinical trials of 
tremelimumab in combination with durvalumab and the on- going GSK3359609 
monotherap y clinical trial are incorporated i ntothe calculation of DLT probability (note: 
DLT information for tremelimumab monotherapy  clinical trial is not available). For each 
dose combination, a prior observed number of DLTs and number of
 observations are 
specified in Table 13.
Table 13 Prior Observed DLTs and Number of Observations
GSK3359609 (mg)
0 8 24 80
Tremelimumab (mg)225 2/34 0/0 0/0 0/0
75 0/57 0/0 0/0 0/0
0 0/0 0/15 0/29 0/32
The simulation results for dose selection under various scenarios based on the priors of 
parameter (α,β)and prior DLT information are shown in Table 14. It is noted that the
simulation results areentirely  based on bivariate CRM model for every  dose escalation 
recommendation ;
however, per the Part 1 design, bivariate CRM mode l would not be 
employ ed until the first DL T occurs.
2018N362439_01 CONFIDENTIA L
207871
88arm, and 345 participants (230 in the study  intervention and 115 in the SOC arm) in the 
hypothetica l Phase 3 study , if the true effect of study  intervention is as expected ( Figure 
5), the power will be 82.5%.
Table 15 Operating Characteristics for Part 2 Design
Sample Size Success Criterion 
for Phase 3Number of Events for Final 
Analysis Power Alpha
90 > 60% 72 82.5% 0.087
If the null hy pothesis is true, i.e. the OS of study  intervention does not have significant 
difference compared with the SOC , the ty pe I error ( alpha) w ould be 0.087. 
Note that t he sample size for Part 2 may  be re -evaluated upon completion of Part 1 when 
emerging efficacy  data of Part 1are available .
Details about the simulation method for the sample size determination are provided in
Appendix 10.
9.3. Population s for A nalyses
For purposes of analy sis, the following populations are defined:
Population Description
Screened All participants who were screened for eligibility
Enroll ed All participants who passed screening and entered the study. Included are: 
Participants in Part 1 who receive at least one dose of tremelimumab or 
GSK3359609 ; Participants who are randomized for Part 2.
Intent to Treat (ITT) All participants who are randomized in the study . This will be the primary 
population for Part 2 efficacy analyse s.
All Treated All participants who receive at least onedose of SOC or tremelimumab or 
GSK3359609 .This will be the population for s afety and efficacy analysesforPart 
1 and safety analyses for Part 2.
PK All participant s from the All Treated p opulation for whom a PK sample is obtained
andanalysed. This will be the primary population for PK analyses .
Pharmacodynamic All participants from the All Treated population for whom a 
pharmacodynamic/biomarker sample is obtained and analysed. This will be th e 
primary population for Pharmacodynamic/Biomarker analyses.
Additional analy sis populations may  be defined in the Reporting and Anal ysis Plan 
(RAP).
2018N362439_01 CONFIDENTIA L
207871
899.4. Statistical A nalyses
Data will be listed and summarized according to the GSK reporting standards, where 
applicable . Complete details will be documented in the RAP . Any deviations from, or 
additions to, the original anal ysis plan described in this protocol will be documented in 
the RAP and final study  report.
As it is anticipated that accrual will be spread th inly across centers and summaries of data 
by center would be unlikely  to be informati ve, data from all participating centers will be 
pooled prior to anal ysis.
All data up to the time of study  completion/withdrawal from study  will be included in the 
analysis, regardless of duration of treatment.
As the duration of treatment for a given participant will depend on efficacy  and 
tolerability , the duration of follow -up will vary  between participant s. Consequently ,there 
will be no imputation for missing data. 
Demographic and baseline characteristics will be summarized.
9.4.1. Efficacy  Analyses
Lesion assessment method and timing, evaluation of disease, disease progression and 
response criteria will be conducted according to RECI ST 1.1 [Eisenhauer , 2009] and 
iRECI S T as outlined in Appendix 7 of the protocol . iRECI STwillbeused todetermine
treatment decisions and RECI ST 1.1will be used for the primary anal ysis of anticancer 
activity .
The ITT population wi ll be used for anticancer activity analyses for Part 2, and All 
Treated Population will be used for anticancer activity  analyses for Part 1. Since this is a n
early phase study , anticancer activity  will be evaluated based on clinical evidence and 
response c riteria . If data warrant, the response data will be summarized by  part and dose 
level . Correlation analy sis may be conducted to explore any  relationship between the 
biomarkers and tumor response based on RECI ST 1.1 . Full details will be specified in the 
RAP.
9.4.1.1. Overall Survival (OS)
For Part 1 participants, o verall survival is defined as time from the date of first dose to
the date of death due to any  cause. For Part 2 participants, overall survival is defined as 
time from the date of randomization to the date of death due to an y cause. For the 
analysis of overall survival (OS), the last date of known contact will be used for those 
participant s who have not died at the time of anal ysis; such participant s will be 
considered censored. OS will be summarized for Pa rt 2 using Kaplan- Meier estimates 
along with 2- sided 95% C I at the time of final analy sis. Log -rank tests will be performed 
for Part 2 data to compare the overall survival between the study  intervention and the 
SOC .
2018N362439_01 CONFIDENTIA L
207871
909.4.1.2. Overall Response Rate (ORR)
ORR is defi ned as percentage of p articipant s with confirmed complete response or partial 
response at an y time as per RECI ST 1.1 .The observed ORR and 95% exact confidence 
interval (CI) will be reported for final anal yses.
9.4.1.3. Disease Control Rate (DCR )
DCRis defined as percentage of participants with confirmed complete response or partial 
response or at least 1 8weeks of stable disease. DCR and 95% exact confidence interval 
(CI) will be reported forfinal anal yses.
9.4.1.4. Duration of Response (DOR )
DOR is defined as time from the first documented evidence of response until the first 
documented sign of disease progression or death among 
participants who achieve a 
response ( CR or PR ). DOR will be summarized descriptivel y using Kaplan- Meier 
method . 
9.4.1.5. Progression Free Survival (PFS )
For Part 1 participants, PFS duration is defined as the time from the date of first dose to 
first documented evidence of disease progression or death (regardless of cause of death), 
whichever comes first . For Part 2 participants, PFS duration is defined as the time from 
the date of randomization to first documented evidence of disease progression or death 
(regardless of cause of death), whichever comes first. PFS will be summarized using 
Kaplan -Meier estimates along with 2- sided 95% C is forfinal anal ysis. 
9.4.1.6. Time to Response (TTR)
TTR is defined as the time from the 
first dose to the first documented evidence of CR or 
PRfor participants with a confirmed CR or PR. TTR will be summarized descriptivel y
using Kaplan-Meier estimates along with 2- sided 95% C is forfinal anal ysis.
9.4.1.7. Predictive Probability  of Phase 3Success
Thepredictive probability  of Phase 3study  success with respect to OS will provide 
evidence whether the study  will graduate into a future Phase 3 trial based on the Part 2 
survival data.
The prima ry comparison of OS between the study  intervention and SOC will be anal ysed 
by a log rank test with treatment as fixed effect. The hazard ratio (HR) will be derived 
based on the ratio of the hazard rate sinthe study  intervention and SOC observed from 
the Part 2 overall survival data. The predictive probability  of success for the hypothetical 
Phase 3 study  will be calculated as detailed below, assuming both the data and prior 
follow normal distributions. By using conjug ateprior ,we can obtain a closed -form
solution for posterior and predictive distribution of θ log(HR) at the end of Part 2 of the 
study .
Minimal -informative prior ofθ:
2018N362439_01 CONFIDENTIA L
207871
91θ∼N(θ 0, V0),where θ00,V04.5/n 0forarandomization ratio 2:1.N0isthenumber of
events inprior andassumed tobe a small value 0.1forthenoninformative prior
Posterior distribution of θgiven Part2overall survival results X(the estimated log
Hazard Ratio atthefinal analysis):
θ|∼N( , Vpost),
where m ;
             V post  1/(1/v p2+1/v 0);
andVp21/n t+1/n c,where ntandncaretheexpected number ofevents inthestudy
intervention armandSOC arm, respectively .
Then, thepredictive distribution of
Phase 3 log(HR) Y given Part2results Xis:
Y∣X,∼ N( ,4.5/m + V post),
where Xis the estimated log Hazard Ratio from final analysis of Part 2, and Y is 
predictive distribution of log Hazard Ratio in the future Phase 3 study. M istheexpected
number ofevents inthefuture Phase 3trialandispre-specified as240, which is
approximately 70% of thesample sizeinPhase 3.
One thousand predictive distributions are sampled and the predictive probability  of Phase 
3 success is calculated based on the proportion of test statistics less than -1.96
(
corresponding to one- sided type I error of 0.025) out of samplings drawn from the 
predictive distribution
. The test statistic is Phase 3 signal/noise ratio of HR between the 
study  intervention and S O
C. 
9.4.2. Safety  Analyses
The All Treated Population will be used for the analy sis of safet y data. All serially 
collected safet y endpoints (e.g.
,laboratory  tests, vital signs) will be summarized 
according to the scheduled, nominal visit at which they  arecollected and across all on-
treatment time points using a “wors t-case” analy sis. Complete details of the safet y 
analyses will be provided in the RAP.
9.4.2.1. Extent of Exposure
The number of participants administered study  intervention or SOC will be summarized 
according to the duration of therap y.
9.4.2.2. Adverse Events
AEs will be coded using the standard MedDRA and grouped by  system organ class . AEs 
will be graded b y the Investigator according to the NCI -CTCAE (version 5.0) [NCI, 
2017] .
2018N362439_01 CONFIDENTIA L
207871
92Events will be summarized by  frequency  and proportion of total participant s,by system 
organ class and preferred term . Separate summaries will be given for all AEs, treatment-
related AEs, SAEs and AEs leading to discontinuation of study  intervention . AEs, if 
listed in the NCI -CTCAE (version 5.0) will be summarized by the maximum grade . 
Otherwise, the AEs will be summarized by  maximum intensity .
Characteristics (e.g. ,number of occurrences, action taken, grade, etc .) of AEs of special 
interest will be summarized separatel y.
The incidence of deaths and the primary  cause of death will be summarized.
9.4.2.3. Clinical Laboratory  Evaluations
Hematology  and clinical chemistry  data will be summarized using frequencies and 
proportions according to the NCI -CTCAE ( version 5.0) [NCI, 201 7]. Laboratory  test 
results outside the refer ence ranges that do not have an associated NCI -CTCAE criteria 
will be summarized using proportions . Further details will be provided in the RAP.
9.4.2.4. Other Safety  Measures
Data for vital sig ns and electrocardiograms (ECGs) will be summarized based on 
predetermi ned criteria identified to be of potential clinical concern (PCI) . Further details 
will be provided in the RAP.
9.4.3. Other A nalyses
PK, pharmacod ynamic, immunogenicit y(ADA) and biomarker exploratory anal yses will 
be described in the RAP .The population PK anal ysis and pharmacod ynamic anal yses 
may be presented separately  from the main clinical study  report (CSR). 
9.4.3.1. Pharmacokinetic A nalyses
Pharmacokinetic Parameters
PKanaly sis will be the responsibility  of the Clinical Pharmacology  Modeling and 
Simulation (CPMS) Department, GSK.
PK analy sis of drug concentration -time data will be performe d by non-compartmental 
methods under the direction of CPMS, Quantitative Sciences, GSK . The following PK 
parameters will be determined for GSK3359609 and tremelimumab separately ,if data 
permit:  
maximum observed plasma concentration (Cmax)
minimum observed plasma concentration (Cmin )
area under the plasma conce ntration- time curve AUC(0- t) (repeat dosing) .
2018N362439_01 CONFIDENTIA L
207871
93Statistical Analysis of Pharmacokinetic Data
Statistical analy ses of the PKparameters data will be the responsibility  of Clinical 
Statistics & Programming .
Drugconcentration -time data will be listed for each participant and summarized by  
descriptive statistics at each time point by  dose level/cohort for each part , and for 
GSK3359609 and tremelimumab separatel y. 
9.4.3.2. Pharm acokinetic/Pharmacodynamic A nalyses
If deemed appropriate and if data permit, exposure response relationship between 
GSK 3359609 /tremelimumab (e.g., dose, concentration, Cmax, or AUC) and clinical 
endpoints (e.g.,antitumor response, biomarkers) may be conducted. The details of such 
exposure -response anal ysis will be outlined in the RAP.
9.4.3.3. Immunogenicity  Analyses
Results of anti -drug antibodies (ADA) testing will be reported at the end of the study  and 
will include i ncidence and titer. The presence or absence of antibodies to GSK3359609 
and tremelimumab in dosed participants will be analy sed, then be summarized 
descriptivel y and/or graphically presented , respectively .Further details will be provided 
in the RAP.
9.4.3.4. Tran slational Research A nalyses
The results of translational research investigations will be reported separately  from the 
main clinical study  report (CSR) . All endpoints of interest from all comparisons will be 
descriptivel y and/or graphically summarized as ap propriate to the data.
Further details on the translational research anal yses will be addressed in the RAP or a 
separate biomarker RAP .
9.4.3.5. Tumor Kinetic A nalyses
Exploratory  anal yses may  be performed to evaluate the effect of study  intervention on the 
growth kinetics of individual tumor lesions. These anal yses may  include tumor lesion 
measurements from imaging scans performed earlier in the disease course (i.e., prior to 
screening scans).
If deemed necessary , additional statistical analy ses will be discussed i n RAP.
9.5. Interim Analyses
9.5.1. Part 1 : Dose Escalation
In Part 1, interim anal yseswill be performed to determine if a dose -escalation is 
appropriate and to support the dose escalation decision following the completion of each 
dose cohort . The primary driver for the dose -scalation decision(s) in Part 1 will be safet y 
and tol erability  of each dose cohort. T he DLT information along with preliminary  safet y 
2018N362439_01 CONFIDENTIA L
207871
94data, including AEs, changes in laboratory  values and other safet y parameters, and 
available PK/pharmacody namic data will be evaluated for each dose escalation cohort 
prior to making dose escalation decisions.
Further details regarding such anal yses will be provided in the RAP.
9.5.2. Part 2: Cohort Expansion
No interim anal ysis for futility  or efficacy  will be performed in Part 2. The study  team 
may evaluate safet y, PK and Pharmacod ynamic data and make the recommendation to 
discontinue the study at any  time due to safet y concerns. 
2018N362439_01 CONFIDENTIA L
207871
9510. SUPPORTING DOCUMENTA TION AND OPERA TIONAL
CONSIDERA TIONS
10.1. Appendix 1: Regulatory , Ethical, an d Study  Oversight 
Considerations
10.1.1. Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Counc il for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents ( e.g., advertisements) must be submitted to an IRB/IEC by  the 
Investigator and reviewed and approved by  the IRB/IEC before the study  is initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of cha nges made to the study  design, except for changes necessary  to 
eliminate an immediate hazard to study  participants. 
The Investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC annually  
or more frequentl y in accordance with the requirements, policies, and 
procedures established by the IRB/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as required by 
IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations
10.1.2. Financial Disclosure
Investigators and sub- Investigator s will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for pro viding information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
10.1.3. Informed Consent Process
The Investigator or his/her representative will explain the nature of the study  to the 
participant or his/her le gally  authorized representative and answer all questions 
regarding the stud y. 
2018N362439_01 CONFIDENTIA L
207871
96Participants must be informed that their participation is voluntary . Participants or 
their legally  authorized representative will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, I CH 
guidelines, Health Insurance Portability  and Accountability  Act (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enroll ed in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
Participants must be re -consented to the mos t current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative. 
Participants who are rescreened are required to sign a new ICF.
The ICF may  contain a separate section that addresses the use of remaining mandatory  
samples for optional exploratory  research in accordance with SOP- GSKF -410. The 
Investigator or authorized designee will explain to each participant the objectives of the 
explo ratory  research. Participants will be told that they  are free to refuse to participate 
and may  withdraw their consent at any  time and for an y reason during the storage period. 
A separate signature will be required to document a participant ’s agreement to a llow any  
remaining specimens to be used for exploratory  research. Participants who decline to 
participate will not provide this separate signature.
10.1.4. Data Protection
Participants will be assigned a unique identifier by  the Sponsor . Any participant records 
ordatasets that are transferred to the Sponsor will contain the identifier only ; participant 
names or an y information which would make the participant identifiable will not be 
transferred. 
The participant must be informed that his/her personal study -relate d data will be used by  
the Sponsor in accordance with local data protection law. The level of disclosure must 
also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  
Clinical Quality  Assurance auditors or other authorized personnel appointed by  the 
Sponsor , by appropriate IRB/IEC members, and by inspectors from regulatory  
authorities.
10.1.5. Dissemination of Clinical Study  Data
Where required b y applicable regulatory  requirements, an Investigator signatory will be 
identified for the approval of the clinical study  report. The Investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a GSK sit e or other mutually -
agreeable location.
2018N362439_01 CONFIDENTIA L
207871
97GSK will also provide the Investigator with the full summary  of the stud y results . The 
Investigator is encouraged to share the summary  results with the study  participant s, as 
appropriate.
The procedures and timing fo r public disclosure of the protocol and results summary  and 
for development of a manuscript for publication for this study  will be in accordance with 
GSK Policy .
GSK intends to make anony mized participant -level data from this study available to 
external researchers for scientific anal yses or to conduct further research that can help 
advance medical science or improve patient care. This helps ensure the data provided b y 
study participants are used to maximum effect in the creation of knowledge and 
understanding
10.1.6. Data Quality  Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or designee electronically  (e.g., laboratory  data). The 
Investigator is responsible for verify ing that dat a entries are accurate and correct by  
physicall y or electronically  signing the CRF. 
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
Monitoring details describing strategy  (e.g., risk -based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategi es and Anal ytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in Monitoring Plan.
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data. 
The Sponsor assumes accountability  for actions delegated to other individuals ( e.g., 
Contract Research Organizations).
Study  monitors will perform ongoing source dat a verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that 
the study  is being conducted in acc ordance with the currently  approved protocol and any  
other study  agreements, ICH GCP, and all applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this study  
must be retained b y the Investigator for25 years from the issue of the final Clinical Study  
Report (CSR)/ equivalent summary unless local regulations or institutional policies 
require a longer retention period. No records may  be destroy ed during the retention 
period without the written approval of the Sponsor . No records may  be transferred to 
another location or part y without written notification to the Sponsor . 
2018N362439_01 CONFIDENTIA L
207871
9810.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data col lected. Source documents are filed at the Investigator ’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The Investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the Investigator Site File.
10.1.8. Study and Site Closure
GSK or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of GSK. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The Investigator may initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reaso ns for the earl y closure of a stud y site b y the Sponsor or Investigator may include 
but are not limited to:
Failure of the Investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor ’s procedures, or G CP guidelines
Inadequate recruitment of participants by  the Investigator
Discontinuation of further study  intervention development
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor
before submission. This allows the Sponsor to protect proprietary  information and to 
provide comments.
The Sponsor will comply with the requirements for publication of study  results. In 
accordance with standard editorial and ethical practice, the Sponsor will generall y 
support publication of multicenter studies only in their entiret y and not as individual site 
data. In this case, a coordinating Investigator will be designated b y mutua l agreement.
Authorship will be determined by  mutual agreement and in line with I nternational 
Committee of Medical Journal Editors authorship requirements.
2018N362439_01 CONFIDENTIA L
207871
9910.2. Appendix 2: Clinical Laboratory  Tests
Table 16 Protocol -Required Safety  Laboratory  Assessments
Laboratory Assessments Parameters
Hematology RBC Indices WBC count with Differential Platelets
Hemoglobin Neutrophils
Hematocrit Lymphocytes
RBC count Monocytes
Eosinophils
Basophils
Clinical Chemistry BUNa Potassium Bilirubin AST (SGOT)
Creatinineb Sodium Total protein ALT (SGPT)
Glucose Calcium Albumin Alkaline phosphatase
LDH
Coagulation INR or PT
aPTT
Cardiac Function Troponin I or Troponin T
Thyroid Function Thyroid stimulating hormone
Free T4
Free T3 (when clinically indicated)
Pancreatic Function Amylase
Lipase
Routine Urinalysis Specific gravity
pH, glucose, protein, blood and ketones by dipstick
Other Screening Tests Hepatitis B (HbsAg)
Hepatitis C (Hep C antibody)c
Serum -hCG Pre gnancy test ( for women of child bearing poten tial)
HIV testing 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; -hCG=beta -human chorionic 
gonadotropin; BUN=blood urea nitrogen; H bsAg=Hepatitis B surface antigen; RBC=red blo od cells; SGOT=serum 
glutamic oxaloacetic transaminase; SGPT= serum glutamic pyruvic transaminase; T3= triiodothyronineT4= 
thyroxine; WBC = white blood cells; INR = International Normalized Ratio; PT = Prothrombin Time; aPTT = 
Activated Partial Thromboplastin Time
a. Required if local laboratory testing is available
b. Creatinine clearance is also required to be calculated using the formula provided in Appendix 8 .
c. Participant s with positive Hepatitis C antibody due to prior r esolved disease can be enroll ed, only if a confirmatory 
negative Hepatitis C RNA test is obtained. Hepatitis C RNA Test is optional with negative Hepatitis C antibody 
test.
2018N362439_01 CONFIDENTIA L
207871
105telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
Initial notification via tele phone does not replace the need for the Investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found at the beginning of this protocol and in the 
SRM on the Sponsor/Medical Monitor Contact Information page.
2018N362439_01 CONFIDENTIA L
207871
10610.4. Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy  Information
10.4.1. Definition: Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanent ly sterile (see below).
If fertility  is unclear ( e.g., amenorrhea in adolescents or athl etes) and a menstrual cy cle 
cannot be confirmed before first dose of stud y intervention/SOC , additional evaluation 
should be considered.
Women in the follo wing cate goriesare not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
Documented h ysterectomy
Documented bilateral salpingectomy
Documented bilateral oophorectom y
For individuals with permanent infertility due to an alternate medical cause other 
than the above, ( e.g., Mullerian agenesis, androgen insensitivity ), Investigator
discretion should be applied to determining stud y entry .
Note: Documentation can come from the site personnel’s: review of the 
participant’s medical records, medical ex amination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. 
A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in women not 
using hormonal contraception or hormonal replacement therap y (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement is required. 
Females on HRT and whose menopau sal status is in doubt will be required to 
use one of the non -estrogen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study . Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before 
study  enroll ment.
2018N362439_01 CONFIDENTIA L
207871
10710.4.2. Contraception Guidance
Male participants
Male participants with female partners of child- bearing potential are eligible to 
participate if they  agree to ONE of the following during the protocol -defined 
time frame in Section 5.1: 
Are abstinent from penile -vaginal intercourse as their usual and preferred 
lifesty le (abstinent on a long term and persistent basis) and agree to remain 
abstinent 
Agree to use a male condom plus an additional method of contracep tion with 
a failure rate of <1% per y e ar as described in Table 17when having 
penile -vaginal intercourse with a woman of childbearing potential 
Men with a pregnant or breastfeeding partner must agree to remain abstinent from peni le-
vaginal intercourse or use a male condom during each episode of penile penetration for 
the duration of the stud y and for at least 1 80 day s after the last dose of study  treatment if 
receiving GSK3359609 and tremelimumab.
In addition, male participants mu st refrain from donating sperm for duration of study  and 
for at least 180 day s after the last dose of GSK3359609 and tremelimumab .
If the participant is randomized to SOC, then the duration of contraception after the last 
dose is at per the package insert and/or Institutional guidelines . 
Female participants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently  and correctly  as described in
Table 17 . 
Table 17 Highly  Effective Contraceptive Methods
 CONTRACEPTIVESaALLOWED DURING THE STUDY INCLUDE:
 Highly Effective MethodsbThat Have Low User Dependency 
 Implantable progestogen -only hormone contraception associat ed with inhibition of ovulationc
 Intrauterine device (IUD)
 Intrauterine hormone -releasing system (IUS)c
 Bilateral tubal occlusion
 Vasectomized partner
Note: Vasectomized partner is a highly effective contraceptive method provided that the 
partner is th e sole sexual partner of the woman of childbearing potential and the absence 
of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.
 Highly Effective MethodsbThat Are User Dependent
2018N362439_01 CONFIDENTIA L
207871
108 Combined (estrogen -and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc
oral
intravaginal
transdermal
injectable
 Progestogen -only hormone contraception associated with inhibition of ovul ationc
oral
injectable
 Sexual abstinence
Note :Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with 
the study intervention. The reliability o f sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the participan t
a. Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for those participating in clinical studies.
b. Failure rate of <1%  per year when used consistently and correctly. Typical use failure rates differ from those when 
used consistently and correctly.
c. Male condoms must be used in addition to hormonal contra ception .Iflocally required, in accordance with Clinical 
Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those which inhibit 
ovulation as the primary mode of action.
Note: Periodic abstinence (calendar, sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception for this 
study. Male condom and female condom should not be used together (due to risk of failure with friction)
10.4.3. Collection of Pregnancy  Information:
Male participants with partners who become pregnant
Investigator will attempt to collect pregnancy  information on any  male participant’s 
female partner of a male study  participant who become s pregnant while participating 
in this study . This applies only  to male participants who receive GSK3359609 plus 
tremelimumab .
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the Investigator will record pre gnancy  information on the 
appropriate form and submit it to GSK within 24 hours of learning of the partner’s 
pregnancy . 
The female partner will also be followed to determine the outcome of the pregnancy . 
Information on the status of the mother and child w ill be forwarded to GSK.
Generally , follow -up will be no longer than 6 to 8 weeks following the estimated
delivery  date. An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for proce dure. 
2018N362439_01 CONFIDENTIA L
207871
109Female Participants who become pregnant
Investigator will collect pregnancy  inform ation on any  female participant who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to GSK within 
24 hours of learning of a participant’ s pregnancy . 
Participant will be followed to determine the outcome of the pregnancy . The 
Investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK .Generall y, follow- up will not be required for longer than 6 to 
8 weeks bey ond the estimated delivery  date . 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, an y pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such. 
Any SAE occurring as a result of a post- study  pregnancy  which is considered 
reasonabl y related to the study  intervention b y the Investigator , will be reported to 
GSK as described in Appendix 3 . While the Investigator is not obligated to activel y 
seek this information in former stud y participants, he or she may learn of an SAE 
through spontaneous reporting. 
Any female participant who becomes pregnant while participating will discontinue study  
intervention or SOC .
2018N362439_01 CONFIDENTIA L
207871
11010.5. Appendix 5: Genetics
USE/ANALYSIS OF DNA
Genetic variation may  impact a participant’s response to study  intervention , 
susceptibility , severit y and progression of disease. Variable response to study  
intervention may be due to genetic determinants that impact drug absorption, 
distribution, m etabolism, and excretion; mechanism of action of the drug; disease 
etiology ; and/or molecular subty pe of the disease being treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analysis
DNA samples will be used for research related to GSK3359609 or in selected, 
advanced solid tumors and related diseases. They  may  also be used to develop 
tests/assay s including diagnostic tests) related to GSK3359609, and in selected, 
advanced solid tumors .Genetic research ma y consist of the anal ysis of one or more 
candidate genes or the analy sis of genetic markers throughout the genome or anal ysis 
of the entire genome (as appropriate)
DNA samples will be analy zed for by using appropriate descriptive and/or statistical 
analysis methods. A detailed description of any  planned analy ses will be documented 
in a RAP prior to initiation of the anal ysis.
The samples may  be analy zed as part of a multi- study  assessment of genetic factors 
involved in the response to GSK3359609 or study i nterventions of this class. The 
results of genetic anal yses may  be reported in the clinical study  report or in a 
separate study  summary .
The Sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained while research on GSK3359609 (or study  interventions 
of this class) or in selected, advanced solid tumors continues but no longer than 15 
years after the last participant last visit or other period as per local requirements.
2018N362439_01 CONFIDENTIA L
207871
11110.6. Appendix 6: Liver Safety : Required A ctions and Follow -up 
Assessments and Study  Intervention Rechallenge 
Guidelines
10.6.1. Liver Chemistry Stopping and Monitoring Criteria
10.6.1.1. ALT up to 2.5x ULN at B aseline
Phase I/II liver chemistry stopping and increased monitoring crite riahave been 
designed to assure participant safet y and evaluate liver event etiology.
Liver Chemistry Stopping Criteria – Liver Stopping Event
ALT-absolute ALT 5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN andcannot be monitored weekly for 4 weeks
Symptomatic3ALT  3xULN associated with symptoms (new or worsening) believed to be related to 
liver inju ry or hypersensitivity
Required Actions and Follow -upAssessments following ANY Liver Stopping Event
Actions Follow -upAssessments
Report the event to GSK within 24 hours
Complete the liver event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE2
Perform liver event follow -upassessments 
Monitor the participant until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge participant with 
study interv ention unless allowed per protocol 
and GSK Medical Governance approval is 
granted (refer to language within this 
Appendix) 
If restart/rechallenge not allowed per 
protocol or not granted , permanently 
discontinue study intervention and may 
continue particip antin the study for any 
protocol specified follow -upassessments Viral hepatitis serology4
Only in those with underlying chronic hepatitis B at 
study entry (i dentified by positive hepatitis B surface 
antigen) quantitative hepatitis B DNA and hepatitis 
delta antibody5. 
Blood sample for pharmacokinetic (PK) analysis, 
obtained 48 hours after last dose6
Serum creatine phosphokinase (CPK) and lactate 
dehydrogenase (LDH).
Fractionate bilirubin, if total bilirubin 2xULN
Obtain complete blood count with differential to 
assess eosinophilia
Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on the 
AE report form
Record use of co ncomitant medications on the 
concomitant medications report form including 
2018N362439_01 CONFIDENTIA L
207871
112MONITORING:
For bilirubin or INR criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow -upassessments within 24 
hrs
Monitor participants twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow -upassessments within 24-72 
hrs 
Monitor participant s weekly until liver 
chemistries resolve, stabilize or return to within 
baselineacetaminophen, herbal remedies, other over the 
counter medications
Record alcohol use on the liver event alcohol intake 
case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle antibody, 
Type 1 anti -liver kidney microsomal antibodies, and 
quantitative total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC assay 
(quantifies potential acetaminophen contribution to 
liver injury in participant s with definite or likely 
acetaminophen use in the preceding week 
[James ,2009]). 
Liver imaging (ultrasound, magnetic resonance, or 
computerized tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver Imaging 
and/or Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available . If serum bilirubin fractionation is not 
immediately available, discontinue study intervention for that participant if ALT 3xULN andbilirubin  2xULN . 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin 
on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is no t required and the threshold value stated will 
not apply to participant s receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C RNA; 
Cytomegalovirus IgM antibody; Epstein -Barr viral capsid a ntigen IgM antibody (or if unavailable, obtain heterophile 
antibody or monospot testing); Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus (where 
needed) [Le Gal , 2005].
6. PK sample may not be required for participant s known to be receiving placebo or non -GSK comparator treatments.)  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study interventio nprior to 
blood sample draw on the CRF . If the date or time of the last dose is unclear, provide the participant ’s best 
approximation . If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in the 
time period indicated above, do not obtain a PK sample . Instructions for sample handling and shipping are in the 
SRM . 
2018N362439_01 CONFIDENTIA L
207871
11310.6.1.2. Baseline A LT up t o 5xULN for Participants with Documented Liver 
Metastases/T umor Infiltration
Liver Chemistry Stopping Criteria – Liver Stopping Event
ALT absolute Both ALT 5xULN and 2x baseline value
ALT Increase Both ALT 3xULN and≥ 1.5x baseline value that persists for 4 weeks
Bilirubin1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN andINR>1.5
Cannot Monitor BothALT 3xULN and≥ 1.5x baseline value that cannot be monitored for 4 
weeks
Symptomatic3Both ALT 3xULN and≥ 1.5x baseline value associated with symptoms (new 
or worse ning) believed to be related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stopping Event
Actions Follow Up Assessments
Immediately discontinue study treatment
Report the event to GSK within 24 hours
Complete the liver event eCRF and complete SAE 
data collection tool if the event also meets the 
criteria for an SAE2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries
resolve, stabilize, or return to within baseline (see 
MONITORING below)
Do not restart/rechallenge participant with study 
treatment unless allowed per protocol and GSK 
Medical Governance approval is granted (refer to 
guidance in this Appendix) 
If restart/rechallenge not allowed per protocol or 
not granted , permanently discontinue study 
treatment and may continue participant in the 
study for any protocol specified follow up 
assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin and INR ) and 
perform liver event follow up assessments within 
24 hrsViral hepatitis serology4
Obtain INR and recheck with each liver 
chemistry assessment unt il the transaminases 
values show downward trend
Only in those with underlying chronic hepatitis 
B at study entry (identified by positive hepatitis 
B surface antigen) quantitative hepatitis B DNA 
and hepatitis delta antibody5.  
Blood sample for pharmacokin etic (PK) 
analysis, obtained 48 hours after last dose6
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total bilirubin 2xULN
Obtain complete blood count with differential to 
assess eosinophilia
Record the appea rance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on 
the AE report form
Record use of concomitant medications on the 
concomitant medications report form including 
acetaminophen, herbal remedies, other over 
the counter medication s
Record alcohol use on the liver event alcohol 
2018N362439_01 CONFIDENTIA L
207871
114Monitor parti cipants twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin and INR )and 
perform liver event follow up assessments within 
24-72 hrs 
Monitor participants weekly until liver chemistries 
resolve, stabilize or return to within baselineintake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal 
antibodies, and quantitative total 
immunoglobulin G (IgG or gamma globulins)
Serum acetaminophen adduct HPLC assay 
(quantifies potential acetaminophen 
contribution to liver injury in participants with 
definite or likely acetaminophen use in the 
preceding week [James , 2009]). 
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) and 
/or liver biopsy to evaluate liver disease; 
complete Liver Imaging and/or Liver Biopsy 
CRF forms
1. Serum bilirubin fractionation should be performed if testing is available. If serum b ilirubin fractionation is 
not immediately available, discontinue study treatment for that participant if ALT 3xULN and bilirubin 
2xULN. Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable 
urinary bilirub in on dipstick, indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5
which may indicate severe liver injury (possible ‘Hy’s Law’), must be re ported as an SAE (excluding 
studies of hepatic impairment or cirrhosis); the threshold value stated will not apply to participants
receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as 
fever, rash or eosinophilia)
4. Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegal ovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, 
obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepa titis D RNA 
virus (where needed) [ Le Gal , 2005].
6. PK sample may not be required for participants known to be receiving placebo or non -GSK comparator 
treatments.)  Record the date/time of the PK blood sample draw and the date/time of th e last dose of 
study treatment prior to blood sample draw on the CRF. If the date or time of the last dose is unclear, 
provide the participant ’s best approximation. If the date/time of the last dose cannot be approximated OR 
a PK sample cannot be collected in the time period indicated above, do not obtain a PK sample. 
Instructions for sample handling and shipping are in the SRM.  
2018N362439_01 CONFIDENTIA L
207871
11510.6.1.3. Liver Chemistry  Increased Monitoring Criteria with Continued T herapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT 3xULN but <5xULN and
bilirubin <2xULN, without symptoms believed 
to be related to liver injury or hypersensitivity 
andwho can be monitored weekly for 4 weeksNotify the GSK Medical Monitor within 24 hours of 
learnin g of the abnormality to discuss participant
safety. 
Participant can continue study intervention   
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabili ze or return to 
within bas eline 
If at any time participant meets the liver chemistry 
stopping criteria, proceed as described above .
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participant s twice monthly 
until liver chemistries normalize or return to w ithin 
baseline.
10.6.2. Liver Safety Drug Restart or Re -Challenge Guidelines
If participant meets liver chemistry  stopping criteria do not restart/re -challenge 
participant with study  intervention unless all the following conditions are met:
GSK Medical Governanc e approval is granted (as described below)
IRB/IEC approval is obtained, if required
Separate consent for treatment restart/re -challenge is signed by  the participant
If GSK Medical Governance approval to restart/re- challenge participant with study  
intervention is not granted, then participant must permanentl y discontinue study  
intervention and may  continue in the study  for protocol- specified follow -upassessments.
10.6.2.1. Re-challenge Follo wing Liver Stopping Events that are Possibly  
Related to Study intervention
Re-challenge refers to resuming study  intervention following drug -induced liver injury  
(DILI) . Because of the risks associated with re -challenge after DILI, this should only  be 
considered for a participant for whom there is compelling evidence of benefit fr om a 
critical or life -saving medicine, there is no alternative approved medicine available, and a 
benefit: risk assessment of re -challenge is considered to be favorable.
Following DILI, drug re -challenge is associated with a 13% mortality  across all drugs in 
prospective studies [Andrade , 2009] . Clinical outcomes vary  by drug with nearl y 50% 
2018N362439_01 CONFIDENTIA L
207871
116fatality  with halothane re -administered within 1 month of initial injury . However, some 
drugs seldom result in recurrent liver injury  or fatality . 
Risk factors for a fatal drug re -challenge outcome include the following:
Hypersensitivity [Andrade , 2009] with initial liver injury  (e.g., fever, rash, 
eosinophilia) 
Jaundice or bilirubin >2 x ULN with initial liver injury  (direct bilirubin >35% of 
total)
Participant currently  exhibits severe liver injury  defined by  ALT >3 x ULN, bilirubin 
>2 x UL N (direct bilirubin >35% of total), or INR >1.5
SAE or fatality  has been observed with drug rechallenges [Papay ,2009; Hunt, 2010]
Evidence of drug -related preclinical liability  (e.g., reactive metabolites; 
mitochondrial impairment) [ Hunt , 2010]
Approval b y GSK for re -challenge with study  intervention can be considered under the 
following conditions:
Investigator requests consideration of re -challenge with study  intervention for a 
participant who is receiving compelling benefit (partial response or complete 
response) with study  intervention that exceeds risk, and no effective alternative 
therap y is available
The ALT at the time of rechallenge is <3x UL N
The participant did not have additional risk factors for a fatal outcome following the
initial injury  including hy persensitivity , jaundice, bilirubin >2x ULN (direct bilirubin
>35% of total bilirubin), or INR >1.5.
IRB/IEC approval for re -challenge with study  intervention must be obtained, as 
required . 
If the re -challenge is approved by  GSK Medical Governance in writing, the 
participant must be provided with a clear description of the possible benefits and 
risks of study  intervention administration including the possibility  of recurrent, more 
severe liver injury  or death . 
The participant must also provide signed informed consent specifically  for the 
rechallenge -with study  intervention. Documentation of informed consent must be 
recorded in the study  chart. 
Study  intervention must be administered at the dose specified b y GSK.
Participants approved b y GSK Medical Governance for re -challenge with study  
intervention must return to the clinic twice a week for liver chemistry  tests until 
stable liver chemistries have been demonstrated and then standard laboratory  
monitoring may  resume as per protocol.
If after study  intervention re-challenge, participant meets protocol -defined liver 
chemistry  stopping criteria, study  intervention must be permanentl y discontinued. 
2018N362439_01 CONFIDENTIA L
207871
117GSK Medical M onitor, and the I RB/IEC as required, must be informed of the 
participant’s outcome following study  intervention re-challenge. 
GSK must be notified of any  AEs asper Section 8.3.
10.6.2.2. Re-challenge Follo wing Transient Liver Stopping Events Not Related to 
Study  intervention
Restart refers to resuming study  intervention following liver stopping events in which 
there is a clear underl ying cause (other than DILI) of the liver event (e.g., biliary  
obstruction, pancreatic events, hy potension, and acute viral hepatitis) . Furthermore, there 
should be no evidence of alcoholic hepatitis or h ypersensitivity , and the study  
intervention should not be asso ciated with human leukocy te antigen (HLA) markers of 
liver injury .
Approval b y GSK for study  intervention restart can be considered under the following 
conditions:
Investigator requests consideration for study  intervention restart if liver chemistries 
have a clear underl ying cause (e.g., biliary  obstruction, hy potension and liver 
chemistries have improved to normal or are within 1.5 x baseline and AL T 
<3xULN).
Possible study  intervention -related liver injury has been excluded by  the Investigator
and the s tudy team. This includes the absence of markers of h ypersensitivity  
(otherwise unexplained fever, rash, eosinophilia). Where a study  intervention has an 
identified genetic marker associated with liver injury  (e.g., lapatinib, abacavir, 
amoxicillin/clavulan ate), the presence of the marker should be excluded. If study  
intervention -related liver injury  cannot be excluded, the guidance on re -challenge in 
Section 10.6.2.1 will apply .
There is no evidence of alcoholic hepatitis.
IRB/IEC approval of study  intervention restart must be obtained, as required.
If restart of study  intervention is approved by  GSK Medical Governance in writing, 
the participant must be provided with a clear description of the possible benefits and 
risks of stud y intervention administration including the possibility  of recurrent, more 
severe liver injury  or death.
The participant must also provide signed informed consent specifically  for the study  
intervention restart. Documentation of informed consent must be re corded in the 
study  chart.
Study  intervention must be administered at the dose specified b y GSK.
Participants approved b y GSK Medical Governance for restarting study  intervention
must return to the clinic once a week for liver chemistry  tests until stable liver 
chemistries have been demonstrated and then laboratory  monitoring may resume as 
per protocol.
If after study  intervention restart, participant meets protocol- defined liver chemistry  
stopping criteria, follow usual stopping criteria instructions.
2018N362439_01 CONFIDENTIA L
207871
118GSK Medical M onitor, and the I RB/IEC as required, must be informed of the 
participant’s outcome following study  intervention restart.
GSK must be notified of any  AEs, as perSection 8.3.
2018N362439_01 CONFIDENTIA L
207871
11910.7. Appendix 7: Guidelines for A ssessment of Disease, Disease 
Progression and Response Criteria
10.7.1. Assessment Guidelines by  RECIST 1.1
Please note the following:
The same diagnostic method, including use of contrast when applicable, must be 
used throughout the study to evaluate a lesion. Co ntrast agents must be used in 
accordance with the Image Acquisition Guidelines.
All measurements must be taken and recorded in millimeters (mm), using a ruler 
or calipers.
Ultrasound is not a suitable modality  of disease assessment. If new lesions are 
identified by  ultrasound, confirmation by  CT or MRI  is required.
Fluorodeox yglucose (FDG) -PET is generally  not suitable for ongoing assessments 
of disease. However, FDG -PET can be useful in confirming new sites of disease 
where a positive FDG -PET scans correla tes with the new site of disease present 
on CT/MRI  or when a baseline FDG -PET was previously  negative for the site of 
the new lesion. FDG -PET may  also be used in lieu of a standard bone scan 
providing coverage allows interrogation of all likely sites of bo ne disease and 
FDG -PET is performed at all assessments.
If PET/CT is performed then the CT component can only  be used for standard 
response assessments if performed to diagnostic quality, which includes the 
required anatomical coverage and prescribed use o f contrast. The method of 
assessment must be noted as CT on the eCRF.
Clinical Examination: Clinically  detected lesions will only  be considered measurable 
when they  are superficial (e.g., skin nodules). In the case of skin lesions, documentation 
by color p hotograph y, including a ruler/calipers to measure the size of the lesion, is 
required.
CT and MRI: Contrast enhanced CT with 5mm contiguous slices is recommended.
Minimum size of a measurable baseline lesion must be twice the slice thickness, with a 
minimu m lesion size of 10 mm when the slice thickness is 5 mm. MRI  is acceptable, but 
when used, the technical specification of the scanning sequences must be optimized for 
the evaluation of the t ype and site of disease and lesions must be measured in the same 
anatomic plane b y use of the same imaging examinations. Whenever possible, the same 
scanner should be used.
X-ray: In general, X -rayshould not be used for target lesion measurements owing to 
poor lesion definition. Lesions on chest X -ray may be considered measurable if they  are 
clearl y defined and surrounded by aerated lung; however ,chest CT is preferred over 
chest X -ray.
Brain Scan:   If brain scans are required, then contrast enhanced MRI is preferable to 
contrast enhanced CT.
2018N362439_01 CONFIDENTIA L
207871
12010.7.2. Guidelines for Evaluation of Disease by RECIST 1.1
Measurable and Non -Measurable Definitions
Measurable lesion:
A non-nodal lesion that can be accuratel y measured in at least one dimension (longest 
dimension) of
  10mm with MRI  or CT when the scan slice thickness is no greater than 5 mm. If 
the slice thickness is greater than 5 mm, the minimum size of a measurable lesion 
must be at least double the slice thickness (e.g., if the slice thickness is 10 mm, a 
measurable lesion must be 20mm).
  10mm caliper/ruler measurement b y clinical exam or medical photography . 
  20mm by  chest X -ray.
Additionally , lymph nodes can be considered pathologicall y enlarged and 
measurable if:
15mm in the short axis when assessed b y CT or MRI  (slice thickness recommended to 
be no more than 5 mm). At baseli ne and follow -up, only  the short axis will be measured.
Non-measurable lesion:
All other lesions including lesions too small to be considered measurable (longest 
diameter <10 mm or pathological l ymph nodes with ≥10 mm and <15 mm short axis) as 
well as truly  non-measurable lesions, which include: leptomeningeal disease, ascites, 
pleural or pericardial effusions , inflammatory  breast disease, l ymphangitic involvement 
of the skin or lung, abdominal masses/abdominal organomegal y identified by ph ysical 
exam that is not measurable by  reproducible imaging techniques 
Measurable disease : The pre sence of at least one measurable lesion. Palpable lesions 
that are not measurable by radiologic or photographic evaluations may  not be utilized as 
the only  measurable lesion.
Non-Measurable only disease : The presence of only  non-measurable lesions. 
Note : non-measurable only  disease is not allowed per protocol.
10.7.3. Evaluation of Response by iRECIST
iRECI ST is based on RECI ST 1.1, but adapted to account for the unique tumor response 
seen with immunotherapeutic drugs. iRECIST will be used to assess tumor response and 
progression, and make treatment decisions. When clinically  stable, participants should 
not be discontinued until progression is confirmed according to the rules described 
below. This allowance to continue treatment despite initial radiologic PD takes into 
account the observation that some participants can have a transient tumor flare in the first 
few months after the start of immunotherap y, and then experience subsequent disease 
response. These data will be captured in the clinical database.
Clinical stability  is defined as meeting all of the following: 
2018N362439_01 CONFIDENTIA L
207871
121Absence of sy mptoms andsigns indicating clinically significant progression of
disease
No decline in ECOG performance status 
No requirements for intensified management, including increased analgesia, 
radiation, or other palliative care
Any participant deemed clinically unstable may be discontinued from study  intervention
at site -assessed first radiologic evidence of PD. It is strongl y preferred to obtain the 
repeat tumor imaging, when feasible, for conf irmation of PD by  iRECI ST. 
In a clinicall y unstable participant, if the Investigator decides to continue treatment, 
following consultation with the Sponsor Medical M onitor, the participant may  continue 
to receive study  intervention . The tumor assessment s hould be repeated at least 4 weeks 
and up to 8weeks later to confirm PD by  iRECIST . Images should continue to be sent in 
to the central imaging vendor for potential central review. 
If repeat imaging does not confirm PD per iRECI ST and the participant con tinues to be 
clinically  stable, study  intervention may continue and follow the regular imaging 
schedule . If PD is confirmed, participants will be discontinued from study  intervention .
If a participant has confirmed radiographic progression (iCPD) as define d below, study  
intervention should be discontinued; however, if the participant is achieving a clinically 
meaningful benefit, continuation of study  intervention may be considered following 
consultation with the Sponsor . In this case, if study  intervention is continued, tumor 
imaging should continue to be performed following the intervals as outlined in Section
8.1and submitted to the central imaging vendor. 
Description of the iRECIST Process for Assessment of Disease Progressi on
Assessment at Screening and Prior to RECIST 1.1 Progression
Until radiographic disease progression based on RECI ST 1.1, there is no distinct 
iRECI ST assessment.
Assessment and Decision at RECIST 1.1 Progression
For participants who show evidence of radiological PD by  RECI ST 1.1the Investigator 
will decide whether to continue a participant on study  intervention until repeat imaging is 
obtained (using iRECIST for participant management (see Table 18andFigure 4). This 
decision should be based on the participant’s overall clinical condition. (See discussion of 
clinical stability  in Section 1.2 above .) 
Tumor flare may  manifest as any  factor caus ing radiographic progression per RECI ST 
1.1, including:
Increase in the sum of diameters of target lesion(s) identified at baseline to ≥20% 
and ≥5mm from nadir
2018N362439_01 CONFIDENTIA L
207871
122oNote: the iRECI ST publication uses the terminology  “sum of measurements”, but 
“sum of diameters” will be used in this protocol, consistent with the ori ginal 
RECI ST 1.1terminology.
Unequivocal progression of non- target lesion(s) identified at baseline
Development of new lesion(s)
iRECI ST defines response categories, including iUPD (unconfirmed progressive disease) 
and iCPD (confirmed progressive disease) . For purposes of iRECI ST assessment, the first 
visit showing progression according to RECI ST 1.1will be assigned a visit (overall) 
response of iUPD, regardless of which factors caused the progression.
At this visit, target and non- target lesions identified at baseline b y RECI ST 1.1 will be 
assessed as usual.
New lesions will be classified as measurable or non-measurable, using the same size 
thresholds and rules as for baseline lesion assessment in RECI ST 1.1. From measurable 
new lesions, up to 5 lesions t
otal (up to 2 per organ), may  be selected as New Lesions 
Target . The sum of diameters of these lesions will be calculated, and kept distinct from 
the sum of diameters for target lesions at baseline . All other new lesions will be followed 
qualitatively  asNew Lesions Non-target.
Assessment at the Confirmatory Imaging
At the confirmatory  imaging visit assessment, the participant will be classified as 
progression confirmed (with an overall response of iCPD), or as showing persistent 
unconfirmed progression (with an overall response of iUPD), or as showing disease 
stability  or response (iSD/iPR/iCR). Timing of confirmatory  imaging is described in 
Section 8.1.
Confirmation of Progression
Progression is considered confirmed, and th e overall response will be iCPD, if ANY of 
the following occurs:
Any of the factors that were the basis for the initial iUPD show worsening
oFor target lesions, worsening is a further increase in the sum of diameters of 
≥5mm, compared to any prior iUPD tim e point
oFor non -target lesions, worsening is any  significant growth in lesions overall, 
compared to a prior iUPD time point; this does not have to meet the 
“unequivocal” standard of RECI ST 1.1
oFor new lesions, worsening is an y of these:
An increase in the new lesion sum of diameters by ≥5mm from a prior 
iUPD time point 
Visible growth of new non- target lesions 
The appearance of additional new lesions
2018N362439_01 CONFIDENTIA L
207871
123Any new factor appears that would have triggered PD by  RECI ST 1.1
Persistent iUPD
Progression is considere d not confirmed, and the overall response remains iUPD, if:
None of the progression -confirming factors identified above occurs AND
The target lesion sum of diameters (initial target lesions) remains above the initial 
PD threshold (by  RECIST 1.1)
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the imaging 
on which iUPD is seen. This may  correspond to the next visit in the original visit 
schedule . The assessment of the subsequent confirmation imaging proceeds in an 
identical manner, with possible outcomes of iCPD, iUPD, and iSD/iPR/iCR.
Resolution of iUPD
Progression is considered not confirmed, and the overall response becomes iSD/iPR/iCR, 
if:
None of the progression -confirming factors identified above occurs, AND
The target lesion s um of diameters (initial target lesions) is not above the initial PD 
threshold. 
The response is classified as iSD or iPR (depending on the sum of diameters of the target 
lesions), or iCR if all lesions resolve.
In this case, the initial iUPD is considered to be pseudo-progression, and the level of 
suspicion for progression is “reset”. This means that the next visit that shows 
radiographic progression, whenever it occurs, is again classified as iUPD b y iRECI ST, 
and the confirmation process is repeated befor e a response of iCPD can be assigned.
Management Following the Confirmatory Imaging
If repeat imaging does not confirm PD per iRECI ST, as assessed by  the Investigator, and 
the participant continues to be clinically  stable, study  intervention may continue a nd 
follow the regular imaging schedule. If PD is confirmed, participants will be discontinued 
from study  intervention .
NOTE: If a participant has confirmed radiographic progression (iCPD) as defined above, 
but the participant is achieving a clinicall y mean ingful benefit, continuation of study  
intervention may be considered following consultation with the Sponsor. I n this case, if 
study  intervention is continued, tumor imaging should continue to be performed 
following the intervals as outlined in Section 8.1and submitted to the central imaging 
vendor.
Detection of Progression at Visits After Pseudo -Progression Resolves
After resolution of pseudo-progression (i.e., achievement of iSD/iPR/iCR), iUPD is 
indicated b y any of the following events:
2018N362439_01 CONFIDENTIA L
207871
124Target lesions
oSum of diameters reaches the PD threshold ( ≥20% and ≥5 mm increase from 
nadir) either for the first time, or after resolution of previous pseudo -progression. 
The nadir is alway s the smallest sum of diameters seen during the entire study , 
either before or aft er an instance of pseudo- progression.
Non-target lesions
oIf non -target lesions have never shown unequivocal progression, doing so for the 
first time results in iUPD.
oIf non -target lesions have shown previous unequivocal progression, and this 
progression ha s not resolved, iUPD results from any  significant further growth of 
non-target lesions.
New lesions
oNew lesions appear for the first time
oAdditional new lesions appear
oPreviously  identified new target lesions show an increase of ≥ 5mm in the new 
lesion sum of diameters, from the nadir value of that sum
oPreviously  identified non -target lesions show an y significant growth
If any of the events above occur, the overall resp onse for that visit is iUPD, and the iUPD 
evaluation process (see Assessment at the Confirmatory  Imaging above) is repeated. 
Progression must be confirmed before iCPD can occur.
The decision process is identical to the iUPD confirmation process for the ini tial PD, with 
one exception:  if new lesions occurred at a prior instance of iUPD, and at the 
confirmatory  imaging the burden of new lesions has increased from its smallest value (for 
new target lesions, the sum of diameters is ≥5 mm increased from its nadir), then iUPD 
cannot resolve to iSD or iPR. I t will remain iUPD until either a decrea se in the new lesion 
burden allows resolution to iSD or iPR, or until a confirmatory  factor causes iCPD.
Additional details about iRECI ST are provided in the iRECI ST publication 
[Seym our ,2017].
2018N362439_01 CONFIDENTIA L
207871
125Table 18 Imaging and Treatment after First Radiologic Evidence of 
Progressive Disease
Clinically Stable Clinically Unstable
Imaging Treatment Imaging Treatment
First radiologic 
evidence of PD by 
RECIST 1.1Repeat imaging at 
4 to 8 weeks to 
confirm PD.May continue study 
intervention at the 
Investigator’s 
discretion while 
awaiting confirmatory 
tumor imaging by site 
by iRECIST.Repeat imaging at 
4 to 8 weeks to 
confirm PD per 
Investigator’s 
discretion only.Discontinue treatment
Repeat tumor 
imaging confirms 
PD (iCPD) by 
iRECIST per 
Investigator 
assessmentNo additional 
imaging required.Discontinue treatment 
(exception is possible 
upon consultation with 
Sponsor).No additional 
imaging required.Not applicable
Repeat tumor 
imaging shows 
iUPD by iRECI ST 
per Investigator 
assessmentRepeat imaging at 
4 to 8 weeks to 
confirm PD . May 
occur at next 
regularly 
scheduled imaging 
visit.Continue study 
intervention at the 
Investigator’s 
discretion.Repeat imaging at 
4 to 8 weeks to 
confirm PD per 
Investigator’s 
discretion only.Discontinue treatment
Repeat tumor 
imaging shows iSD, 
iPR, or iCR by 
iRECIST per 
Investigator 
assessment.Continue regularly 
scheduled imaging 
assessments.Continue study 
intervention at the 
Investigator’s 
discretion.Continue regularly 
scheduled imaging 
assessments.May restart study 
intervention if condition 
has improved and/or 
clinically stable per 
Investigator’s discretion . 
Next tumor imaging 
should occur according 
to the regular imaging 
schedule.
iCPD = iRECIST confirmed progressive disease; iCR = iRECIST complete response; iRECIST = modified Response 
Evaluation Criteria in Solid Tumors 1.1for immune -based therapeutics; iSD = iRECIST stable disease; iUPD = 
iRECIST unconfirmed progressive disease; PD = progressive disease; RECIST 1.1= Response Evaluation 
Criteria in Solid Tumors 1.1.
2018N362439_01 CONFIDENTIA L
207871
126Figure 4 Imaging and Treatment for Clinically  Stable Participants after First 
Radiologic Evidence of PD A ssessed by  the Investigator

2018N362439_01 CONFIDENTIA L
207871
128This participant ’s actual body weight is >30% over ideal body weight. In this case, the 
participant ’s ideal body weight of 68.4 kg should be used in calculating estimated 
creatinine clearance.
CKD -EPI Formula:
CKD stage: Kidney  Disease Outcomes Quality  Initiative (KDOQI) CKD stages 3/4/5 
defined b y eGFR using the CKD Epidemiology Collaboration (CKD -EPI) formula 
[Leve y, 2009] .
GFR  141 × min (S cr/κ, 1)α× max(S cr/κ, 1)-1.209× 0.993Age× 1.018 [if female] × 
1.159 [if black]
where:
Scris serum creatinine in mg/dL,
κ is 0.7 for females and 0.9 for males,
α is -0.329 for females and - 0.411 for males,
min indicates the minimum of S cr/κ or 1, and
max indicates the maximum of S cr/κ or 1.
	
	
 	


*;+9+ .9%
" !
1!
0F3"CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected 
by third party copyright laws and therefore have been excluded.
2018N362439_01 CONFIDENTIA L
207871
13010.10. Appendix 10: Statistical Methods for Study  Design
10.10.1. Bivariate CRM Method for Part 1 Dose Escalation
10.10.1.1. Description of the Bivariate Continual Reassessment Method
The bivariate CRM model -based design is a B ayesian adaptive dose escalation scheme 
that assumes a 5-parameter Bayesian logistic regression model [Neuenschwander , 2014 ]
for the toxicity  rate based on dose s. The CRM method is fully  adaptive and makes use of 
all DL T info rmation, therefore is expected to locate the target dose level efficiently .
Dose escalation decisions will be held after participants within any  given cohort have 
been observed for 28 days of DLT observation period after starting the study  
intervention . Atthe time of each dose escalation decision, the Fixed and Adaptive 
Clinical Trial Simulator (FACTSTMversion 6.1 or higher [Tessella, Abington, United 
Kingdom]) will be used to obtain the posterior probabilities that the DL T rate for t hat 
dose lies in each of 4toxicity  intervals (under dosing, target dose range, excessive 
toxicity , and unacceptable toxicity ) for each potential dose. The CRM estimates, for each 
potential dose combination level, the posterior probabilities that the DL T rate lies in each 
of four toxicity  ranges :
[0%, 16%) Under dosing
[16%, 33%) Target toxicity
[33%, 60%) Excessive toxicity
[60%, 100% ]Unacceptable toxicity
The recommended dose will be the dose with the highest posterior probability  of having a 
toxicity  rate inthe target inte rval with the additional requirement that the sum of the 
posterior probabilities of the DLT rate in the excessive toxicity  or unacceptable toxicity
range is less than 25 %. The use of over dose control limits the risk of exposing 
participants in the next co hort to an unsafe dose combination by  ensuring the posterior 
probability  of the DLT rate exceeding 33% at an y dose is capped at 25%. An updated 
estimate of the toxicity  curve will be provided at the time of each dose escalation 
meeting . Note that de -escala tion as well as escalation is possible using this method.
Dose recommendations based on the bivariate CRM analy sis will be used as guidance for 
the Safet y Committee. To ensure safet y of participants, additional participants may be 
enroll ed at a current dos e level at the discretion of the Safet y Committee, even though a 
higher dose is recommended by  CRM analy sis.
10.10.1.2. Logistic Model for Bivariate CRM
A 5-parameter logistic model will be used for bivariate CRM anal ysis to guide dose 
selection during Part 1 dose escalation. This model will estimate the probability  of 
observing a DLT at each combination dose in the study  as DLT information becomes 
available.
The logistic model that used for describing the dose -toxicity  relationship is: 
2018N362439_01 CONFIDENTIA L
207871
131where Pijis the pro bability  of DLT at dose d 1i(of drug 1 ) in combination with dose d2j(of 
drug 2 ),P1iis the probability  of DLT if single agent drug 1 at dose d 1iis administer ed,P2j
is the probability  of DLT if single agent drug 2 at dose d 2jis administer ed,  
, , and d1sand d2tarethereference dose s for drug 1 and drug 2, 
respectivel y.Η is the interaction term. Α and β are Bay esian priors.
10.10.2. Simulation Method for Part 2 Sample Size Estimation
The sample size estimation for Part 2 cohort expa nsion is based on simulation . Figure 5
shows the flow chart of simulation.
2018N362439_01 CONFIDENTIA L
207871
133Figure 6 Simulated overall survival forstudy intervention (red line) and SOC
(blue line)
The key  variables /parameters used for the simulation are:
Accrual rate 5 participants /Month
No. of events at final analys es 72
Hypothetical P hase 3 sam ple size 345
No. of events for hypothetical Phase 3 analysis 240
Prior information for log(HR) ~N (0, 45)
Success criterion at final analyses Predictive probability of Ph3 success > 60%
Type I error for the hypothetical Phase 3 trial 0.025 (one -sided)
2018N362439_01 CONFIDENTIA L
207871
13410.11. Appendix 11: A bbreviations and Trademarks
Abbrev iations
ADA Anti- drug antibodies
AE Adverse Event
AESI Adverse Events of Special Interest
ALT Alanine Aminotransferase
ANC Absolute Neutrophil Count
AST Aspartate Aminotransferase
AUC(0 -t) Area under the plasma concentration- time curve from time 
0 to the time of the last quantifiable concentration)
-hCG Beta-human chorionic gonadotropin
ccRCC Clear C ell Renal Cell Carcinoma
CD28 Cluster of Differentiation 28
cfDNA cell-free DNA
CKD -EPI Chronic K idney  Disease Epidemiology  Collaboration
Cmax Maximum observed concentration
Cmin Minimum Observed Concentration;
CNS Central Nervous S ystem
CONSORT Consolidated Standards of Reporting Trials
CR Complete Response
CrCl Creatinine Clearance
CRM Contin ual Reassessment Method
CRP C Reactive Protein
CRPC Castrate Resistant Prostate Cancer
CRF Case Report Form
CRS Cytokine Release Sy ndrome
CT Computed tomograph y
CTFG Clinical Trial Facilitation Group
CTL A-4 Cytotoxic T -Lym phocy te-Associated Protein 4 
CV Cardiovascular
CYP3A Cytochrome P 3A
DCR Disease Control Rate
DILI Drug -induced Liver Injury
dL Deciliter
DLT Dose L imiting Toxicity
DNA Deox yribonucleic Acid
DoR Duration of Response
EC Effective Concentration
ECG Electrocardiogram
ECHO Echocardiograph y
ECI Events of Clinical I nterest
ECOG Eastern Cooperative Oncology  Group
ECOG- PS Eastern Cooperative Oncology  Group Performance Status
eCRF Electronic Case Report Form
2018N362439_01 CONFIDENTIA L
207871
135eGFR Estimated Glomerular Filtration Rate
EORTC QL Q-C30 and 
H&N35European Organization for Research and Treatment of 
Cancer Quality  of Life Questionnaire Core 30 and Head and 
Neck Cancer 35 Module
FACT GP5 Functional Assessment of Cancer Therap y General 
Population
FACTS Fixed and Adaptive Clinical Trial Simulator
FDG-PET Fluorodeox yglucose positron emission tomography
g Gram
GCP Good Clinical Practice
G-CSF Granulocy te-Colony  stimulating factor
GI Gastrointestinal
GSK GlaxoSmithKline
HPV Human Papilloma Virus
HNSCC Head and Neck Squamous Cell Carcinoma
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use
ICOS Inducible T Cell Co-Stimulator
ICOS -L-Fc Inducible T Cell Co- Stimulator L igand Fragment 
crystallizable region of an Antibody
iCPD iRECI ST confirmed progressive disease
iCR iRECI ST complete response
IEC Independent Ethics Committees
IFN Interferon, gamma
IL Interleukin
Ig Immunoglobulin
INR International Normalized Ratio
iPR iRECI ST progressive disease
irAE Immune -related Adverse Event
IRB Institutional Review Board
IRR Infusion- related Reactions
iRECI ST Modified RECIST1.1for Immune -based Therapeutics
iSD iRECI ST stable disease
iUPD iRECI ST unconfirmed progressive dis ease
IV Intravenous
IVIG IV Immunoglobulin
IVRS Interactive Voice Response Sy stem
IWRS Interactive Web Response Sy stem
KDOQI Kidney  Disease Outcomes Quality  Initiative
kg Kilogram(s)
LLN Lower Limit of Normal
LVEF Left Ventricular Ejection Fraction
m2Square Meters 
2018N362439_01 CONFIDENTIA L
207871
136mAb Monoclonal Antibody
MAD Maximum Administered Dose
MedDRA Medical Dictionary  for Regulatory  Activities
mg Milligram(s)
min Minute
mm Millimeters
mmHg Millimeters of Mercury
mL Milliliter(s)
MPM Malignant pleural mesothelioma
MRI Magnetic resonance imaging
MSDS Material Safet y Data Sheet
msec Millisecond(s)
MTD Maximum Tolerated Dose
MUGA Multigated Acquisition Scan
NCI-CTCAE National Cancer Institute Common Toxicity  Criteria for 
Adverse Events 
NSCL C Non-small -cell L ung Cancer
ORR Overall Response Rate
OS Overall Survival
OTC Over the Counter
PBMC Peripheral Blood Mononuclear Cell
PD Progressive Disease
PD-1 Programmed death receptor protein-1
PD-L1 Programmed death -ligand 1
R/R Relapsed/Refractory
RP2D Recom mended P hase 2 Dose
PFS Progression- free Survival
PI Principal I nvestigators
PJP Pneumocystis jirovecii pneumonia
PK Pharmacokinetics
PO Per oral
PP Predictive probability
PR Partial Response
PRO -CTCAE Patient Reported Outcomes Version of the Commo n 
Terminology  Criteria for Adverse Events
PS Performance Status
Q3W Every  3 Weeks
Q6W Every  6 Weeks
Q12W Every  12 Weeks
QoL Quality  of Life
QTc Corrected QT interval duration, corrected
QTcB QT interval corrected b y Bazett’s Formula
QTcF QT interva l corrected by  Fridericia’s Formula
RANKL Receptor Activator of Nuclear Factor -kappa B L igand
RAP Reporting and Anal ysis Plan
RECI ST Response Evaluation Criteria in Solid Tumors
2018N362439_01 CONFIDENTIA L
207871
137RNA Ribonucleic Acid
RP2D Recommended Phase 2 Dose
SAE Serious Adverse Event
Scr Serum Creatinine
sCRS Severe C ytokine Release Sy ndrome
SD Stable Disease
SoA Schedule of Activities
SOC Standard of Care
SRM Study  Reference Manual
TCR T Cell Receptor
TDV Treatment Discontinuation Visit
Th1 Type 1 T helper (cells)
Th2 Type 2T helper (cells)
Th17 T helper 17 (cells)
TNF Tumor Necrosis Factor, alpha
Treg T Regulatory  Cells
TTR Time to Response
ULN Upper Limit of Normal
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
FluMist FACTS
2018N362439_01 CONFIDENTIA L
207871
13810.12. Appendix 1 2: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC).
2018N362439_01 CONFIDENTIA L
207871
13911. REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The 
European Organization for Research and Treatment of Cancer QLQ- C30: a quality -of-life 
instrument for use in international clinical trials in oncology . J Natl Cancer Institute. 
1993;85:365 -76.
Andrade RJ, Robles M, Lucena MI. Rechallenge in drug -induced liver injury : the 
attractive hazard. Expert Opin Drug Saf. 2009; 8:709-714.
Antonia S, Goldberg S, Bamanoukian A, Chaft J, et al. Safet y and antitumour activity of 
durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b 
study ; Lancet Oncology ; 2016;17:299 -
308.
Ara G, Baher A, Storm N, et al. Potent activity of soluble B7RP -1-Fc in therap y of 
murine tumors in sy ngeneic hosts. 
Int J Cancer . 2003; 103:501 -07.
Argiris A, Ha rrington KJ, Tahara M, Schulten J, Chomette P et al. Evidence- Based 
Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head 
and Neck. Front Oncol. 2017; 7: 72. doi:  10.3389/fonc.2017.00072.
AstraZeneca. Investigator’s Brochure for Tremelimumab. Edition 8; 02 November 2017. 
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. 
Development of the National Cancer Institute patient -reported outcomes version of the 
common terminology  criteria for adverse events (PRO -CTCAE). J Natl Cancer Inst. 
2014;106:1-11.
Bjordal K, Hammerlid E, Ahlner- Elmqvist M, et al. Quality  of life in head and neck 
cancer patients: validation of the European Organization for Research and Treatment of 
Cancer Quality  of Life Questionnaire -H&N35. Journal of Clinical Oncology . 17: 1008-
19, 1999.
Brahmer JR, Ty kodi SS, Chow L Q, et al. Safet y and activity of anti -PD-L1 antibody  in 
patients with advanced cancer. N Engl J Med. 2012;366:2455 2465.
Brennan FR, Morton LD, Spindeldreher S, et al. Safe ty and immunotoxicity  assessment 
of immunomodulatory  monoclonal antibodies. mAbs. 2010; 2:233 -255.
Calabrò L, Morra A, Fonsatti E et al. Tremelimumab for patients with chemotherap y-
resistant advanced malignant mesothelioma: an open- label, single -arm, phase 2 trial. 
Lancet Oncol. 2013; 14:1104- 1111 .
Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTL A
-4 blockade: Tolerability  and 
immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010; 
16:2861-71.
2018N362439_01 CONFIDENTIA L
207871
140Cella DF, Tulsk y DS, Gray G, Sarafian B, L loyd S, L inn E, et al. The Functional 
Assessment of Cancer Therapy (FACT) scale: Development and validation of the general 
measure. Journal of Clinical Oncology  1993; 11: 570 -579.
Chen DS, Mellman I . Oncology  meets immunology : The cancer -immunity  cycle. 
Immunity . 2013; 39:1-10.
Chen H, L iakou CI, Kamat A, et al. Anti -CTLA -4 therapy  results in higher CD4+I COShi 
T cell frequency  and IFN -gamma levels in both nonmalignant and malignant prostate 
tissues. Proc Natl Sci USA. 2009; 106:2729-2734.
Chen L , Han X. Anti PD-1/PD -L1 therapy  of human cancer: past, present, and future. J 
Clin I nvest. 2015;125:3384 3391.
Devine BJ.  Case Number 25 Gentam ycin Therapy: Clinical Pharmacy Case Studies.  
Drug Intelligence and Clinical Pharmacy .  1974; 8:650 -655.
Di Giacomo AM, Calabrò L , Danielli R, et al. L ong-term survival and immunological 
parameters in metastatic melanoma patients who respond to ipilimumab 10 mg/kg within 
an expanded access program. Cancer Immunol Immunother . 2013; 62:1021-28.
Eisenhauer EA, T herasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECI ST guidelines (version 1.1). 
Eur J Cancer. 2009; 45:228-47.
Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of th e ICOS 
pathway  markedly  enhances efficacy  of CTLA -4 blockade in cancer immunotherapy . J 
Exp Med, 2014; 211: 715-725.
Ferris RL , Blumenschein G, Fay ette J Jr, Guigay  J, Colevas AD, Licitra L, et al. 
Nivolumab for Recurrent Squamous -Cell Carcinoma of the Hea d and Neck. N Engl J 
Med. 2016, 375: 1856
-1867
Ferris RL . Immunology  and I mmunotherapy  of Head and Neck Cancer. J Clin Oncol. 
2015 Oct 10;33(29):3293 -304.
Fu T, He Q, Sharma P. The I COS / I COS L pathway  is required for optimal anti -tumor 
responses mediated by anti-CTL A-4 therapy . Cancer Research. 2011; 71: 5445 -5454.
Galluzzi L , Buque A, Kepp O, et al. Immunological Effects of Conventional 
Chemotherap y and Targeted Anticancer Agents. Cancer Cell. 2015; 28: 690 -714.
GlaxoSmithKline Document Number 2017N319717_01. I nvestigator’s Brochure for 
GSK3359609. 10 May  2018.
Gupta B, Johnson NW, Kumar N. Global Epidemiology  of Head and Neck Cancers: A 
Continuing Challenge. Oncology  2016;91:13 -23. doi: 10.1159/000446117.
2018N362439_01 CONFIDENTIA L
207871
141Hunt CM. Mitochondrial and immunoallergic injury  increase risk of positive drug 
rechallenge after drug -induced liver injury : a systematic review. Hepatol. 2010; 52:2216 
22.
Hutloff A, Dittrich AM, Beier KC,  et al. ICOS is an inducible T cell co -stimulator 
structurally  and functionally  related to CD28. 
Nature . 1999;397:263-266.
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784.
Jensen R, Potosky  A, Reeve B, Hahn E, Cella D, Fries J, et al. Validation of the PROMI S 
Physical Function Measures in a Diverse Us Population- Based Cohort of Cancer Patients. 
Quality  of Life Research 2015: 24(10), 2333- 2344. 
Jensen RE, Moinpour CM, Potosky AL, Lobo T, Hahn EA, Hay s RD, et al. 
Responsiveness of 8 Patient- Reported Outcomes Measurement Information Sy stem 
(PROMI S) Measures in a L arge, Community -Based Cancer Study  Cohort. Cancer 201 7
Oct 3. doi: 10.1002/cncr.30354..
Kim HR, Ha SJ, Hong MH, Heo S J, Koh YW, Choi EC, et al. PD -L1 expression on 
immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck 
cancer patients. Sci Rep. 2016 Nov 14;6:36956.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al. Combined Nivolum ab and 
Ipilimumab or Monotherapy  in Untreated Melanoma. N Engl J Med. 2015; 373:23-34.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  Consensus Real -Time PCR I ndicates 
Differe nt Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43:2363 2369.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts 
in the diagnosis and management of cy tokine release s yndrome. Blood. 2014; 124:188 -
195.
Levey  AS, Stevens LA, Schmid CH, et al. A New Equation to Estimate Glomerular 
Filtration Rate. Ann Intern Med. 2009; 150:604 -612.
Li F, Ravetch JV. Inhibitory  FCreceptor engagement drives adjuvant and anti- tumor 
activities of agonostic CD40 antibodies. Science 2011; 333: 1030
-34.
Liakou CI, Kamat A, Tang D, et al. CTLA- 4 blockade increases IFN-gamma producing 
CD4+I COShi cells to shift the ratio of effector to regulatory  T cells in cancer patients. 
Proc Natl Aca d Sci USA. 2008; 105:14987 -14992.
Mandal R, Şenbabaoğlu Y , Desrichard A , Havel JJ, Dalin MG, Riaz N ,et al. The head 
and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 
2016 Oct 20;1(17):e89829.
2018N362439_01 CONFIDENTIA L
207871
142Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibod y 
development in cancer. Nat Rev Drug Discov. 2018.
Melero I, Grimaldi AM, Perez -Gracia J L, Ascierto PA. Clinical development of 
immunostimulatory  monoclonal antibodies and opportunities for combination. Clin 
Cancer Res. 2013;19:997 1008. 
Meng X, L iu Y, Zhang J, Teng F, Xing L, Yu J, PD -1/PD -L1 checkpoint blockades in 
non-small cell lung cancer: New development and challenges, Cancer Letters 2017; 405: 
29-37
Mesia R, Pastor M, Grau JJ, del Barco E. SEOM clinical guidelines for the treatment of 
head and neck cancer (HNC) 2013. Clin Transl Oncol. 2013 Dec;15(12):1018 -24. doi: 
10.1007/s12094 -
013-1096- z.
National Comprehensive Cancer Network (NCCN). Head and Neck Cancers (Version 
2.2018). https://www.nccn.org /professionals/phy sician_gls/pdf/head -and-
neck.pdf. 
Accessed July  13, 2018.
NCI. National Cancer Institute Common Terminology  Criteria for Adverse Events v5.0 
NCI, NIH, DHHS. November 27, 2017.
Neuenschwander B, Branson M, Gsponer T. Critical aspects of th e Bay esian approach to 
phase I cancer trials. Statistics Med. 2008;27:2420-2439.
Neuenschwander B, Matano A, Tang Z, Roy choudhury  S, Wandel S. A Bay esian 
Industry  Approach to Phase I Combination Trials in Oncology . Chapter 6 “Statistical 
Methods in Drug Co mbination Trials”. Chapman & Hall/CRC. 2014 .
Oken, MM, Creech, RH, Tormey , DC, Horton, J, Davis, TE, McFadden, ET, et al. 
Toxicity  and response criteria of the Eastern Cooperative Oncology  Group. Am J Clin 
Oncol. 1982; 5:649-655.
Papay  JI, Clines D, Rafi R , Yuen N, Britt SD, Walsh JS, Hunt CM. Drug -induced liver 
injury  following positive drug rechallenge. Regul Tox Pharm. 2009; 54:84 -
90.
Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (I COS) is critical for 
the development of human Th17 c ells. Sci Transl Med . 2010; 2:55ra78.
Powles T, Eder JP , Fine GD, et al. MPDL380A  (anti -PD-L1) treatment leads to clinical
activity  in metastatic bladder cancer . Nature. 2014; 515:558-562.
Rose M, Bjornerc JB, Gandek B, Bruce B, Fries JF, Ware JE Jr. The PROMI S Phy sical 
Function item bank was calibrated to a standardized metric and shown to improve 
measurement efficiency . J Clin Epi. 2014; 67:516 -526.
Schwartz LB. Diagnostic value of try ptase in anaphy laxis and mastocy tosis. I mmunol 
Allergy  Clin. 2006; 26:451-463.
2018N362439_01 CONFIDENTIA L
207871
143Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz L H, Mandrekar S, et al. iRECI ST: 
guidelines for response criteria for use in trials testing immunotherapeutics. L ancet Oncol 
2017; 18: e143-52.
Sharpe AH, Freeman GJ. The B7 -CD28 Superfamily . Nat R ev Immunol. 2002; 2:116
-
126.
Swaika A, Hammond W, Joseph R. Current state of anti- PD-L1 and anti -PD-1 agents in
cancer therapy . Mol Immunol. 2015;67:4
-17.
Tang DN, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. I ncreased 
frequency  of ICOS + CD4+ T cells as a pharmacody namic biomarker for anti -CTL 4 
therap y. Cancer Immunology  Research. 2013; 1: 229 -234.
Tarhini AA, Kirkwood JM. Tremelimumab (CP- 675,206): a fully  human anticy totoxic T 
lymphocy te-associated antigen 4 monoclonal antibody  for tre atment of patients with 
advanced cancers. Expert Opin Biol Ther 2008;8:1583 -93.
The EuroQol Group (1990). EuroQol -a new facility  for the measurement of health -related 
quality  of life. Health Policy  16:199-208.
Topalian SL , et al. Safet y, activity , and immu ne correlates of anti -PD-1 antibody  in 
cancer. N Engl J Med. 2012;366:2443 2454
Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with 
exemestane in patients with advanced breast cancer and treatment -associated modulation 
of inducibl e costimulator expression on patient T cells. Clin Cancer Res. 2010; 16:3485 -
94.
Wakamatsu EL , Mathis D, Benoist C. Convergent and divergent effects of costimulatory  
molecules in conventional and regulatory  CD4+ T cells. PNAS . 2013; 110:1023-28.
Wolchok J D, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. 
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369:122 -133.
Zamarin D, Postow MA. Immune checkpoint modulation: Rational design of
combination strategies. Pharmacol Ther . 2015 Jan 10 pii: S0163 -7258(15)00004-2. 
doi:10.1016/j.pharmthera.2015.01.003 .
Zhao X, Sury awanshi, S; Hruska, M. Assessment of nivolumab benefit- risk profile of a 
240-mg flat dose relative to a 3 mg/kg dosing regimen in patient with advanced tumors. 
Anna ls of Oncology . 2017;28:2002 -
2008 .